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ABSTRACT 
 
Malaria is one of the most serious global health challenges. Approximately 3.3 
billion people live in malaria-endemic areas and the disease threatens the lives of more 
than one-third of the world’s population. Malaria is caused by an eukaryotic protozoa 
Plasmodium and transmitted through the bite of female Anopheles mosquito. The 
known causative agents of human malaria include Plasmodium vivax, P. falciparum, P. 
malariae, P. ovale, and recently included P. knowlesi which is recognized as a zoonotic 
parasite. Malaria is a treatable disease, however the disease can become severe, leading 
to morbidity if untreated, especially for infections by two potential fatal species, i.e., P. 
falciparum and P. knowlesi. In the effort to improve the global health status, institution 
of control and surveillance of malaria, and subsequently enhancing the effectiveness of 
treatment management, it is critical to develop a rapid, accurate, species-
specific/species-sensitive, and cost-efficient diagnostic tool for malaria detection. 
Therefore, a straightforward single-step multiplex polymerase chain reaction (PCR) 
targeting five human Plasmodium 18S small subunit ribosomal RNA (ssu rRNA) gene 
with an internal positive control was developed. This system is specific in detecting all 
five human malaria parasites with high sensitivity (i.e., 0.025 parasites/µl for P. vivax, 
0.027 parasites/µl for P. ovale, 0.15 parasites/µl for P. falciparum, 0.25 parasites/µl for 
P. knowlesi, and 0.27 parasites/µl for P. malariae), and most significantly enables the 
simultaneous identification and differentiation of mixed infections at least up to the 
two-species level without any diagnostic constrains. In addition, the accuracy 
(sensitivity and specificity) of the detection system were also assured by random blind 
testing (n=50), clinical screening (n=246), and simulated mixed infections based on 
clinical samples (n=30) and clone DNA (n=60). All results were in agreement with the 
results from nested PCR which served as a molecular gold standard. Overall, this 
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multiplex system will definitely enhance the accuracy and accelerate the speed in the 
malaria diagnosis, and improve the efficacy of malaria treatment and control.  
Plasmodium is an obligate intracellular parasite. Therefore, the understanding of 
how the parasites enter their host’s cell is of great interest and this offers an attractive 
target for the development of novel therapeutics. Apical membrane antigen 1 (AMA1) 
is the most prominent and well characterized malarial surface antigen that is essential 
for parasite-host cell invasion, i.e., sporozoite into hepatocyte in liver stage and 
merozoite into erythrocyte in asexual stage. AMA1 has long served as a potent 
antimalarial drug target and pivotal vaccine candidate. In the present study, recombinant 
AMA1 proteins of P. knowlesi (rPkAMA1) as well as P. vivax (rPvAMA1) were 
expressed using Escherichia coli and the binding peptides were identified using a 
random dodecapeptide phage display library. Phage display is a powerful and cost-
effective tool that can be used for assessing the protein-protein interactions. After third 
rounds of biopanning, two and three phage-displayed binding peptides with affinity to 
rPkAMA1 and rPvAMA1 respectively were identified and validated through peptide 
binding assays.  
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ABSTRAK 
 
Malaria merupakan salah satu cabaran kesihatan global yang serius. Terdapat 
kira-kira 3.3 bilion orang menetap di kawasan endemik-malaria dan penyakit ini 
mengancam nyawa lebih daripada satu pertiga penduduk sedunia. Jangkitan malaria 
disebabkan oleh protozoa eukariotik Plasmodium dan ditularkan melalui gigitan 
nyamuk Anopheles betina. Agen-agen penyebab malaria manusia termasuk Plasmodium 
vivax, P. falciparum, P. malariae, P. ovale dan termasuk P. knowlesi yang diiktirafkan 
sebagai parasit zoonotik. Malaria adalah penyakit yang boleh dirawat, namun penyakit 
ini boleh menjadi teruk dan membawa morbiditi jika tidak dirawat, terutamanya bagi 
jangkitan oleh dua spesies yang berpotensi mambawa maut, iaitu, P. falciparum dan P. 
knowlesi. Dalam usaha untuk meningkatkan status kesihatan global, institusi kawalan 
dan survelans malaria, dan seterusnya peningkatan keberkesanan pengurusan rawatan, 
adalah kritikal untuk membangunkan alat diagnostik yang cepat, tepat, spesies-
spesifik/spesies-sensitif, dan menjimatkan kos untuk pengesanan malaria. Oleh itu, PCR 
multipleks jelas satu langkah mensasarkan lima jenis gen 18S RNA ribosom subunit 
kecil (ssu rRNA) bagi Plasmodium manusia dengan satu kawalan positif dalaman telah 
dibangunkan. Sistem ini khusus untuk mengesan kesemua lima parasit malaria manusia 
dengan tahap sensitiviti yang tinggi (i.e., 0.025 parasit/μl untuk P. vivax, 0.027 
parasit/μl untuk P. ovale, 0.15 parasit/μl untuk P. falciparum, 0.25 parasit/μl untuk P. 
knowlesi, dan 0.27 parasit/μl untuk P. malariae), dan paling ketara sekali membolehkan 
pengenalian dan pembezaan serentak jangkitan campuran sekurang-kurangnya sehingga 
ke tahap dua-spesies tanpa sekatan diagnostik. Di samping itu, ketepatan (sensitiviti dan 
spesifisiti) sistem pengesanan juga dijamin oleh ujian rawak buta (n=50), pemeriksaan 
klinikal (n=246), dan jangkitan campuran simulasi berdasarkan sampel klinikal (n=30) 
dan klon DNA (n=60). Kesemua keputusan adalah selaras dengan keputusan daripada 
PCR bersarang sebagai piawaian emas molekul. Keseluruhan, sistem multipleks ini 
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pasti akan meningkatkan ketepatan dan mempercepatkan jangkamasa diagnosis malaria, 
dan meningkatkan keberkesanan rawatan dan kawalan malaria.  
Plasmodium adalah parasit intrasel obligat dan pemahaman tentang bagaimana 
parasit ini memasuki sel hos mereka menjadi tumpuan kerana ini menawarkan sasaran 
menarik bagi pembangunan terapeutik novel. Antigen membran apikal 1 (AMA1) 
adalah antigen permukaan malaria yang paling menonjol dan memainkan peranan 
penting bagi parasit memasuki sel hos, iaitu sporozoite ke dalam hepatosit di peringkat 
hati dan merozoite ke dalam eritosit di peringkat aseksual. AMA1 sudah lama dikenali 
sebagai sasaran tumpuan ubat antimalaria dan calon vaksin terpenting. Dalam kajian ini, 
protein AMA1 rekombinan bagi P. knowlesi (rPkAMA1) serta P. vivax (rPvAMA1) 
telah dihasilkan dengan menggunakan Escherichia coli dan peptida-peptida mengikat 
telah dikenal pasti dengan menggunakan perpustakaan paparan faj dodekapeptida. Faj 
paparan adalah suatu alat berkesan dan berkos efektif yang boleh digunakan untuk 
menilai interaksi protein-protein. Selepas pusingan ketiga biopanning, dua dan tiga faj-
paparan peptida mengikat kepada rPkAMA1 dan rPvAMA1 telah masing-masing 
dikenal pasti dan disahkan melalui ujian-ujian mengikat peptida. 
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CHAPTER ONE: INTRODUCTION 
1.1 Introduction 
Malaria is a mosquito-borne parasitic disease cause by the unicellular, 
eukaryotic protozoa of the genus Plasmodium and Anopheles mosquitoes are vectors of 
transmission. Malaria continues to be one of the most severe worldwide public health 
problems that affects many of the poorest nations, especially in the African regions. 
Malaria is a devastating disease, killing one to two child/children every minute in Africa, 
representing a serious threat to travelers. Almost half of the world populations are live 
in areas at risk of malaria transmission and World Health Organization (WHO) main 
focal regions include most of African regions, many parts of Southeast Asia, Eastern 
Mediterranean, Western Pacific, and areas of Americas.  
Thus far, five causative Plasmodium parasites namely Plasmodium falciparum, 
Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and Plasmodium 
knowlesi have been recognized by WHO as able to infect humans. All parasites that 
cause human malaria develop through a general life cycle, which alternates between 
human host (liver and erythrocytic stages for asexual reproduction) and anopheline 
mosquito (sporogonic stage for sexual reproduction). In human host, there is a clinically 
silent replication during the liver stage (asymptomatic); while parasites density expands 
exponentially as a consequence of repetitive rounds of invasion, growth, and replication 
during erythrocytic stage, and thus leading to the symptoms and complications of 
malaria due to intensive rupture of infected erythrocytes and release of huge amounts of 
infective asexual merozoites into blood stream. Therefore, erythrocytic cycle always 
served as an importance diagnostic and therapeutic stage during human infections. This 
cyclical accumulation of parasites in blood causes a recurring flu-like illness 
characterized by fevers, headaches, chills, and sweating with periodicity cycle, i.e., 
quotidian (24 hours) for P. knowlesi, tertian (48 hours) for P. vivax, P. falciparum, and 
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P. ovale, and quartan (72 hours) for P. malariae infections. The present studies also 
mainly focus on this stage. 
In terms of disease severity by species, P. falciparum and P. knowlesi are the 
two most virulent species and are potentially fatal. Falciparum malaria also known as 
malignant and fatalistic malaria accounts for approximately 15 % global malaria cases 
and more than 90 % of global malaria deaths annually, mainly in African region and 
threaten the majority of young children below 5 year of ages. Sequestrating 
characteristic to vital organs of falciparum infection is the pathogenesis of this deathly 
disease (Hay, et al., 2009). Knowlesi malaria is a zoonotic parasite and recently 
recognized as the fifth human malaria that is widespread in the forested areas of 
Southeast Asia especially in Malaysian Borneo and extends to Peninsular Malaysia and 
neighboring countries (Cox-Singh, et al., 2008; White, 2008). Severe complications are 
common in knowlesi infection and potentially lethal associated with hyperparasitemic 
and developed marked hepatorenal dysfunction. Thus far, 19 knowlesi deaths have been 
reported in Malaysia (Cox-Singh, et al., 2008; Cox-Singh, et al., 2010; Daneshvar, et al., 
2009; Rajahram, et al., 2012; William, et al., 2011). Plasmodium vivax has the widest 
global distribution, contributing to more than 80 % of global malaria cases. Even though 
P. vivax infection is known as benign malaria in many cases, however the surge of drug 
resistance strain, which is potentially fatal has weaken the malaria treatment and control 
(Mueller, et al., 2009). Malaria cause by P. malariae and P. ovale infections are 
relatively rare, account for less than 5 % of malaria cases worldwide and have mild 
disease outcomes (Collins & Jeffery, 2005; Collins & Jeffery, 2007). 
Malaria is actually a curable disease; however disease can become severe if left 
untreated, especially in P. falciparum and P. knowlesi infections. Therefore, the 
accuracy of malaria diagnosis plays a crucial role for the institution of effectiveness of 
treatment management and malaria control. Generally, cost effectiveness, rapidity of 
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test results, ease of diagnostic procedure and result interpretations, as well as personnel 
training are the major considerations in malaria diagnosis. Currently, available malaria 
diagnostic tools mainly targeting erythrocytic cycle, including microscopic 
discriminations, immunochromatographic tests and molecular PCR assays.  
Despite low sensitivity and specificity, especially in the diagnosis of low 
parasitemia and mixed infections, conventional light microscopic examination of 
Giemsa stained thin/thick blood smears remain the gold standard procedure in the 
routine diagnosis of malaria. Microscopic examination is based on the morphology 
appearances of asexual Plasmodium species in the blood circulation and the diagnostic 
accuracy greatly depends on the experience and skill of microscopists. Overall, 
microscopy approach is only accurate when the parasitemia exceed 50 parasites/µl of 
blood sample; however, it enables the identification and quantification of Plasmodium 
parasites, both of which are significant in accessing the disease severity and monitoring 
the prescription of adequate therapy. Generally, confusion due to morphological 
similarities of blood stages of some Plasmodium species to others is one of the major 
challenges in microscopic identification. For instance, P. knowlesi is undistinguished 
from P. falciparum in early blood ring stage and P. malariae in other stages. 
Immunochromatographic dipstick tests (ICTs) or rather rapid diagnostic tests 
(RDTs) that are based on detection of Plasmodium antigen are adjuncts to microscopic 
examination and widely used in many diagnostic laboratories. This rapid malaria 
detection assay requires only 15 to 20 minutes to obtain results and demands less 
technical interpretation. Nonetheless, factors such as low sensitivity (required 100 to 
200 parasites/µl), variable detection thresholds and field stability, and most importantly 
the inability to distinguish the parasites at species level limit the usage of available 
commercial kits in some cases.  
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The advent of molecular tools such as PCR based diagnostics in many cases has 
shown the highest specificity and sensitivity in the identification of all five human 
malaria parasites. Overall, PCR is able to detect parasites at low titer of 5 parasites/µl of 
blood and most recent study attained a detection limit of 0.5 parasites/µl in the latent 
and recrudescence stage of malaria disease (malERA Consultative Group on Diagnoses 
and Diagnostics, 2011). Conventional PCR assays (i.e., nested PCR, semi-nested PCR, 
and multiplex PCR), real-time or quantitative PCR (qPCR) assays, and loop-mediated 
isothermal amplification (LAMP) assay have been developed to identify and 
differentiate malaria parasites up to species levels. In general, nested PCR (Singh, et al., 
1999; Singh, et al., 2004; Snounou, et al., 1993) has been considered the molecular gold 
standard for malaria detection. If compared with microscopy and RDTs, conventional 
PCR-based assays certainly are more time-consuming, especially in semi-nested PCR 
that require at least two PCRs (6 hours) and nested PCR that require six PCR 
procedures (20 hours) to test for the five human parasites up to species levels. To date, 
the published descriptions of semi-nested PCR (Rubio, et al., 1999) and single-step 
multiplex PCR (Kho, et al., 2003; Padley, et al., 2003; Patsoula, et al., 2003) could only 
differentiate from two (mainly focused on P. falciparum and P. vivax) to four species 
(excluding P. knowlesi). On the other hand, qPCR is a rapid assay and the result is 
obtained in a more straightforward manner based on completion of amplification 
without any downstream analysis through gel electrophoresis (Mangold, et al., 2005; 
Perandin, et al., 2004; Rougemont, et al., 2004; Safeukui, et al., 2008). The qPCR assay 
also allows parasite quantification, which cannot be achieved by conventional PCR 
approaches; however, the cost and reagents and equipment are much higher than for any 
conventional PCR assays. More recently, LAMP assay has claimed to be the most 
simple and less technically demanding approach that involves an isothermal 
amplification of targeted DNA for identification of each Plasmodium species (Han, et 
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al., 2007). LAMP results can be either detected by agarose gel electrophoresis or 
turbidity assessment by naked eye or a turbidimeter. However, the result obtained by 
using LAMP is qualitative and there is no specific indicator to determine whether it is a 
true positive or false positive result due to contamination. Furthermore, large scale 
screening using LAMP is still under assessment and the development of multiplex 
LAMP that involves many primers could also be challenging.  
To overcome these limitations and challenges, therefore the present study aimed 
to develop and establish a straightforward single-step multiplex PCR based detection 
assay, which enables the simultaneous identification and differentiation of all five 
human Plasmodium parasites in a single tube reaction. This is an attractive option for 
routine malaria diagnosis, since mixed infections can be detected in a single round PCR. 
Furthermore, multiplex PCR could shorten the time and cut down the costs for reagents 
and disposable consumables in molecular diagnosis of human malaria.  
Besides the urgency to develop a diagnostic method for the detection of all five 
human Plasmodium species, it is also important to study the protein that appears to be 
essential during the invasion of host cells by the malaria parasite. Plasmodium is an 
obligate intracellular parasite and the appearance of parasite in merozoite form is the 
most infective stage during human infection. The survivors of these parasites rely on the 
ability of these parasites in host cell penetration and replication. Nowadays, a number of 
proteins have been implicated in the invasion process, but their precise functions remain 
unknown in most cases. Apical membrane antigen (AMA1) is one the most well 
characterized malaria surface antigen that is crucial for host cell invasion. AMA1 is type 
I integral membrane protein, build up of a prosequence domain, an ectodomain 
(ectoplasmic region), a single transmembrane domain, and a small C-terminal 
cytoplasmic domain. Ectoplasmic region of AMA1 comprises of 16 invariant cysteine 
residues that are cross linked and folded into eight pairs of conserved disulfide bonds, 
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which are dispersed and defined the ectodomain into three distinct subdomains, i.e., 
domain I (DI), domain II (DII), and domain III (DIII). The disulfide bonds are essential 
for structure stability and functionality of the AMA1 protein (Hodder, et al., 1996). 
Despite AMA1 being a low abundance malaria surface antigen; it represents the most 
prominent immunogen that is able to stimulate strong immune response in both human 
and animal models, therefore widely regarded as a potent target of antimalarial drugs 
and pivotal malaria vaccine candidate (Macraild, et al., 2011; Remarque, et al., 2008). 
AMA1 is expressed abundantly in sporozoites (pre-erythrocytic stage) as well as 
merozoites at the end of the tissue schizogony (pre-erythrocytic stage) and erythrocytic 
schizogony (erythrocytic stage), therefore offers the potential for the development of 
therapeutics or vaccines acting against these two critical stages. Numerous studies have 
confirmed that monoclonal and polyclonal antibodies against AMA1 block the entry of 
parasite into host cell in vitro or protect against blood stage growth in vivo. Besides the 
anti-AMA1 antibodies, there is evidence of peptides derived from or with affinity for 
AMA1 of P. falciparum that can also inhibit invasion of erythrocyte by parasite in vitro.  
Although AMA1 is long thought to be a target of natural immune response that 
can inhibit invasion, little is known about the molecular mechanisms by which 
immunologically relevant portions of AMA1 could facilitate the invasion process, 
therefore, characterization and identification of peptide ligands as well as ligand- or 
receptor-binding sites that specifically interact with, and block the function of AMA1 is 
essentially important.  
Phage display technique is a cost-effective and powerful tool that is widely 
applied in the study of protein-protein interactions. Studies in protein-protein 
interactions might contribute to some exploration of biological/molecular function of 
plasmodia proteins thus enhance the development of novel therapeutics. The phage 
display library is an assembly of peptides library which consists of billion of short and 
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variable amino acid sequences displayed on the surfaces of bacteriophage M13. The 
peptide library allows the selection of peptides, which have high binding affinity to the 
immobilized target protein. Previous phage display studies on AMA1 protein are mainly 
focused on P. falciparum, there is a vital need to include studies based on two other 
significant Plasmodium species, i.e., P. vivax and P. knowlesi.  
The present study was aimed to investigate and identify the possible binding 
peptides, which are highly bond to recombinant AMA1 ectodomain proteins of P. 
knowlesi (rPkAMA1) and P. vivax (rPvAMA1) using a phage display random 
dodecapeptide library. The study was initiated with heterologous recombinant protein 
expression using E. coli to produce sufficient starting material for latter used in 
biopanning against rPkAMA1 and rPvAMA1 in phage display study. The correct 
folding of eight disulfide bonds within AMA1 ectodmain has been shown to be crucial 
for its immunological activity. Irreversibly reduced AMA1 is not recognized by 
antibodies raised against the native AMA1. Furthermore, immunization with reduced 
and alkylated AMA1 was failed to induce protective immune response, therefore the 
present study also include the protein renaturation step that is aimed to restore the 
function of rPkAMA1 and rPvAMA1, which were expressed in forms of insoluble 
inclusion body and purified under denatured conditions.  
 
1.2 Objectives 
1. To develop a more accurate, species-sensitive/species-specific, cost-effective, as 
well as rapid single step multiplex PCR method for the diagnosis of five main 
human malaria parasites, P. falciparum, P. vivax, P. malariae, P. ovale (P. ovale 
curtisi and P. ovale wallikeri), and P. knowlesi.  
2. To identify the binding peptides for refolded recombinant apical membrane antigen 
1 (AMA1) ectodomain of P. knowlesi (rPkAMA1) and P. vivax (rPvAMA1).
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CHAPTER TWO: LITERATURE REVIEW 
The global impact of malaria, a parasitic disease transmitted through the bite of 
an infective female Anopheles species mosquito is still serious. Malaria in humans is 
caused by intracellular protozoa of the genus Plasmodium. The known causative agents 
of human malaria include Plasmodium vivax, Plasmodium falciparum, Plasmodium 
malariae, Plasmodium ovale (exist in two forms, i.e., P. ovale curtisi and P. ovale 
wallikeri), and most recently Plasmodium knowlesi which is a zoonotic species. 
 
2.1 Malaria disease 
Malaria remains one of the major killers of humankind worldwide and threatens 
the lives of more than one-third of the world’s population, provoking public health 
challenges in global malaria control. Each year, there are at least 250-600 million 
clinical cases of malaria being reported worldwide with more than a million (1.5-2.7 
million) deaths, occurring mostly among African children (Greenwood, Bojang, Whitty, 
& Targett, 2005; Wellems, Hayton, & Fairhurst, 2009). Globally, malaria ranks as the 
fifth cause of death from infectious diseases, after respiratory infections, diarrhoeal 
diseases, HIV/AIDS, and tuberculosis; while in Africa, malaria is the second leading 
cause of death after HIV/AIDS (WHO, 2013a). Besides that, malaria is re-emerging as 
the first infectious killer and it is the number one priority tropical disease of the WHO 
(Malaria Site, 2012). 
The latest malaria statistics reported that almost half of the world’s population 
(approximately 3.3 billion people) lives in malaria-endemic areas including 104 
countries and territories of the tropical and subtropical areas, encompassing Africa 
region; Amazon, Central, and Southern of Americas; Mediterranean region; Central, 
South, and Southeast Asia; as well as Pacific region (WHO, 2012).  
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Generally, the transmission of malaria is more intense in warmer regions closer 
to the equator, such as in areas of the Americas, many parts of Asia, and much of Africa. 
The prevalence of malaria in tropical regions is due to the significant amounts of rainfall 
with consistent high temperatures and humidity, along with stagnant waters, which 
allow the Anopheles mosquito to thrive and breed. In contrast, malaria transmission is 
unstable with a low incidence rate (limited cases) at the high altitude areas over 
elevations of 1,500 m, desert areas (excluding oases), as well as during dry and colder 
seasons even in some parts of malaria-endemic countries. Figure 2.1 shows the 
geographic distribution of malaria worldwide in the year 2010 (Arguin & Mali, 2012). 
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2.2 Vector of transmission 
Female Anopheles mosquitoes are the exclusive vector of malaria disease. 
Generally, malaria parasites are transmitted from human to human through the bites of 
infected female Anopheles mosquito, typically at night time. Currently, there are 
approximately 530 Anopheles species found around the world, only 70 to 80 Anopheles 
species transmit malaria in nature, with diverse breeding and feeding habits, and thus 
result in vast disease spectra in different population target groups and epidemiological 
settings. The intensity of malaria transmission depends on factors related to the vector, 
the parasite, the human host, and the environment [Alonso, et al., 2011; Centers for 
Disease Control and Prevention (CDC), 2012; Choochote & Saeung, 2013; Manguin, 
Bangs, Pothikasikorn, & Chareonviriyaphap, 2010; Manguin, Garros, Dusfour, Harbach, 
& Coosemans, 2008]. 
The parasites require the mosquito host to complete their sexually development. 
Once a mosquito is infected, it is infected for life and continues to transmit infections, 
therefore the lifespan of mosquito also play a crucial role in disease transmission. Only 
female mosquitoes feed on blood as they require high protein diets in order to reproduce 
rafts of eggs. Even though Anopheles mosquitoes breed in water, each of the Anopheles 
species has its own breeding preference, for example some prefer shallow collections of 
fresh water, such as puddles, paddy fields, tire tracks, as well as irrigation water. The 
areas of distribution also differ, for instance, Anopheles gambiae is the major vector in 
Africa that can breed in diverse habitats, Anopheles fluviatilis and Anopheles minimus 
are found in the foothill regions, whereas Anopheles philippinensis and Anopheles 
culicifacies are found in the plains, Anopheles stephensi and Anopheles sundaicus are 
found in the coastal regions. Species like An. stephensi are highly adaptable and are 
found to be potent vectors of human malaria (CDC, 2012; WHO, 2013a).  
CHAPTER TWO: LITERATURE REVIEW 
 
 
 
12 
Generally, Anopheles mosquitoes are found worldwide except Antarctica. 
Environmental factors including climate conditions, such as temperature, humidity, 
rainfall pattern, etc. play a larger role in malaria transmission, since wet, tropical areas 
are conductive for mosquito breeding. For instance, in many places, transmission of 
malaria is seasonal, surging during and just after the rainy season. Besides that, the 
urbanization and land use might also bring changes to the ecosystem, which contribute 
to the changing pattern of malaria transmission (Gallup & Sachs, 2001; WHO, 2013a).  
Vector control measures, such as the use of insecticides and larva controls play a 
critical role in malarial elimination and eradication, however some of the mosquitoes 
may shift resistance to that insecticide after prolong exposure over several generations, 
thus impairing the successful in vector controls (Alonso, et al., 2011). 
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2.3 Global impacts of malaria  
In 2010, there were an estimated 219 million of malaria cases (with an 
uncertainty range of 154 million to 289 million) and 660,000 malaria deaths worldwide 
(with an uncertainty range of 490,000 to 836,000) being reported, and the WHO main 
focal regions include Africa, Southeast Asia, and Eastern Mediterranean regions (WHO, 
2012). Generally, people living in the poorest countries are more vulnerable to malaria. 
There were approximately 80 % of global malaria cases and more than 90 % deaths that 
have occurred in the African region (between the years 2008 to 2010). This was 
followed by Southeast Asia region that attributed to approximately 14 % of clinical 
cases and 6 % of global deaths, as well as Eastern Mediterranean region with 
approximately 5 % of clinical cases and 2 % of deaths (Table 2.1).  
 
Table 2.1: Reported malarial cases and deaths in the year 2008, 2009, and 2010 (WHO, 
2012). 
 2008 2009 2010 
World population (in billions) 6.7 6.8 6.9 
M
a
la
ri
a
 c
a
se
s 
(i
n
 m
il
li
o
n
s)
 
World 225 222 219 
Africa 182 (81 %) 179 (81 %) 174 (79 %) 
Southeast Asia 29 (13 %) 30 (14 %) 32 (15 %) 
Eastern Mediterranean 11 (5 %) 11 (5 %) 10 (5 %) 
Western Pacific  2 (< 1 %) 2 (< 1 %) 2 (< 1 %) 
Americas 1 (< 1 %) 2 (< 1 %) 1 (< 1 %) 
M
a
la
ri
a
 d
ea
th
s 
World 711,000  691,000 660,000  
Africa 654,000 (92 %)  630,000 (91 %) 596,000 (90 %) 
Southeast Asia 37,000 (5 %) 39,000 (6 %) 43,000 (7 %) 
Eastern Mediterranean 15,000 (2 %) 16,000 (2 %) 15,000 (2 %) 
Western Pacific 4,200 (< 1 %) 4,700 (< 1 %) 4,000 (< 1 %) 
Americas 1,000 (< 1 %) 1,200 (< 1 %) 1,100 (< 1 %) 
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Young children, pregnant women, and immunocompromised individual, i.e., 
HIV/AIDS carrier are the three most vulnerable groups to malaria (Shetty, 2012). Of 
these malaria-related deaths, overwhelming majority are children under 5 years of age 
because their immune systems have not developed enough to fend off the parasites 
attack (Figure 2.2). In 2010, approximately 86 % deaths globally were found among 
child < 5 years of age, making this disease one of the major causes of infant and 
juvenile mortality (WHO, 2012). Malaria kills one to two African child in every minute 
(Shetty, 2012). For those children who survive, malaria also drains vital nutrients from 
children, impairing their physical and intellectual developments. Malarial sickness is 
also one of the principal reasons for poor school attendance (Girard, Reed, Friede, & 
Kieny, 2007; Rogerson & Carter, 2008).  
Pregnant women living in malaria endemic areas are 4-times more likely than 
non-pregnant women to get severe malaria and twice as likely to die of disease because 
her immune system is partially suppressed during pregnancy (Shetty, 2012). Besides, 
malaria attack during pregnancy can be more severe and they have an increase risk of 
serious pregnancy outcomes, including prematurity, miscarriage, stillbirth, and death. 
Infected mother can transmit malaria to her infant before or during delivery. There were 
an estimated 10,000 maternal deaths and up to 200,000 newborn deaths annually due to 
malaria during pregnancy (Desai, et al., 2007; Steketee, Nahlen, Parise, & Menendez, 
2001).  
HIV infection weakens the immune system, thus making people living with HIV 
more vulnerable to malaria. Malaria infection causes HIV viral loads to shoot up, which 
could increase its transmission (Shetty, 2012).  
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Malaria can also be transmitted through a blood transfusion although this is very 
rare. The asexual parasites are directly inoculated into the blood without pre-
erythrocytic replication, therefore has a shorter incubation period and relapses do not 
occur (Chauhan, Negi, Verma, & Thakur, 2009).  
The fact that the local community had reduced natural immunity to malaria may 
also have contributed to the high mortality rate. For instance, non-immunized travelers, 
refugees, displaced persons, immigrants, and laborers from malaria-free areas are more 
likely to become very sick and die when they get infected (Erdman & Kain, 2008). In 
addition, mortality rates were high as the area has poor health infrastructures and 
services. Poor people and indigenous living in rural areas, who lack the knowledge, 
money, or access to health care are at greater risk of getting this disease.  
Malaria is commonly associated with poverty and may also be a major hindrance 
to the social-economic development. Malaria not only causes illness and lives lost, but 
also a great drain on many national economies. The breakdown of the public health 
system and high expenditure on health care and malarial treatment cause the 
consequence of poverty of a community or country (Sachs & Malaney, 2002). People 
with malaria are less productive resulting in loss of income due to the sickness, and thus 
cause reduction in economic output (Greenwood, et al., 2005; Wellems, et al., 2009). 
Other economic impacts include loss of foreign investment and tourism. According to 
WHO, the annual costs (direct or indirect) related to malaria in Africa are estimated to 
be more than US$ 12 billion every year (Shetty, 2012). 
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2.3.1 Global distribution of Plasmodium species 
Plasmodium is a parasite which is widely distributed all over the world. Each of 
the Plasmodium species has a defined area of endemicity, although geographic overlap 
is common. Plasmodium species causing human malaria are generally restricted to 
tropical and subtropical regions. However, global warming and population migrations 
do have a bearing on the distribution of these parasites. Table 2.2 and Table 2.3 show 
the global distribution of five human Plasmodium species. 
 
Table 2.2: Geographical distribution of the different species of Plasmodium in the 
tropics. 
 P.  falciparum P. vivax P. ovale P. malariae P. knowlesi 
North Africa frequent predominant absent frequent none 
West Africa predominant very rare frequent rare none 
Central Africa predominant very rare rare frequent none 
East Africa predominant rare rare frequent none 
Indian Ocean predominant rare rare frequent none 
Central 
America 
frequent frequent absent rare none 
South 
America 
frequent predominant absent rare none 
Indian 
subcontinent 
frequent predominant very rare rare none 
Southeast 
Asia 
predominant frequent rare rare frequent 
Pacific Islands frequent frequent rare rare none 
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Table 2.3: Global distribution of malaria cases by species. 
Plasmodium 
species 
Global distribution References 
P. vivax * 
Contribution to > 80 % of global cases and widespread 
throughout the subtropical and temperate regions with 
low rate of infection in West and Central Africa (high 
prevalence of Duffy negativity population that 
naturally resistant to P. vivax infection). 
Mueller, et 
al., 2009 
P. falciparum* 
Contributed to ~ 15 % global malaria cases and > 90 % 
global deaths. Concentrated in tropical and subtropical 
region and most prevalent at Africa region (~ 60 % of 
the global total falciparum malaria) with the highest 
burden in Nigeria and Democratic Republic of Congo 
as well as 19 countries of Central, South, and East Asia 
(39 %) with the highest burden in India and Myanmar. 
Hay, et al., 
2009 
P. malariae 
Restricted to subtropical area. Most common in sub-
Saharan Africa and Southwest Pacific. Less frequently 
encountered in Asia, Middle East, Central and South 
America.  
Collins & 
Jeffery, 
2007  
P. ovale curtisi 
(classic type) 
P. ovale 
wallikeri 
(variant type) 
Distributed in sub-Saharan Africa, South-East Asia 
(Philippines, Cambodia, Myanmar, Vietnam, and 
Thailand), Middle East, India subcontinent, Papua New 
Guinea, Irian Jaya, and East Timor in Indonesia. 
Collins & 
Jeffery, 
2005; 
Sutherland, 
et al., 2010 
P. knowlesi 
Widespread in forested areas of Southeast Asia and 
most prevalent in Malaysia. Cases also have been 
reported in Philippines, Thailand, Indonesia, Vietnam, 
Myanmar, and Singapore. 
Singh, et 
al., 2004; 
Antinori, 
Galimberti, 
Milazzo, & 
Corbellino, 
2013 
 
* Drug resistant strains present in most species of endemic regions (Karyana, et al., 
2008; Tjitra, et al., 2008).  
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Generally, P. vivax infections have the widest global distribution and prevalent 
in subtropical and temperate regions, with 2.5 billion people at risk and 80-300 million 
cases reported annually (Mueller, et al., 2009). Plasmodium vivax is more tolerant to 
lower ambient temperature, thus the transmission is not restricted to cooler regions 
(Carlton, et al., 2008). Plasmodium falciparum is the second most prevalent, but the 
most lethal species, being responsible for more than 90 % of malaria mortality annually. 
Plasmodium falciparum infections are concentrated in the tropical and subtropical 
regions such as Africa, Central and Southeast Asia, and America (Hay, et al., 2009). 
Infections caused by other species are relatively scanty; with P. malariae being limited 
to subtropical area (Collins & Jeffery, 2007) as well as P. ovale being restricted to Sub-
Saharan Africa (Collins & Jeffery, 2005). 
The newcomer fifth human malaria parasite, P. knowlesi, which formerly cause 
malaria only in macaques, is now widespread in forested areas of Southeast Asia 
countries (White, 2008). So far, human P. knowlesi infections have been described in 
high numbers only in Malaysia with a great majority of cases originating from Malaysia 
Borneo, i.e., Sabah and Sarawak states (Barber, et al., 2011; Cox-Singh, et al., 2008; 
Cox-Singh & Singh, 2008; Daneshvar, et al., 2009; Singh, et al., 2004; William, et al., 
2011). Numerous cases have also been described in Peninsular Malaysia (Cox-Singh, et 
al., 2008; Lee, Adeeba, & Freigang, 2010; Vythilingam, et al., 2008). Since the 
availability of P. knowlesi species-specific nested PCR in the year 2004 (Singh, et al., 
2004), several P. knowlesi cases have been reported in other Southeast Asian countries, 
including Thailand (Jongwutiwes, Putaporntip, Iwasaki, Sata, & Kanbara, 2004; 
Putaporntip, et al., 2009; Sermwittayawong, Singh, Nishibuchi, Sawangjaroen, & 
Vuddhakul, 2012), Myanmar (Jiang, et al., 2010; Zhu, Li, & Zheng, 2006), Indonesia 
(Figtree, et al., 2010; Sulistyaningsih, Fitri, Loscher, & Berens-Riha, 2010), Philippines 
(Luchavez, et al., 2008), Singapore (Berry, et al., 2011; Jeslyn, et al., 2011; Ng, et al., 
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2008; Ong, Lee, Koh, Ooi, & Tambyah, 2009), and Vietnam (Van den Eede, et al., 2009; 
Van den Eede, et al., 2010) (Figure 2.3A); only limited traveler’s cases were reported in 
Europe countries (Berry, et al., 2011; Bronner, Divis, Farnert, & Singh, 2009; Chin, 
Contacos, Coatney, & Kimball, 1965; Ennis, et al., 2009; Hoosen & Shaw, 2011; 
Kantele, Marti, Felger, Muller, & Jokiranta, 2008; Ta, et al., 2010; Van Hellemond, et 
al., 2009), Taiwan (Kuo, Chiang, Chan, Tsai, & Ji, 2009; Link, et al., 2012), and Japan 
(Tanizaki, et al., 2013) after returning from forested areas of Southeast Asia (Figure 
2.3B).  
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Figure 2.3: Distribution of human P. knowlesi cases. (A) Human P. knowlesi cases have 
been reported nearly in all countries in Southeast Asia (adapted from Singh, 2011). (B) 
Traveller’s cases of P. knowlesi, whereby red dot indicate where travellers probably 
acquired their infection, while flags indicate the countries where infection was 
diagnosed (adapted from Antinori, et al., 2013). 
A 
B 
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2.3.2 Malaria in Malaysia  
Malaysia is situated in the hot, humid equatorial region and therefore is 
receptive and vulnerable to the transmission of malaria. Malaysia consists of West 
Malaysia or known as Peninsular Malaysia as well as East Malaysia separated by the 
South China Sea. East Malaysia also known as Malaysian Borneo located on the island 
of Borneo consists of the two Malaysian states, Sabah and Sarawak. East Malaysia is 
less populated and less developed compared to West Malaysia and its landmass is larger 
and mainly surrounded by natural forested areas.  
Malaysia has been characterized as in the pre-elimination stage by WHO, with 
only 3 % of the population at risk of malaria. The target to achieve elimination of 
malaria in Peninsular Malaysia is by 2015 and Malaysian Borneo by 2020 (Ministry of 
Health Malaysia, 2012; WHO, 2012). 
According to the Ministry of Health Malaysia and Malaria World Report 2012, 
the reported malaria cases in Malaysia were 7,390 in 2008 but decreased to 7,010 cases 
in 2009 and 6,650 in 2010. The numbers of malaria deaths have remained steady at 
between 20-40 deaths per year over the last decade. There were slight increases in 
malaria deaths from 26 cases in year 2009 to 33 cases in year 2010 (Ministry of Health 
Malaysia, 2012; WHO, 2012). 
In Malaysia, the majority of malaria cases were reported in Sabah state, followed 
by Sarawak state, and the rest were distributed in Peninsular Malaysia with a majority 
of cases in the central, southeastern and northern coastal regions (Kheong, 2010). 
Table 2.4 shows the reported malaria cases and deaths in years 2008 to 2010, 
whereas Figure 2.4 indicates the distribution of cases in Malaysia in year 2009.  
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Table 2.4: Reported malaria cases and deaths in Malaysia, 2008-2010. 
Malaysia 2008 2009 2010 
Population (million) 27.0 27.5 28.9 
Total malaria cases 7,390 7,010 6,650 
Malaria deaths 30 26 33 
C
a
se
s 
d
is
tr
ib
u
ti
o
n
 
Peninsular 1,342 (18.2 %) 1,178 (16.8 %) N/A (20 %) 
Sarawak 1,909 (25.8 %) 1,823 (26.0 %) N/A (22 %) 
Sabah 4,135 (56.0 %) 4,009 (57.2 %) N/A (58 %) 
P
re
v
a
le
n
ce
 b
y
 s
p
ec
ie
s 
(%
) 
P. falciparum 31 27 25 
P. vivax 51 48 57 
P. ovale - - - 
P. malariae 6 8 7 
P. knowlesi 8 13 8 
Mixed infection 4 4 3 
N/A indicates not available. 
 
 
Figure 2.4: Distribution of malaria cases in Malaysia in year 2009 (adapted from 
Kheong, 2010). 
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The pie charts in Figure 2.4 show the classification of the cases in year 2009. 
Malaria cases were commonly reported in rural areas, which have high density of 
indigenous tribal groups, who live within the remote forested or forest-fringe areas. 
Other high-risk groups include outdoor laborers such as agriculture, logging camp, and 
jungle workers. These occupations may predispose them to high risk of exposure to 
malaria vector. However, with regards to malaria cases in urban areas, it has been noted 
that malaria imported by immigrant and foreign workers from endemic countries have 
surged in urban district, i.e., Selangor state (Lee, et al., 2010; Masitah, Aini, & AyuSaid, 
2008). In 2010, 12 % of malaria cases are attributed to the imported cases from malaria-
endemic neighboring countries, primarily from Indonesian and Filipino workers, while 
the multi-drug resistance infections are from Indonesia, Myanmar, and Thailand 
(Ministry of Health Malaysia, 2012; Shetty, 2012).  
With regards to malaria cases by species in Malaysia, P. vivax remains the most 
common cause of infection, followed by P. falciparum, and P. knowlesi infections 
(Table 2.4). Even though P. knowlesi ranked the third most common infectious agent, 
the incidence rate is relatively high in Malaysian Borneo if compared to Peninsular 
Malaysia (Kantele & Jokiranta, 2011) (Figure 2.5). Plasmodium knowlesi can cause 
severe malaria complications with a rate of 6 to 9 % (e.g., respiratory distress, acute 
renal impairment, shock, and hyperbilirubinemia, etc.) and with a case fatality rate of 3 % 
(Antinori, et al., 2013). Severe disease cause by P. knowlesi infection has been reported 
in Sarawak (Cox-Singh, et al., 2008; Cox-Singh, et al., 2010; Cox-Singh & Singh, 2008), 
Sabah (Barber, et al., 2011; Cox-Singh, et al., 2010; Joveen-Neoh, Chong, Wong, & 
Lau, 2011; Rajahram, et al., 2012; William, et al., 2011), and Peninsular Malaysia (Cox-
Singh, et al., 2008; Lee, et al., 2010; Vythilingam, et al., 2008), including 19 fatal cases, 
in where 12 knowlesi deaths were in Sabah state and seven in Sarawak state (Cox-Singh, 
et al., 2008; Cox-Singh, et al., 2010; Daneshvar, et al., 2009; Rajahram, et al., 2012; 
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William, et al., 2011).  
Cases with P. malariae infection as well as mixed infections are occasionally 
reported, whereas P. ovale infection is very rare in Malaysia (Ministry of Health 
Malaysia, 2012). However, recently the first imported case of P. ovale from a 20-year-
old Nigerian male student was reported in Malaysia (Lim, et al., 2010). Figure 2.5 show 
the distribution of the three most common Plasmodium species in Malaysia. 
 
 
Figure 2.5: The distributions of three most common infectious species in Malaysia, 
2010 (adapted from Ministry of Health Malaysia, 2012; Rundi, 2011). 
CHAPTER TWO: LITERATURE REVIEW 
 
 
 
26 
2.4 Biology of Plasmodium species 
Malaria is an infectious disease caused by protozoan single-celled (unicellular 
eukaryotic) parasite from the genus called Plasmodium. There are over 200 different 
species of Plasmodium that produce disease in non-human primates, rodents, reptiles, 
and birds, in addition to humans. Thus far, about 30 species naturally infect non-human 
primates (monkeys, great apes, and others), whilst only five identified species, i.e., P. 
vivax, P. falciparum, P. malariae, P. ovele, and P. knowlesi cause malaria in humans. 
The most recent evidence indicates that P. ovale is composed of two subspecies, i.e., P. 
ovale curtisi (classic type) and P. ovale wallikeri (variant type) (Sutherland, et al., 2010). 
 
2.4.1 Taxonomic classification of Plasmodium species  
In 1885, the genus Plasmodium was first created by Ettore Machiafava and 
Angelo Celli. They used unstained blood smears and the new Zeiss oil-immersion 
lenses to describe a blood-borne parasites first observed by Charles Louis Alphonse 
Laveran in 1880 from blood of a malaria victim. Marchiafava and Celli confirmed that, 
the parasite can inhibit erythrocytes and cause an infectious disease called malaria. The 
nomenclature of Plasmodium is derived due to these protozoa took the form of a 
plasmodium, a cell with multiple nuclei and an amorphous shape. After that, Ronald 
Ross identified the mosquito vector in 1897, whereas Henry Shortt and Cyril Garnham 
identified the hepatic stages in 1947 (McFadden, 2012).  
Plasmodium belongs to the family Plasmodiidae, order Haemosporidia and 
phylum Apicomplexa. Unusual characteristics of this organism in comparison to general 
eukaryotes include the presence of rhoptry, micronemes, and polar rings near the apical 
end. Figure 2.6 is a general phylogenetic tree of Plasmodium species and Table 2.5 
shows the scientific classification of the five human protozoa of the genus Plasmodium. 
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Figure 2.6: Phylogenetic tree of Plasmodium species (obtained from 
http://bioweb.uwlax.edu/bio203/s2007/augustin_laur/family_tree.htm). 
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Table 2.5: Scientific classification of human protozoa of the genus Plasmodium 
(adapted from Antinori, Galimberti, Milazzo, & Corbellino, 2012). 
Scientific classification Reason of classification 
Domain Eukaryota Cellular structure containing organelle. 
Kingdom Chromalveolata 
Contains protists (cellular organism without 
specialized tissue). 
Superphylum Alveolata 
Phylum Apicomplexa 
Contains organisms that have no individual 
form of motion, except for their gametes. 
(cells with cluster of organelles known as 
apical complex). 
Class Aconoidasida 
Have a tip at the end of their form which 
allows them to enter/penetrating the other 
organisms/species. 
Order Haemosporida Haemosporidia literally means blood spores. 
All members of this phylum are parasitic in 
vertebrate hosts and share similar life cycle. Sub-order Haemosporidiidea 
Family Plasmodiidae 
Exhibits asexual reproduction in a vertebrate 
host and sexual reproduction in a definitive 
host (a mosquito, in the case of the 
Plasmodium species that infect all mammals, 
including humans). 
Genus 
Plasmodium; 
Laverania 
Laverania was the old generic name for 
malaria causing Haemosporidia protozoa. 
Species 
P. falciparum Malignant malaria 
P. vivax 
Plasmodium vivax is divided into two 
subtypes, a dominant form, VK210 and a 
variant form, VK247. This division is 
dependent on the amino acid composition of 
the circumsporozoite (CS) protein (Kim, et al., 
2010).  
P. malariae Benign malaria 
P. ovale 
P. ovale has been found to exist in two forms, 
P. ovale curtisi (classic type) and P. ovale 
wallikeri (variant type) (Sutherland, et al., 
2011). 
P. knowlesi Simian malaria 
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2.4.2 General life cycle 
The life cycle of Plasmodium species is extraordinarily complex and specific for 
the particular parasite species (Florens, et al., 2002). In general, the Plasmodium 
parasites live part of its life in human and part in female mosquitoes (exclusively of the 
genus Anopheles) (Figure 2.7). Infected female Anopheles plays a role as vector in 
human-human transmission. Basically, it can be distinguished into three main stage-
cycles, i.e., pre-erythrocytic and erythrocytic cycles in human host, and sporogonic 
cycle in mosquito.  
In human host, infection starts after the inoculation of few sporozoites into the 
blood stream during the blood meal of an infected mosquito. Within minutes after 
entering the blood circulation, sporozoites are able to travel quickly to liver and invade 
hepatocytes, whereby they replicate and developed into liver schizonts. The liver stage 
development also known as pre-erythrocytic or tissue schizogony. The sporozoite will 
initially undergo the early liver stage to form trophozoite and then mature into tissue 
schizont during the next 5-15 days. For some instance, the sporozoites of P. vivax and P. 
ovale will keep dormancy or persists in hepatocytes as hypnozoites, which may remain 
for years and are responsible for new attacks of the disease if re-activated; probably 
relapse is due to incomplete treatment. Basically, the rupture of tissue schizonts will 
subsequently release several thousands of infectious merozoites into blood stream, 
whereby they invade the red blood cells (RBCs) and thus initiating the erythrocytic 
cycle.  
In erythrocytic cycle, parasites can either undergo asexual multiplication 
(erythrocytic schizogony) or sexually differentiated into either macro- or micro-
gametocytes, which will eventually be ingested by female Anopheles mosquito during a 
blood meal. In general, the erythrocytic schizogony process is similar to the tissue 
schizogony in liver stage, whereby parasite also multiplies to form trophozoite within 
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RBC, and then mature into schizont that carries 6-36 infectious merozoites. The 
trophozoites mature over the course of 24-72 hours and the rupture of erythrocytes 
releases a new wave of merozoites that are able to infect other erythrocytes into the 
blood stream.  
The parasites multiplication in the midgut of the female Anopheles mosquito is 
known as sporogonic cycle, which starts after ingestion of both female and male 
gametocytes from human host during blood meal acquisition. The sporogonic cycle 
involves the fertilization of those mature microgametocyte and macrogametocyte to 
form zygote that may subsequently develop into ookinate and then multiply to form 
oocysts. Upon maturation, one oocyst contains thousands of sporozoites. The life cycle 
in mosquito ends up with the rupture of matured oocysts and release of infectious 
sporozoites into mosquito salivary gland (Greenwood, et al., 2005). The duration of the 
sexual life cycle takes about 9-16 days, being largely dependent on temperature 
conditions. Figure 2.7 shows the overview of the general life cycle of human 
Plasmodium species. 
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2.4.3 Characteristics of Plasmodium species infecting human 
Even though, five human Plasmodium parasites have to share a common life 
cycle in human host, however the details in life cycle, such as host erythrocyte cells 
preference, prepatent period, length of tissue and erythrocytic schizogony (including 
number of merozoites produced in each schizogony), as well as the presence or absence 
of the dormant liver stage are species dependent. Each species also differs with regard 
to their blood-stage morphology, clinical manifestations, and disease severity. 
In the human liver, the sporozoites undergo their replication becoming a tissue 
schizont that contains thousands of merozoites (can up to 40, 000 in P. falciparum), and 
the pre-erythrocytic schizogony takes a minimum maturation time of 6 days in P. 
falciparum and a maximum of 16 days in P. malariae. The rupture of mature tissue 
schizonts and releasing of merozoites will be subsequently followed by blood stage 
infection. For some exception, P. vivax and P. ovale are able to persist in liver as 
hypnozoites that are eventually responsible of the phenomenon of late relapse of 
infection. The period of time between sporozoites inoculation to the appearance of first 
merozoites in the peripheral blood, is known as prepatent period. The incubation period 
is somewhat longer because signs and symptoms do not appear until the parasitemia is 
sufficiently advanced.  
In contrast to tissue schizogony, erythrocytic trophozoites mature over the 
course of 24-72 hours to form blood schizonts, each composed of 6-36 merozoites 
(Table 2.6). The rupture of blood schizonts and releasing of infectious merozoites are 
responsible for the appearance of cycle similar to periodicity of febrile paroxysm, i.e., 
quotidian (fever spikes every 24 hours) for P. knowlesi, tertian (fever every 48 hours) 
for P. falciparum, P. vivax, and P. ovale, as well as quartan (fever every 72 hours) for P. 
malariae infections. Therefore, erythrocytic cycle always serves as an important 
diagnostic and therapeutic stage in malaria. 
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In general, P falciparum and P. knowlesi are able to infect RBCs of all ages, 
resulting in high levels of parasitemia (hyperparasitemia; more than 5 % RBCs infected 
or 250,000 parasites/µl). In contrast, P vivax and P ovale infect only young RBCs and 
thus cause a lower level of parasitemia (maximum parasitemia is 2 % or 100,000 
parasites/µl). Whereas, P. malariae infection is responsible of chronic low parasitemia 
(rarely exceeding 30,000 parasites/µl) due to the preference of the parasite to develop in 
older erythrocytes, reduced growth rate, i.e., long development cycles (pre-erythrocytic 
and erythrocytic cycles with 14-16 hours and 72 hours, respectively), and also the low 
number of merozoites produced per erythrocytic cycle (Gaur, Mayer, & Miller, 2004).  
The characteristics of infection with the five Plasmodium species have 
consequently influence the clinical outcome of malaria infection. Table 2.6 summarizes 
all the characteristics of infection with the five species of Plasmodium infecting human.  
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Table 2.6: Characteristics of infection with the five human Plasmodium species 
(modified from Antinori, et al., 2012). 
Characteristics P. falciparum P. vivax P. ovale P. malariae P. knowlesi 
Incubation period 
(days) 
7-14 12-17 10-14 15-18 N/A 
Pre-erythrocytic 
stage (days) 
5-7 6-8 9 14-16 8-9 
Prepatent period 
(days) 
9-10 11-13 12-20 15-16 9-12 
Erythrocytic cycle 
(hours) 
48 48 49-50 72 24 
Febrile paroxysm 
Tertian or sub-
tertian  
Tertian  Tertian Quartan Quotidian 
Erythrocytes 
preference 
All Reticulocytes Reticulocytes 
Mature 
erythrocytes 
All 
Merozoites/tissue 
schizogony 
40,000  > 10,000 15,000 2,000 N/A 
Merozoites/RBC 
schizogony 
8-24 12-24 6-14 
6-12   
(usually 8) 
10-16 
Parasitemia/µl 
Average 
 
20,000-500,000 
 
20,000 
 
9,000 
 
6,000 
 
600-10,000 
Maximum 2,000,000 100,000 30,000 20,000 236,000 
Febrile paroxysm 
(hours) 
16-36 or longer 8-12 8-12 8-10 8-12 
Symptom duration 
(untreated) 
2-3 weeks 3-8+ weeks 2-3 weeks 3-24 weeks N/A 
Maximum 6-17 months 5-8 years 12-20 months 20-50+ years N/A 
Severe malaria Yes Yes No No Yes 
Relapses from 
hypnozoites 
No Yes Yes No No 
Recurrences 
Yes (treatment 
failure) 
Yes 
(treatment 
failure) 
No 
Yes (can 
persists in 
blood up to 
30 years) 
Yes 
Initial clinical 
manifestations and 
severity 
Severe/life 
threatening/lethal/ 
maglinant/ 
fatalistic 
Moderate to 
severe 
Mild 
Mild/chronic/ 
asymptomatic  
Potentially 
life 
threatening 
Severe malaria Up to 24 % Up to 22 % Very rare Very rare 6-10 % 
Drug resistance Yes** Yes** No No No 
References - - 
Collins & 
Jeffery, 2005 
Collins & 
Jeffery, 2007 
Lee, Cox-
Singh, & 
Singh, 2009 
 
*    N/A indicates not available. 
**  Chloroquine resistance P. falciparum and P. vivax (Tjitra, et al., 2008). 
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2.4.4 Blood stage morphologies  
Each of the five causative agents of human malaria has a distinctive appearance 
under microscope observation. Two or more species can simultaneously infect a single 
person causing mixed infections. Complete knowledge of the morphological features of 
the different blood stages of the different Plasmodium species represents the essential 
basis of a correct laboratory diagnosis confirmation of malaria infection. Generally, 
Atlas of Human Malaria (Figure 2.8) is used as a major guideline for Plasmodium 
identification. Table 2.7 summarizes the appearances of parasitized RBCs as well as 
morphological features of five human Plasmodium species in stained thin blood films. 
 
 
Figure 2.8: Atlas of human malaria (illustrations adapted from Coatney, Collins, Warren, 
& Contacos, 1971). 
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Table 2.7: Morphological features of the parasitized red blood cell and five Plasmodium 
species in different stages (adapted from CDC, 2009). 
Species Stages Appearance of RBCs Appearance of Parasites 
P
. 
fa
lc
ip
a
ru
m
 
Ring 
Normal; multiple infection of 
RBC more common than in 
other species, Maurer’s clefts 
under certain staining conditions 
Delicate cytoplasm; 1 to 2 small chromatin dots; occasional 
appliqué (accollé) forms 
Trophozoite 
Normal; rarely, Maurer’s clefts 
under certain staining conditions 
Seldom seen in peripheral blood; compact cytoplasm; dark 
pigment 
Schizont 
Seldom seen in peripheral blood; contains 8-24 small 
merozotes; dark pigment, clumped in one mass 
Gametocyte Distorted by parasite 
Crescent or sausage shape; chromatin in a single mass 
(macrogametocyte) or diffuse (microgametocyte); dark 
pigment mass 
P
. 
vi
va
x
 
Ring 
Normal to 1.25×, round; 
occasionally fine Schüffner’s 
dots; multiple infection of RBC 
not uncommon 
Large cytoplasm with occasional pseudopods; large 
chromatin dot 
Trophozoite 
Enlarged 1.5-2×; may be 
distorted; fine Schüffner’s dots 
Large amoeboid cytoplasm; large chromatin; fine, yellowish-
brown pigment 
Schizont 
Large, may almost fill RBC; contains 12 to 24 merozoites; 
yellowish-brown, coalesced pigment 
Gametocyte 
Round to oval; compact; may almost fill RBC; chromatin 
compact, eccentric (macrogametocyte) or diffuse 
(microgametocyte); scattered brown pigment 
P
. 
o
va
le
 
Ring 
Normal to 1.25×, round to oval; 
occasionally fine Schüffner’s 
dots; occasionally fimbriated; 
multiple infection of RBC not 
uncommon 
Sturdy cytoplasm; large chromatin 
Trophozoite 
Normal to 1.25×; round to oval; 
some fimbriated; Schüffner’s 
dots 
Compact with large chromatin; dark-brown pigment 
Schizont 
Contains 6 to 14 merozoites with large nuclei, clustered 
around mass of dark-brown pigment 
Gametocyte 
Round to oval; compact; may almost fill RBC; chromatin 
compact, eccentric (macrogametocyte) or more diffuse 
(microgametocyte); scattered brown pigment 
P
. 
m
a
la
ri
a
e 
Ring Normal to 0.75× Sturdy cytoplasm; single large chromatin 
Trophozoite 
Normal to 0.75×; rarely, 
Ziemann’s stippling under 
certain staining conditions 
Compact cytoplasm; large chromatin; occasional band forms; 
coarse, dark-brown pigment 
Schizont 
Contains 6 to12 (usually 8) merozoites with large nuclei, 
clustered around mass of coarse, dark-brown pigment ; 
occasional rosettes 
Gametocyte 
Round to oval; compact; may almost fill RBC; chromatin 
compact, eccentric (macrogametocyte) or more diffuse 
(microgametocyte); scattered brown pigment 
P
. 
k
n
o
w
le
si
 
Ring 
Normal to 0.75×; multiple 
infection of RBC not uncommon 
Delicate cytoplasm; 1 to 2 prominent chromatin dots; 
occasional appliqué (accolé) forms  
Trophozoite 
Normal to 0.75×; rarely, Sinton 
and Mulligan’s stippling (under 
certain staining conditions) 
 
Compact cytoplasm; large chromatin; occasional band forms; 
coarse, dark-brown pigment 
Schizont 
Contains  up to 16 merozoites with nuclei, clustered around 
mass of course, dark-brown pigment; merozoites irregularly 
scattered or grape-like cluster; mature merozoites appear 
segmented 
Gametocyte 
Round to oval, compact; may almost fills RBC; chromatin 
compact, eccentric (macrogametocyte) or more diffuse 
(microgametocyte); scattered brown pigment  
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2.5 Signs, symptoms and complications of malaria 
Malaria infection is asymptomatic during maturation in liver. Clinical malaria 
disease will be apparent during the erythrocytic cycle of infection and can present in a 
wide range of symptoms. The common symptom is characterized by a cycle similar to 
periodicity of the paroxysm fever and chill, and this febrile paroxysm typically lasting 
8-12 hours and characterized by three main stages, i.e., the cold stage (rapid rise of the 
temperature associated with chill) followed by hot stage (temperature peak, skin 
vasodilatation, headache, and myalgias) and lastly the sweat stage (defervescence).  
World Health Organization has classified malaria into two categories, chronic 
(uncompleted) malaria and severe (complicated) malaria (WHO, 2000). Uncomplicated 
malaria is defined as symptomatic malaria without signs of severity or evidence of vital 
organ dysfunctional. The common manifestations of uncomplicated malaria may be the 
classical flu-like symptoms such as fever, shaking chill, headache, and body pain, but a 
wide spectrum of symptoms are possible. In severe malaria, multi-organs failure, coma, 
and death are typical, especially in non-immune individual, children, and pregnant 
women. Malaria infection is usually associated with a reduction of hemoglobin levels 
due to hemolysis of parasitized RBCs and this largely contributed to severe anemia 
accompanied with jaundice in young children and pregnant women living in highly 
malaria endemic region. Some malaria infections can turned severe and lead to death 
very rapidly if untreated, especially in two fatalistic infections, i.e., P. falciparum and P. 
knowlesi. The emergence of multi-drug resistant strains of P. falciparum and P. vivax is 
also exacerbating the situation (Conway, 2007; Rubio, et al., 1999; Tjitra, et al., 2008). 
Plasmodium falciparum is the most lethal malaria worldwide and can evolve 
rapidly to severe illness and deaths due to the cytoadherence property shown by the 
infected erythrocytes to host epithelium, which allows the parasites to escape from 
clearance by the spleen. The sequestration pathogenesis also allows this parasite hidden 
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away in the deep organs of the body; therefore in most of the blood stages, i.e. late 
trophozoite, schizont and gametocytes stages of P. falciparum are not seen in the 
peripheral blood except in heavy infection (Zimmerman, Mehlotra, Kasehagen, & 
Kazura, 2004). In addition, falciparum infected erythrocytes can clump together or form 
rosette by sticking to other uninfected erythrocytes, thus causing blockages in blood 
capillaries that can consequently lead to malaria death. The main complications linked 
to falciparum death are severe malaria (leading to profound hypoxia and congestive 
cardiac failure), cerebral malaria (leading to coma, altered mental status, multiple 
seizures with P. falciparum in the blood, and other cerebral symptoms) and respiratory 
distress syndrome. The complications in falciparum malaria is lethal if left untreated 
and even with treatment, 15 % of children and 20 % of adults developed cerebral 
malaria die (WHO, 2008).  
In addition to P. falciparum infection, the newly recognized human P. knowlesi 
infections can also result in severe disease and potentially fatal. Currently, increasing 
epidemiology studies based on knowlesi malaria in Malaysian Borneo are being 
published with improved information on the disease severity and clinical complications 
(Cox-Singh, et al., 2008; Cox-Singh, et al., 2010; Daneshvar, et al., 2009; Rajahram, et 
al., 2012; William, et al., 2011). The shortest erythrocytic replication period (24 hours) 
and high parasite loads (hyperparasitemia) have been concluded as the two key features 
that lead to severe malaria and malaria death in P. knowlesi infections. Acute respiratory 
distress, acute renal failure, shock and hyperbilirubinemia are most common 
complications noted in patients with severe disease (Antinori, et al., 2013; William, et 
al., 2011). Thus far, 19 knowlesi deaths have been reported, seven cases were in 
Sarawak state (Cox-Singh, et al., 2008; Cox-Singh, et al., 2010; Daneshvar, et al., 2009) 
and 12 in Sabah state (Rajahram, et al., 2012; William, et al., 2011).  
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In contrast to the above two potentially fatal infections, P. vivax, P. ovale, and P. 
malariae infections always exhibit less severe disease outcome restricting to fever with 
rare complication. Plasmodium vivax and P. ovale exhibit the hypnozoite stage and can 
cause true relapses several months after the primary infection (Collins & Jeffery, 2005). 
Plasmodium malariae does not relapse from persistent liver stage parasites, but the 
parasite is able to persist in the blood at very low density for extremely long period, 
perhaps for entire life of human host causing recrudescence even after more than 40 
years or longer (Collins & Jeffery, 2007).  
Recrudescence, re-infection and relapse are the three main causes of the 
recurrence of malaria after treatment. Recrudescence occurs when parasites are not 
properly cleared by treatment. For instant, P. falciparum that are resistant to 
antimalarial drug and P. malariae can remain in the blood for months or even years and 
cause recurrent symptoms from time to time. Re-infection indicates complete clearance 
of parasites in the previous infection and the new infection is actually established from a 
separate infective mosquito bite and the infection can occur with any malaria parasites. 
On the other hand, relapse infection is a unique characteristic of P. vivax and P. ovale 
infections that involves re-emergence of blood-stage parasites from hynozoites in the 
liver. This can occur any time after several weeks or months of the primary attack.  
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2.6 Diagnosis of malaria 
The empirical clinical diagnosis remains the most common method to diagnose 
malaria that is based on the observation of the clinical features of the disease. However, 
the accuracy of this clinical presumptive diagnosis is poor due to the extremely wide 
spectrum of clinical signs and symptoms ranging from mild to severe malaria. 
Furthermore, the flu-like symptoms (e.g., fever, headache, myalgias, etc.) and other 
severe signs (e.g., acute anemia, coma, renal failure, etc.) are extremely non-specific, 
mimicking a large series of other clinical conditions of many other febrile type tropical 
diseases (WHO, 2000). Moreover, the efficacy of the clinical diagnosis is also subjected 
to many other factors, such as the endemicity of different species; the population 
movements; the inter-relation between the levels of transmission, immunity, 
parasitemia, and symptoms; the problems of recurrent-malaria and/or drug resistance; 
and the previous anti-malaria medication or used of chemoprophylaxis etc. (Karyana, et 
al., 2008; Rogerson & Carter, 2008; Shetty, 2012). Therefore, once malaria is suspected 
on clinical grounds, it is mandatory to obtain the parasitological laboratory confirmation 
of the presence of malaria parasites or its antigens/products in the patient blood prior 
treatment is given. 
The availability of prompt and accurate diagnostic method is paramount in 
effective management of malaria. In general, financial resources, uncomplicated 
diagnostic procedure, personnel training, as well as rapid availability of the results, are 
the major considerations in malaria diagnosis (malERA Consultative Group on 
Diagnoses and Diagnostics, 2011; Moody, 2002). Basically, the erythrocytic cycle of 
infection is responsible for symptoms and signs of infection, thus current malaria 
diagnostic methods are targeting the parasites in peripheral blood. Nowadays, 
microscopic examination (parasite identification), immunochromatographic dipstick 
tests (ICTs) or rapid diagnostic tests (RDTs) (antigen detection), and molecular PCR 
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assays (parasite nucleic acid detection) are the three most common laboratory diagnostic 
methods. 
 
2.6.1 Light microscopic examination 
Conventional light microscopic examination of Giemsa-stained thin and/or thick 
smear films remains the gold standard for routine laboratory diagnosis of malaria and 
this can be attributed to the rapidity of result, low cost, simplicity, reliability in most 
settings even though in many cases this assay has shown to have low sensitivity and 
specificity, especially in cases of low parasitemia, sequestered parasites, as well as 
mixed-infection (malERA Consultative Group on Diagnoses and Diagnostics, 2011; 
Moody, 2002). The microscopy approach is only accurate when the minimum parasite 
titer in the blood sample is 50 parasites/µl; however, it is able to identify and further 
quantify the parasite numbers in the patient samples, both of which are significant in 
assessing the disease severity and prescription of adequate therapy. Overall, the 
accuracy of results varies depending on the experience and skill of laboratory 
technicians (Moody, 2002; Zimmerman, et al., 2004).  
In thin films, the red blood cells (1.5 µl blood) are fixed so that the morphology 
of the parasitized cells can be seen. Species identification can be made based upon the 
size and shape of the various stages of the parasite (Figure 2.8 and Table 2.7; Session 
2.4.4). Generally, thin and thick blood smears have a difference in sensitivity, with 100-
200 parasites/µl and ~ 10 parasites/µl, respectively. Therefore, examination of a thick 
blood film is recommended when there is low parasitemia. The red cells are 
approximately 6-20 layers thick (3-4 µl blood), which results in a larger volume of 
blood being examined. In thick films, the red blood cells are lysed, so diagnosis is based 
on the appearance of the parasite and the parasites tend to be more compact and denser 
than in thin films.    
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Despite these strengths, microscopic examination has created diagnostic 
problem in cases whereby there are changes in the morphological appearances of 
parasites due to drug pressure, genetic variation and also approaches of blood collection. 
Besides that, morphological similarities of blood stages of some Plasmodium species to 
others also leads to misdiagnosis of Plasmodium to species level and the overlooking of 
fatal species, which will consequently weaken the effectiveness of treatments and 
malaria management (Mayxay, Pukrittayakamee, Newton, & White, 2004; Moody, 
2002). For instance, microscopic diagnosis of P. knowlesi infection is quiet challenging 
especially for inexperienced microscopist as the morphology of P. knowlesi is always 
undistinguishable from P. falciparum during the early ring stage and P. malariae during 
the other blood stages, i.e., trophozoite, schizont, and gametocyte (Lee, et al., 2009; 
Singh, et al., 2004). Mixed infections are often missed (Mayxay, et al., 2004); especially 
when P. malariae and P. ovale coexist with other species, as their densities are often 
low in comparison to that of P. falciparum (Conway, 2007; Zimmerman, et al., 2004). 
Furthermore, in P. falciparum infection, usually only very young forms (ring forms) can 
be observed in the peripheral blood because older parasites are being adhere to the 
endothelium of blood vessels in deep organs (e.g. the brain) (Zimmerman, et al., 2004). 
Regardless of some limitations in microscopy technique, there is no alternative method 
that could be established to replace this universally accepted gold standard method.  
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2.6.2 Rapid diagnostic tests (RDTs) 
Various RDTs are commercially available to detect antigens derived from 
malaria parasites. Such immunologic (immunochromatographic) tests are most often 
designed in a dipstick or cassette format, which require only 15 to 20 minutes to obtain 
results and need less technical interpretation. The limitations of RDTs include having 
variable detection thresholds and field stability, low sensitivity (100-200 parasites/µl), 
and that most of the kits are unable to distinguish the parasites up to species level 
(malERA Consultative Group on Diagnoses and Diagnostics, 2011; Moody, 2002). For 
instance, the currently approved RDTs could only detect two different malaria antigens, 
i.e., one is specific for P. falciparum (histidine-rich protein 2) and the other is conserved 
across the human malaria (Plasmodium lactate dehydrogenase or aldolase enzymes), 
thus further microscopy confirmation is still needed to determine the species that is 
detected by the RDTs (Murray, Gasser, Magill, & Miller, 2008). Figure 2.9 show the 
principle and result interpretation of RDTs. 
 
 
Figure 2.9: Principle of immunochromatographic RDT (adapted from Moody, 2002).  
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2.6.3 Molecular PCR diagnosis 
The advent of molecular tools such as PCR has provided more specific, sensitive, 
and reliable molecular techniques for the diagnosis of malaria based on the detection of 
parasite nucleic acid (Conway, 2007; malERA Consultative Group on Diagnoses and 
Diagnostics, 2011). Plasmodium vivax and P. ovale as well as P. malariae and P. 
knowlesi are not always distinguishable on the basis of morphologic characteristics 
alone, and the use of molecular tools will help clarify their diagnosis. The principle of 
PCR is based on the amplification of a selected region of the malarial genome. Genus-
specific and species-specific sequences of the asexual stage-expressed 18S small 
subunit ribosomal RNA (ssu rRNA), circumsporozoite surface protein (csp), a nuclear 
gene encoding a cysteine protease, and the cytochrome b  (Cytb) gene have comprised 
several common targets in molecular studies of malaria (Conway, 2007; Moody, 2002).  
In general, PCR enables the detection of parasites at low titer of 5 parasites/µl 
(Moody, 2002), and the most recent study attained a detection limit of 0.5 parasite/µl in 
the latent or recrudescence stage of malaria disease (malERA Consultative Group on 
Diagnoses and Diagnostics, 2011). Although PCR assays have shown in many cases to 
have improved the sensitivity and specificity for the diagnosis of malaria over 
microscopy or RDTs, in many cases the time duration required to obtain results is much 
longer, with at least three hours to one day for sample processing (malERA Consultative 
Group on Diagnoses and Diagnostics, 2011; Moody, 2002; Tangpukdee, Duangdee, 
Wilairatana, & Krudsood, 2009).  
PCR-based amplification assays, including nested PCR (Singh, et al., 1999; 
Singh, et al., 2004; Snounou, et al., 1993), semi-nested PCR (Rubio, et al., 1999), 
multiplex PCR (Padley, Moody, Chiodini, & Saldanha, 2003; Patsoula, Spanakos, 
Sofianatou, Parara, & Vakalis, 2003), real-time or quantitative PCR (qPCR) (Mangold, 
et al., 2005; Perandin, et al., 2004; Rougemont, et al., 2004; Safeukui, et al., 2008), and 
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a more recently approach, loop-mediated isothermal amplification (LAMP) have been 
developed to identify malaria parasites to species level (Han, et al., 2007).  
In general, nested PCR has been considered as the molecular gold standard for 
malaria identification in clinical diagnosis, sub-clinical (asymptomatic) screening, and 
epidemiology studies (Moody, 2002; Singh, et al., 1999; Singh, et al., 2004; Snounou, et 
al., 1993; Zimmerman, et al., 2004). Nested PCR has been established not only as the 
molecular parameters for the sensitivity and specificity of other PCRs, but also for the 
other diagnostic assays, i.e., microscopy and RDTs. However, this assay is time-
consuming and labor-intensive among conventional PCR assays, as it requires a large 
number of reagents and disposable consumables, given that at least six separate PCRs 
(one round of genus-specific PCR followed by five separate rounds of species-specific 
PCRs) and agorose gel electrophoresis are needed to test for the five human malaria 
infection species. The semi-nested PCR (Rubio, et al., 1999) is based on a combination 
of techniques of nested PCR and multiplex PCR, which involve two rounds of PCR, i.e., 
a genus-specific PCR followed by a species-specific multiplex PCR (able to detect four 
species excluding P. knowlesi). Multiplex PCR on the other hands can simultaneously 
detect more than two plasmodia species in a single tube reaction. To the best of our 
knowledge, the currently available single round multiplex PCR assays could only 
differentiate up to two Plasmodium species that focused on P. falciparum and P. vivax 
(Kho, et al., 2003; Patsoula, et al., 2003) and four species excluding P. knowlesi (Padley, 
et al., 2003). 
The real-time PCR or qPCR enables the detection of parasite nucleic acid based 
on the quantification of the intensity/signal of fluorescence probes [TaqMan and 
fluorescence resonance energy transfer (FRET) probes] and dyes [SYBR Green and 
high-resolution melt (HRM) dyes] using a high end real-time thermocycler, thus also 
allows the parasite quantification, which cannot be achieved by other conventional PCR 
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approaches (de Monbrison, Angei, Staal, Kaiser, & Picot, 2003; Gan & Loh, 2010; 
Mangold, et al., 2005; Perandin, et al., 2004; Rougemont, et al., 2004; Safeukui, et al., 
2008; Shokoples, Ndao, Kowalewska-Grochowska, & Yanow, 2009).  
In contrast to conventional and real-time PCRs, the LAMP is a simple and less 
technically demanding approach that involves isothermal amplification of targeted DNA 
for identification of each Plasmodium species. LAMP results can be detected either by 
agarose gel electrophoresis or turbidity assessment by the naked eye or with a real-time 
turbidimeter (Han, et al., 2007). The combination of real-time turbidimeter in the results 
interpretation allows parasite quantification. 
Table 2.8 shows the overview of the three currently available methods in 
diagnosis of malaria. 
 
Table 2.8: Comparison of diagnostic methods for diagnosing Plasmodium infection in 
blood (adapted from Moody, 2002). 
Parameter Microscopy RDT 
Conventional 
PCR 
Format 
Slides with blood 
smears 
Dipstick PCR reagents 
Equipment Microscope Kit only PCR apparatus 
Sensitivity 
(parasites/μl) 
Expert ~5-10 
Routinely > 50 
100-200 < 5 
Specificity 
All species, except    
P. knowlesi 
P. falciparum only All species 
Parasite density 
or parasitemia 
Yes Crude estimation No 
Time for result 30-60 minutes 20-30 minutes Within 24 hours 
Test result 
Direct visualization 
of the parasites 
Colour changes on 
antibody coated 
lines 
Agarose gel 
electrophoresis 
Skill level High Low High 
Cost/test Low Moderate High 
Remarks 
Gold standard for 
routine laboratory 
Alternative assay 
Nested PCR as 
molecular gold 
standard 
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2.7 Immune responses against Plasmodium species 
In areas of moderate to intense transmission conditions, repeated plasmodial 
infections (over years of exposure) result in the development of acquired immunity, 
which is both species- and stage-specific. This partially protective immunity gradually 
develops with age, thus giving protective effect to older children and adult rather than 
young children. Therefore, most malaria deaths in Africa occur in young children, 
whereas in areas with less transmission and low immunity, all age groups are at risk. 
Acquired immunity is rarely sterile, but rather associated with low-grade parasitemia 
and episodes of clinical disease throughout life. While acquired immunity never provide 
complete protection, but it does reduce the risk to severe malaria (Doolan, Dobano, & 
Baird, 2009). Generally, children born to immune mothers are protected against disease 
during first six months of their life by maternal antibodies before acquisition of an 
adequate active immunity. However, acquisition of active immunity to malaria is slow 
and requires repeated parasite exposure to be maintained. As a result, mortality due to 
malaria is mainly restricted to early childhood. Furthermore, genetic variability of both 
the human host and the parasite, parasite-induced immune-suppression and other 
reasons also account for this instability (Doolan, et al., 2009).  
Malaria infection gives rise to host responses which are regulated by both the 
innate and adaptive immunity as well as establishment of memory (Doolan & Martinez-
Alier, 2006; Douradinha & Doolan, 2011). The mechanisms of immune response 
against malaria parasites are being summarized (Douradinha & Doolan, 2011) in Figure 
2.10. Parasites were injected into human peripheral circulation by infected mosquito 
bite. Some sporozoites enter the hepatocytes initiating liver stage replication. There is 
evidence that specific antibodies generated by previous exposure or immunization could 
inhibit subsequent sporozoite invasion of the hepatocyte. Other sporozoites remains in 
the skin are drained to the nearest lymph node and eventually degraded. Antigen 
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presenting cells, including dendritic cells, uptake parasite remnants from lymph node 
and apoptotic bodies of infected hepatocytes and then present the parasite antigens to 
naive T cells for subsequent immune responses. Malaria-induced cell-mediated immune 
responses may be protective against both extra- and intra-erythrocytic parasites. 
Generally, T-cells play a major role in the acquisition and maintenance of protective 
immunity to malaria. CD4
+
 T-cells regulate immune responses to the asexual blood 
stages of the parasite by cytokine production and providing help for B-cells to produce 
specific antibodies, whereas CD8
+
 T-cells has an important role in the pre-erythrocytic 
immunity as well as protection against severe malaria. There is also evidence that 
macrophages, dendritic cells, and NK cells are important effectors of immunity against 
malaria. The T-cells and B- cells will eventually develop into a memory populations and 
the process occurs over time, which may induce a stronger response against subsequent 
infection with same pathogen. 
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Figure 2.10: Schematic representation of immune responses against Plasmodium 
parasites (adapted from Douradinha & Doolan, 2011). 
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2.8 Treatment and prevention 
Malaria is actually a preventable and treatable disease. A variety of drugs have 
been developed for therapeutic (treatment) and prophylactic (preventive) purposes 
(Table 2.9). Malaria is currently treated using drugs that kill the parasites and many are 
derivates of quinine compound. 
 
Table 2.9: The pharmacology of antimalarials (adapted from WHO, 2010a). 
Antimalarial 
drug 
Target of therapy Examples 
Blood 
schizonticidal 
drugs 
Act on erythrocytic stage of 
the parasites thereby 
terminating clinical illness. 
Quinine, artemisinins, 
amodiquine, chloroquine, 
lumifantrine, tetracycline, 
atovaquone, sulphadoxine, 
clindamycin, proguanil  
Liver/tissue 
schizonticidal 
drugs 
Act on primary tissue forms 
of plasmodia which initiate 
the erythrocytic stage. 
Block further development 
of the infection. 
Primaquine, pyrimethamine, 
proguanil, tetracycline 
Gametocytocidal 
drugs 
Destroy sexual forms of the 
parasites thereby preventing 
transmission of infection to 
mosquitoes. 
Primaquine, artemisinins, quinine 
Hypnozoitocidal 
drugs  
Act on persistent liver 
stages of P. vivax and P. 
ovale, which cause recurrent 
illness. 
Primaquine, tafenoquine 
Sporozontocidal 
drugs 
Act by affecting further 
development of 
gametocytes into oocytes 
within the mosquito thus 
abating transmission. 
Primaquine, proguanil, 
chlorguanil 
Chemoprophylaxis  
Preventive medications.  
The choice of 
chemoprophylaxis varies 
depending on the species 
and drug resistance 
prevalent in a country. 
Combination of antimalarial 
drugs. Use of anti-malarial drugs 
to prevent the development of 
malaria. 
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Prompt and effective treatment of malaria requires a rapid and precise laboratory 
diagnosis. Over-diagnosis of malaria may lead to improper treatment, wastage of drugs, 
and also causes the widespread problems with drug resistance amongst the parasites to 
the currently available drugs. Generally, the effectiveness of antimalarial drugs is 
varying with different species of the parasite as well as the stages of the parasite's life 
cycle (Table 2.9). For instance, rapid diagnosis and prompt treatment is paramount for 
two fatal species, i.e., P. falciparum and P. knowlesi; whereas, treatment of P. vivax and 
P. ovale infections with hypnozoitocidal drugs is essential to eliminate persistent liver 
stage.  
Thus far, effective malaria vaccines are still not available; all currently 
recommended primary chemoprophylaxis regimens involve continuously taking of the 
medicine before travel, during travel, and until a period of time after leaving the malaria 
endemic area. Beginning the prophylactic before travel allows the antimalarial agent to 
be in the blood before the traveler is exposed to malaria parasites. 
Other preventive measures including vector control programmes, such as using 
of dichlorodiphenyltrichloroethane (DDT) has successfully reduced the malaria 
transmission; unfortunately, the rapid emergence of insecticide resistance mosquitoes, 
particularly in Africa have lead to the resurgence of malaria in many countries. 
Therefore, the best protection is the avoidance of mosquito bites such as remaining in 
well-screened areas using bed nets, insect repellants, and residual insecticide sprays. 
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2.9 Malaria vaccine development 
Currently, there are still no effective malaria vaccines available. The complexity 
and multiple life cycle stages as well as a myriad of potential vaccine antigens to each 
stage are the major challenges in the progression towards efficient malaria vaccine 
development (Beeson & Crabb, 2007; Todryk & Hill, 2007). 
Generally, there are several sites in the malaria life cycle that could be 
interrupted by vaccine: (i) pre-erythrocytic vaccines in liver stage are directed against 
schizonts-infected liver cells, thus preventing merozoites release and infection to the 
vaccinated individual (infection blocking), (ii) erythrocytic vaccines in the asexual 
blood stage are aim to reduce or eradicate the parasites in the blood-borne forms, thus 
reduce the severity of malaria infections (antidisease), and (iii) transmission-blocking 
vaccine inside the mosquito do not protect an individual but rather the community at 
large based on the fact that the proteins expressed during the sexual stage did not evolve 
to circumvent the human immune system. As such, antibodies taken up by mosquito 
during a blood meal can act against these parasites, thereby preventing re-infection of 
the population. Figure 2.11 show the three strategies for malaria vaccines development. 
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Figure 2.11: Sites in the malaria life cycle that could be interrupted by vaccines 
(adapted from http://www.malariavaccine.org/malvac-lifecycle.php).  
 
Currently, the attenuated whole parasites (sporozoite) immunization and subunit 
vaccines (recombinant or genetically engineered proteins or antigens from the surface of 
the parasite) are the two main strategies in malaria vaccine development, both of which 
show promising results in clinical trials (Vaughan & Kappe, 2012). Figure 2.12 show 
some of the most potent vaccine candidate antigens that have undergone clinical trials, 
of which effectively stimulate the host immune responses to destroy or arrest the 
malaria parasite.  
BREAKING  
THE CYCLE  
WITH VACCINES 
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Figure 2.12: The malaria life cycle, parasites, and parasite targets (major antigens) used 
for vaccine development (adapted from Vaughan & Kappe, 2012). 
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2.10 Genomes and proteome of Plasmodium species 
The completion of whole genome sequencing of Plasmodium species may allow 
study of the evolution and population biology of the parasite, allow parasite 
transmission patterns to be characterized, and meantime facilitate the identification of 
new drug resistance genes, thus opens up new approaches in the development of 
antimalarial drugs as well as vaccines in order to intervene malaria transmission. 
Thus far, three of the most vital human malaria parasites, i.e., P. falciparum 
(Gardner, et al., 2002), P. vivax (Carlton, et al., 2008), and P. knowlesi (Pain, et al., 
2008) nuclear DNA were fully sequenced with the total genome size of 23.3 million 
bases (Mb), 26.8 Mb, and 23.5 Mb, respectively, that split into 14 linear chromosomes 
with an overall of more than 50 % of A+T content (81 % in P. falciparum, 58 % in P. 
vivax, and 63 % in P. knowlesi). Malaria parasites are highly complex, containing over 
5,000 coding genes, i.e., 5,403 genes in P. falciparum, 5,433 genes in P. vivax, and 
5,188 genes in P. knowlesi (Carlton, et al., 2008; Gardner, et al., 2002; Pain, et al., 
2008), most of which encoding surface proteins or antigens expressed throughout 
several antigenically distinct life cycle forms (Pain, et al., 2008).  
Proteome analysis throughout the life cycle within human host of P. falciparum 
(Florens, et al., 2002; Lasonder, et al., 2002) and P. vivax (Roobsoong, et al., 2011) 
have been studied based on conventional 2D gel and mass spectrometry analyses. 
Differential and stage-specific patterns of gene expression and its products in both host 
and parasite have been identified, which might open up an insight into the pathogenesis 
of the parasites and thus provide potential targets for therapeutic and vaccine 
developments. 
 
 
CHAPTER TWO: LITERATURE REVIEW 
 
 
 
56 
2.11 Plasmodium merozoite  
Merozoite stage was characterized by the expression of surface proteins that 
mediate invasion and immune evasion (Florens, et al., 2002). It is important to 
understand the molecular details of this process, as this machinery can be a target for 
both vaccine and drug developments. The merozoite is the infective forms of 
Plasmodium parasite in human host, release at the final stage of pre-erythrocytic and 
erythrocytic developments due to the rupture of mature liver schizonts as well as 
erythrocyte schizonts, respectively, and after a short period in the blood stream, they are 
bind to and invade new erythrocytes. Therefore, the invasive ability of the merozoite 
into RBC plays a pivotal role in malaria pathogenesis.  
In general, antigens of Plasmodium are not only presented on the surface of 
merozoites, some are stored in the apical organelles located at the leading-end of 
merozoite, which plays a central role in host cell invasion and are responsible for 
antigenic diversity in these organisms. Merozoites are protected from host immune 
attack during replication in erythrocytes, however, once release into blood stream at the 
end of replication cycles; it will consequently stimulate the host immune response 
(Cowman & Crabb, 2006). 
The malaria parasite is the most prominent member of the phylum of 
Apicomplexa that exhibits an apical complex. Apical complex is make-up of a set of 
structural components, which have functionally homologous for host cell invasion and 
mainly located at the anterior end of merozoite, displacing the nucleus and mitochondria 
towards the posterior end (Figure 2.13). Three distinct types of secretory organelles, i.e., 
rhoptries, micronemes, and dense granules are found at the apical end of the invasive 
stages. The conoid, polar rings, and sub-pellicular microtubules are the main 
cytoskeletal components. Other organelles including nucleus, endoplasmic reticulum, 
Golgi apparatus, ribosomes, mitochondrion, and apicoplast are all enclosed by a pellicle 
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(inner membranous structure) (Figure 2.13).  
The host cell invasion process is characterized by the initial random attachment 
of parasite with the target cell, followed by intimate association between the apical end 
of the parasite and the host plasma membrane, and ultimately parasite forced entry into 
a host cell (Cowman & Crabb, 2006; Tyler, Treeck, & Boothroyd, 2011) (Figure 2.13). 
Invasion process is complex, involving sequentially secretion of proteins from 
specialized secretory organelles that are necessary to aid entry of a host cell (Macraild, 
Anders, Foley, & Norton, 2011; Tyler, et al., 2011). During invasion, tight junction or 
so-called moving junction (MJ) is formed due to interaction of a number of parasite 
proteins and host surface receptors that is visible as a ring of contact under electron 
micrographs. Parasite entry into parasitophorous vacuole by movement of the junction, 
followed by the resealing of the parasitophorous vacuole and erythrocytic membranes, 
while the surface coat remained outside is shedding off (Tyler, et al., 2011).  
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2.11.1 Apical membrane antigen 1 (AMA1) 
Numerous molecules that are implicated in the invasion process have been 
identified in the apical organelles (rhoptry and micronemes) as well as on both 
merozoite and erythrocyte surfaces. However, only a handful of the molecules are well 
characterized and the molecular mechanisms involved at each step of invasion are not 
well understood. Among these molecules, apical membrane antigen 1 (AMA1) was first 
identified in P. knowlesi as an invariant merozoite surface antigen since 30 years ago 
(Deans, et al., 1982) and is long thought to be involved in RBC invasion by Plasmodium 
merozoites. The AMA1 is well known as a prime malaria vaccine candidate on 
challenge with blood-stage parasites (Anders, Adda, Foley, & Norton, 2010).  
AMA1 protein is encoded by a single essential ama1 gene present in all 
Plasmodium species. Ama1 gene encodes this protein in varying length ranged between 
556 to 563 amino acids in most Plasmodium species, exclusion of P. falciparum with 
approximately 622 amino acids. AMA1 is a microneme protein as where it is located 
and the expression is abundance in the late schizont stage of the asexual life cycle of the 
Plasmodium parasite. In general, mature AMA1 is a globular, low-abundance, 
structurally conserved type I integral membrane (transmembrane) protein (Hodder, et al., 
1996). The AMA1 protein comprises of several regions including a prosequence, an 
ectodomain (extracellular domain) that build up by three distinct domains (a relatively 
N-terminal domain I, a central domain II, and a C-terminal domain III), a single 
transmembrane region, and a small C-terminal cytoplasmic domain. The ectodomain 
has 16 interspecies conserved cysteine residues that linked to form eight intramolecular 
disulfide bonds, in where three are located in domain I and domain III, and two in 
domain II, which are crucial for structural stabilization and domains discrimination 
(Bentley, 2006; Cowman & Crabb, 2006; Hodder, et al., 1996) (Figure 2.14).  
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Figure 2.14: Structure of AMA1. (A) The primary structure of AMA1. TM indicates 
transmembrane region and CD indicates C-terminal cytoplasmic domain. (B) The 
primary sequence of Plasmodium AMA1 ectodomain, showing the three putative 
domains, I, II, and III, and the location of the eight disulphide bridges. (C) Three-
dimension crystal structure of the PvAMA1 ectodomain (1W8K), showing the 
organization of domains I, II, and III shaded as A (modified from Hodder, et al., 1996 
and MacRaild, et al., 2011).  
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The PfAMA1 molecule is synthesized as a 83-kDa precursor and shortly after 
synthesis, the N-terminal prosequence is cleaved to form 66-kDa polypeptide (Narum & 
Thomas, 1994), whereas other Plasmodium species is synthesized as a 66 kDa protein, 
which is translocated to the merozoite surface via the rhoptry neck prior to the initiation 
of invasion. At or around the point of invasion, AMA1 molecule is then proteolytically 
processed into small fragments in the form of entire AMA1 ectodomain with the size of 
44-48 kDa by a single cleavage of 29 residues distal to the transmembrane domain 
(Collins, et al., 2007). 
Basically, AMA1 in Plasmodium species  is expressed in two critical life-cycle 
forms, the sporozoites and the merozoite, both of which invade human hepatocytes and 
erythrocytes, respectively (Triglia, et al., 2000; Silvie, et al., 2004). The role of AMA1 
in sporozoites has not been well studied. In contrast, AMA1 in merozoites is one of the 
well-characterized and functionally important amongst the merozoites membrane 
proteins that responsible for erythrocytes invasion. The AMA1 knockout strains are not 
viable, implying that AMA1 is crucial in the parasite life cycle (Triglia, et al., 2000).  
Despite its low abundance compared with other merozoite proteins, AMA1 is a 
high immunogenic protein in natural human infections. Although merozoites are 
extracellular for only a short time, surface antigens are subjected to immune attack and 
antibodies against AMA1 blocking the invasion of both hepatocytes by sporozoites 
(Silvie, et al., 2004) as well as erythrocytes by merozoites (Boyle, et al., 2010).  
The three-dimensional structure of AMA1 obtained either by X-ray 
crystallography or nuclear magnetic resonance (NMR) spectroscopy based on complete 
or truncated forms of AMA1 extracellular domains from P. vivax (Pizarro, et al., 2005) 
and P. falciparum (Bai, et al., 2005; Feng, et al., 2005; Nair, et al., 2002) are currently 
available in Protein Data Bank (PDB) (Table 2.10).  
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Table 2.10: Protein Data Bank entries of three-dimensional structure of Plasmodium 
AMA1. 
Recombinant 
AMA1 
Domain/s Method 
PDB 
entry 
Year References 
PfAMA1 III NMR 1HN6 2000 Nair, et al., 2002 
PfAMA1 II NMR 1YXE 2005 Feng, et al., 2005 
PfAMA1 I-II X-ray 1Z40 2005 Bai, et al., 2005 
PvAMA1 I-III X-ray 
1W8K and 
1W81 
2005 
Chesne-Seck, et al., 2005; 
Pizarro, et al., 2005 
Protein Data Bank (PDB): http://www.wwpdb.org/ 
 
 
2.12 Heterologous expression of the recombinant protein 
Generally, protein expression applied the principle of recombinant DNA 
technology by cloning a fragment of target coding DNA (cDNA) into a plasmid vector, 
followed by transformation or transfection and recombinant expression of the target 
protein into a heterologous host cell in the form of fusion protein with specific ‘tag’ 
sequences that can further be retrieved by affinity chromatography. Nowadays, 
heterologous expression of proteins has been widely exploited for the bioproduction of 
many therapeutic proteins as well as antigens for molecular biological assays. There are 
several different types of expression host systems, e.g., prokaryotic system mainly 
focused on Escherichia coli (E. coli) cells, baculovirus system based on insect cells, 
yeast system i.e., Pichia pastoris and Saccharomyces cerevisiae, etc. Heterologous 
expression of plamodial protein is principally carried out for preparative purposes, for 
example, crystallization and structure studies, preparation for recombinant vaccines, 
drug screening, antigen preparation, enzymatic and other in vitro functional assay, etc 
(Birkholtz, et al., 2008; Fernandez-Robledo & Vasta, 2010). The expression systems 
applied in plasmodial studies have been reviewed elsewhere (Birkholtz, et al., 2008; 
Fernandez-Robledo & Vasta, 2010). 
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2.12.1 Expression of protein in E. coli 
In general, E. coli remains as a predominant host for the heterologous expression 
of recombinant proteins in many research, diagnostic, and pharmaceutical studies. 
Bacterial system is the most preferable system due to simple operations control without 
sophisticated laboratory equipment, low costs, high protein yield, short growth time, 
and convenient expression. Furthermore, there is a large selection of vectors and host 
strains that are currently available.  
The limitation of bacterial system is in its inability to perform post-translational 
modifications. Moreover, most overexpressed proteins are frequently found in an 
insoluble form called inclusion body (IB) that lack in biological activity. IB is 
aggregates form of partially folded or misfolded proteins, which have hydrophobic or 
sticky regions exposed that can interact with other similar proteins. The IB is dense and 
usually deposited as dark intracellular particles with 0.2 - 0.5 µm in diameter under 
microscopy observation. The main component of IB is recombinant protein and this 
aggregated protein is usually protected from proteolytic attack. In some circumstance, 
IB also allows expression of toxic proteins that might be harmful to host cells. Since the 
target protein is relatively pure in washed IB, the challenge is not so much to purify the 
target, but rather to solubilize an IB (Burgess, 2009). Nowadays, there has been an 
increase in products and protocols, i.e., expression, cell disruption, IB isolation and 
purification, and IB solubilization, which are generally applicable to the IB issue. The 
downstream process to recover the recombinant protein into its native structure is 
known as refolding.  
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2.12.2 Refolding of insoluble and incorrectly folded proteins 
Following the solubilization of IB with denaturing agent (either 4-8 M urea or 4-
6 M guanidinium hydrochloride) and reducing agent (1-10 mM DTT; if protein contains 
disulphide bonds), recombinant protein can be refolded to regain full biological function 
by slowly removing denaturing agents that allow folding of protein and formation of the 
correct intramolecular associations. Refolding can be straightforward for small proteins 
and for proteins that do not contain disulfide bridges, however, it is challenging in many 
cases. Optimal conditions for refolding are protein dependent and unpredictable. 
However, much refolding data is available through the literatures and has been 
complied in databases, e.g., REFOLD database (http://refold.med.monash.edu.au/). 
Successful refolding is often dependent on the careful optimization of a number of 
parameters such as protein concentration, temperature, reaction time, disulfide exchange 
reagents as well as buffer additives. Dialysis, dilution, on-column refolding are several 
refolding techniques (Burgess, 2009; Cabrita & Bottomley, 2004).  
Protein aggregation is often clearly visible when refolding conditions are not 
optimized. Therefore, virtual inspection can be used to quickly determine which 
samples warrant further analysis. Turbidity measurements at 390 nm may also be 
performed to quantitatively measure aggregation (Tresaugues, et al., 2004; Vincentelli, 
et al., 2004). The most reliable and informative way to assess the quality of protein is by 
using a known activity assay. However, most proteins being studied have no known 
function and structure or have very difficult biological assay. Therefore, the samples can 
also be analyzed using size-exclusion chromatography as well as circular dichroism or 
fluorescence techniques, which the spectrum will provide significant information about 
a protein’s secondary and tertiary structures. However, the latter methods can be labor-
intensive and difficult to interpret, and the protein sample should be > 90 % pure in a 
compatible buffer. The nature of disulphide bonds can be achieved by the most 
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straightforward method using reducing and non-reducing SDS-polyacrylamide gel 
electrophoresis (PAGE). The used of thiol specific dyes (Ellman’s reagent) and mass 
spectrometry are all other techniques that were also employed (Cabrita & Bottomley, 
2004). 
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2.13 Protein-protein interactions 
The erythrocytic stages of the malaria parasite are responsible for the clinical 
symptoms associated with the infection. Therefore, drugs and vaccine against these 
stages would act therapeutically by reducing the severity of the clinical symptoms 
(Richards & Beeson, 2009). Currently, it is increasingly clear that a greater 
understanding of the molecular interaction between the parasite and its host would assist 
in the development of new therapeutics and most importantly, a vaccine for long term 
sustainable reduction in the global burden of malaria.  
There are several methods available for studying the protein-protein interactions 
and the X-ray crystallography is a gold standard method, which allows direct three-
dimensional (3D) view of the interaction between the two compounds such as antigen 
and antibody. However, this method is time-consuming, expensive, and technically 
challenging that requires large amount of homologous and highly purified native protein. 
Three-dimensional structures of Plasmodium surface proteins, such as AMA1, 
merozoite surface antigen 1 (MSP1), erythrocyte-binding antigen 75 (EBA175), duffy-
binding-like (DBL), and surface protein 25 (P25) created either by X-ray 
crystallography or NMR spectroscopy in structural studies are currently available in 
Protein Data Bank (http://www.wwpdb.org/) (Bentley, 2006). Phage display technique 
is an alternative approach that allows large scale screening and identifying protein-
protein, protein-peptide, and protein-DNA interactions. Phage display technology is 
comparably faster and relatively inexpensive interaction assay compared with 3D 
structuring technology. 
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2.13.1 Phage display technology 
In vitro displaying random peptides on the surface of phage was an idea derived 
from George Smith in the year 1985, when he demonstrated the display of foreign 
peptides on filamentous phage by fusing the peptide of interest onto gene III of 
filamentous phage (Smith, 1985). Phage display is a simple functional genomic 
methodology for screening and identifying protein-protein interaction that involves the 
construction of a phage library by inserting DNA fragments into phage or phagemid 
genomes, followed by assembly of peptide libraries, which contains billion of short, 
variable amino acid sequences that are displayed on the surface of phage particles, 
which can then be panned for by enabling the phage to interact with selected 
immobilized targets that have been identified, i.e., recombinant protein (that has interest 
as drug target) and/or antibodies (Mullen, Nair, Ward, Rycroft, & Henderson, 2006). 
This creates a direct physically linked between the single-stranded DNA (ssDNA) 
sequences in the phage genome and their encoding peptide sequence displayed on the 
surface (Wang & Yu, 2004).  
With the further improvement and adaptation of this technology, thus far, there 
is arrays of peptide libraries that have been established (Figure 2.15A). Random peptide 
libraries are the most common and created from synthetic random degenerate 
oligonucleotide inserts. Those libraries are universal in nature and suitable for various 
applications and field of studies on protein-protein interactions, especially to identify 
linear antigenic epitopes (Mullen, et al., 2006). The only limitation is that the peptide 
sequences discovery from this type of libraries might not representative to or found 
within the antigen or intact pathogen (Mullen, et al., 2006). Antibody libraries are 
created from immunoglobulins and express commonly as scFv or Fab fragments 
(Barbas, Burton, Scott, & Silverman, 2001). Whereas, natural peptide libraries display 
natural peptides and proteins created from randomly fragmented DNA from the 
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genomes of selected organisms (Lanzillotti & Coetzer, 2008). The peptides or proteins 
selected from natural peptide libraries are more significant in the stimulation of 
immunity response that cross-reacts with native pathogens and thus can be serve as 
promising subunit vaccines (Matthews, Davis, & Smith, 2002; Mullen, et al., 2006). For 
instance, the Plasmodium cDNA library (Lauterbach, Lanzillotti, & Coetzer, 2003) and 
AMA1 peptide library (Coley, et al., 2001) are two examples of natural peptide libraries 
constructed from P. falciparum.  
The phage display cycle is simple as shown in Figure 2.15B and 2.15C: (i) A 
library of variant DNA sequence encoding short peptides is created, cloned into phage 
or phagemid genomes as fusions to coat protein gene, and phage particles are produced. 
(ii) The phage library displaying variant peptides is exposed to a target molecule 
immobilized onto plate and phages with appropriate specificity are captured. (iii) Non-
binding phages are then washed away. (iv) Bound phages are eluted by conditions that 
disrupt the interaction between the displayed peptides and the target. (v) Eluted phages 
are infected into host bacterial cells and thereby amplified. (vi) Amplified phage library 
is then used for subsequence biopanning cycle, usually repeated between three to five 
rounds to generate a library that is greatly enriched in the number of phage with binding 
affinity to the immobilized protein. (vii) Phage populations may be selected and 
analyzed individually (Willats, 2002). The possibility of individual phage binds either to 
target protein or background can be further confirmed by established phage ELISA as 
well as phage Western blotting assays. The interactions between two proteins can be 
predicted through various computer program and databases of native sequences, e.g., 
mimox (Huang, Gutteridge, Honda, & Kanehisa, 2006) and mimoDB (Huang, et al., 
2012) in mimotope mapping, and 3D-Epitope-Explorer (3DEX) (Schreiber, Humbert, 
Benz, & Dietrich, 2005) in epitope mapping etc.  
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Figure 2.15: Phage display. (A) Different types of phage library. (B) Construction of 
phage library. (C) The phage display cycle (adapted from Willats, 2002). 
B) 
A) 
C) 
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Phage display is a powerful and cost effective tool, which is widely used for the 
investigation of protein-protein interactions, immunoassay development, identification 
of peptide agonists and antagonists for receptors, identification of targets for the 
inhibition, elucidation of neutralizing sites, investigation into pathogenesis of disease, 
identification of peptide drug and vaccine candidates, and the isolation and engineering 
of recombinant antibodies (Mullen, et al., 2006; Wang & Yu, 2004).  
 
2.13.2 Phage display technology and applications in malaria research 
Phage display is a widely applicable technique used in studies of protein 
functions and biological process in malaria especially for probing and characterizing the 
molecular host-parasite interactions, and thus helps to aid in the identification of peptide 
ligands as well as mapping of the epitope and/or mimotope of monoclonal and 
polyclonal antibodies, which could potentially improve diagnostic and therapeutic value.   
Generally, ligand is refer to a substance, usually small molecule that reacts to 
form a complex with another biomolecule to serve a biological purpose or rather it is a 
signal triggering molecule, binding to a site of a target protein. Ligands include 
substrates, inhibitors and activators. Ligand binding to a receptor alters its chemical 
conformation (3D shape) and the conformational state of a receptor protein determines 
its functional state. The tendency of binding is so-called affinity. Epitope is defined as 
contracting points of any molecular interaction in biological system and is more often 
used to describe the region of antigen that involve in specific binding to an antibody (B- 
or T-cell epitopes) (Lanzillotti & Coetzer, 2008; Mullen, Nair, Ward, Rycroft, & 
Henderson, 2006; Wang & Yu, 2004). Epitope mapping is initially termed to describe 
all activity on determination of the sequence or structure of a given epitope towards 
antibodies. Nowadays, epitope mapping is no longer limit to immunology study, and is 
instead being applied in all fields of biology (Wang & Yu, 2004).  
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In an attempt to provide insight into the biological function and immunological 
properties which lie behind the targeted Plasmodium proteins, many studies have been 
done utilizing phage display libraries and have been reviewed and summarized 
(Lanzillotti & Coetzer, 2008). The large repertoire of possible applications of phage 
display has led to it being utilized in the combat against malaria in several ways. Phage 
display human antibodies library was used to identify the antibodies against P. 
falciparum MSP1 and thus inhibit the parasite growth (Sowa, et al., 2001), to identify 
antibody that recognizes parasitized erythocytes (Wajanarogana, Prasomrothanakul, 
Udomsangpetch, & Tungpradabkul, 2006), to elucidate human antibody response to 
sporozoites protein (Chappel, Rogers, Hoffman, & Kang, 2004), and peptides derived 
from human antibodies library that bind to mosquito midgut antigens have great value 
as transmission-blocking agents (Foy, et al., 2002). Random peptides libraries were 
used to identify peptides that block the invasion and development of P. falciparum in 
Anopheles gambiae  (Ghosh, Moreira, & Jacobs-Lorena, 2002; Ghosh, Ribolla, & 
Jacobs-Lorena, 2001), or merozoite invasion of human erythrocyte (Harris, et al., 2005; 
Keizer, et al., 2003; Li, et al., 2002), as well as those targets infected erythrocytes (Eda, 
Eda, & Sherman, 2004). The only study on biopanning of a P. falciparum cDNA library 
against human erythrocyte-membrane proteins successfully identified seven malaria 
proteins that are potentially involved in the entry into or exist from human erythrocyte 
by P. falciparum and such proteins could become vaccine targets (Lauterbach, et al., 
2003).  
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CHAPTER THREE:  MATERIALS AND METHODS 
3.1 Chemical agents and materials 
All chemical agents used in this study were analytical grade or highest grade 
obtained from various companies. Disposable materials, commercial kits, and 
equipments were listed in Appendix 1. 
 
3.2 Buffers, stock solutions, culture media, and other reagents  
3.2.1 Buffers and stock solutions 
Water was purified by a Milli-Q apparatus (Millipore). Buffers and stock 
solutions were prepared as described in Appendix 2.  
 
3.2.2 Culture media, antibiotics, and enzyme substrates  
In general, all culture media (agar or broth) used in bacteria cultivation and 
phage amplification were made as described in Appendix 2N. All culture media were 
autoclaved sterilized prior used. The antibiotics and enzymes substrates are heat labile, 
thus were filter-sterilized through 0.25 µM syringe filter.  
 
3.2.3 PCR reagents and oligonucleotide primers 
The reaction buffers supplied together with DNA polymerase were listed in 
Appendix 3. All oligonucleotide primers with TOP purified PCR grade used in colony 
PCR, multiplex PCR, nested PCR, sequencing, and protein expression were synthesized 
from 1
st
 Base Sdn Bhd (Malaysia). All primers were dissolved in TE buffer (10 mM 
Tris-HCl, 1 mM EDTA, pH 8) to a final concentration of 400 µM as stock solution and 
further diluted into 50 µM as working solution. All PCR reagents and primer solutions 
were stored at -20 ºC. 
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3.2.4 Restriction enzymes 
Restriction enzymes (BamHI and Spe I) together with reaction buffers were 
purchased from Fermentas (USA). All REs and reaction buffers were stored at -20°. 
 
3.3 General Methods 
3.3.1 Sample collection  
A total of 226 whole blood samples were collected from patients suspected with 
malaria and admitted to University of Malaya Medical Center (UMMC), Kuala Lumpur 
(n=54) and Telupid Health Clinic, Sabah (n=172) from 2008 to 2010. An aliquot of 
each sample was used for routine biological diagnostic in the laboratories and the 
remaining was extracted to obtain the total genomic DNA. Another 20 whole blood 
samples were also collected from healthy individuals as negative controls. Written 
informed consent was obtained from each patient and healthy donor before blood 
sample was taken (Appendix 11). The study was approved by the Ethics Committee 
reviewer board of University Malaya Medical Centre (UMMC), Malaysia (MEC 
reference number: 709.2) (Appendix 10).  
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3.3.2 Parasitemia estimation 
For suspected malaria patients, thin and thick blood films were prepared at the 
time of admission prior to anti-malaria treatment. Thin/thick films were stained with 10 % 
Giemsa solution and examined at ×1,000 under oil immersion by experienced 
microscopists at each hospital and the levels of parasitemia were estimated, whereby,  
+  = 1-10 parasites per 100 thick film fields, 
++  = 11-100 parasites per 100 thick film fields, 
+++  = 1-10 parasites per single thick film field, and 
++++ = > 10 parasites per single oil-immersion thick film field.  
In present study, the parasite counts were estimated with a slightly modification, 
whereby,  
 +  = 4-40 parasites/µl,  
++   = 41-400 parasites/µl,  
+++  = 401-4000 parasites/µl, and  
++++  = > 4000 parasites/µl of blood. 
Blood films were defined as negative if no parasite was observed in 300 
microscopic fields. The data from microscopy (species and parasite counts) was retained 
for subsequent comparative analysis. 
In the PCR sensitivity validation, the parasitemia was counted in at least 25 
microscopic fields of thin blood smear (WHO, 2010b). The total parasite count/µl of 
blood was calculated as follows:  
 
    number of observed asexual parasites × total RBC count/µl 
               =  parasite/µl of blood 
        total number of RBC scanned in 25 microscopic fields 
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3.3.3 Malarial DNA extraction from blood sample 
Whole blood samples were equilibrated to room temperature and centrifuged at 
800 × g for 15 minutes. A total of 200 µl infected red blood cells (iRBCs) was drawn 
from the bottom of EDTA-coated blood tube into a 1.5 ml microcentrifuge tube. 
Parasites were isolated by saponin lysis of iRBCs according to Goman, et al. (1982). 
With saponin, the membrane of erythrocytes is selectively lysed, whereas the 
parasitophorous vacuole with the parasite inside remains undamaged. In general, iRBCs 
sample was centrifuged for 10 min at 6,000 × g and the supernatant was discarded. Then, 
the pellet was washed once in 1 ml of cold PBS (pH 7.2) and centrifuge at 6,000 × g for 
10 minutes. The pellet was resuspended in 1 ml of PBS and 10 µl of 5 % (w/v) saponin 
was added at a final concentration of 0.05 % and gently mixed. After that, tube was 
incubated at room temperature for 10 minutes and immediately centrifuged at 6,000 × g. 
The malarial pellet was then washed twice with PBS buffer followed by centrifugation 
at 6,000 × g for 15 minutes to remove the excessive saponin. Washed pellet was then 
dissolved in 200 µl PBS and DNA was extracted using QIAamp
®
 DNA Mini kit 
(Qiagen, Germany), according to the manufacturer’s protocol. 
In general, 20 µl of proteinase K (> 600 mAU/ml) and 4 µl of RNase (100 
mg/ml, Invitrogen) were added into the pellet and mixed by pipetting. After that, 200 µl 
of lysis AL buffer was added to the sample and immediately mixed by vortex for 15 
seconds. The solution was then incubated at 65 ºC for 10 minutes using heat block 
(Major Science). Then, the tube was centrifuged and 200 µl of absolute ethanol was 
added to the sample and mixed again by brief vortex for 15 seconds. The mixture was 
applied to the QIAamp mini spin column, which placed in a 2 ml collection tube and 
centrifuged at 6,000 × g for 1 minute. The spin column was placed in a clean 2 ml 
collection tube and 500 µl of AW1 buffer was added, followed by centrifugation at 
6,000 × g for 1 minute. Again, the spin column was placed into clean collection tube 
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and 500 µl of AW2 buffer was added followed by centrifugation at 20,000 × g for 3 
minute. The QIAamp spin column was placed in a clean 1.5 ml microcentrifuge tube for 
DNA elution. All collection tubes containing the filtrate were discarded. Then, 100 µl of 
AE buffer or dsH2O was added to the column and incubated at room temperature for 5 
minute, followed by centrifugation at 6,000 × g for 1 minute. On the other hand, DNA 
from 20 healthy controls was extracted directly from 200 µl whole blood sample 
utilizing the same kit without saponin adding.  
The DNA sample was eluted in 100 µl of AE buffer, thus corresponding to 
approximately 2 µl of blood per µl of DNA. The concentration and purity of DNA were 
determined using NanoPhotometer
TM
 (IMPLEN, Germany). DNA was stored at -20 ºC 
and 1.5 µl was used for each PCR assay.  
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3.3.4 Preparation of Escherichia coli (E. coli) competent cells 
Chemically-treated competent E. coli cells, Top 10 and C-Max-α used in general 
DNA cloning and BL21-CodonPlus (DE3)-RIL that contains supplementary rare tRNA 
expression plasmid pRIL (Stratagene) used in protein expression were prepared freshly 
prior to DNA cloning.  
In general, a single colony of either Top 10 or C-Max-α E. coli was inoculated 
into 10 ml of LB broth. Whereas BL21-CodonPlus (DE3)-RIL E.coli was inoculated 
into 10 ml LB broth containing 34 µg/ml of chloramphenicol for pRIL selection. The 
culture was grown overnight at 37 ºC.  
Then, 1 ml of the overnight culture was inoculated into 100 ml of LB broth and 
incubated at 37 ºC with shaking at 200 rpm for two hours until the culture reach the 
exponential phase (OD600 reached 0.5), determined by NanoPhotometer
TM
 (IMPLEN, 
Germany). The culture was transferred to 50 ml Falcon tube and centrifuged at 3,000 × 
g for 10 minutes. Supernatant was discarded and the cell pellet was subsequently 
incubated on ice for 10 minutes. The chilled cell pellet was then resuspended in 30 ml 
ice-cold 0.1 M CaCl2 and incubated on ice for one hour followed by centrifugation at 
3,000 × g for 10 minutes. Competent cells are very fragile, thus resuspension in 1 ml of 
ice-cold 0.1 M CaCl2 using disposable Pasteur pipette has to be done gently. The 
competent cells could be used immediately or stored at -80 ºC with 15 % (v/v) glycerol 
for further experiment. For -80 ºC storage, the competent cells were aliquoted into 100 
µl working volume in microcentrifuge tubes and immediately frozen with chilled 
absolute ethanol (kept at -80 ºC) prior to transfer to -80 ºC freezer. 
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3.3.5 Maintenance and recovery of bacteria  
In general, various strains of E. coli were grown overnight in 10 ml of LB broth 
[1 % (w/v) Tryptone, 0.5 % (w/v) Yeast extract, 0.17 M NaCl] at 37 ºC. The cell culture 
was centrifuged at 1,000 × g for 1 minute and pelleted cells was resuspended in 2 ml of 
LB broth containing 15 % (v/v) glycerol and stored at -80 ºC in two aliquots. Culture 
was recovered by scraping off some frozen cells with a sterile loop to subculture the 
bacteria into either a liquid broth or streaked on an agar plate from the stock culture.  
 
3.3.6 Plasmid extraction 
Bacteria containing plasmid DNA was inoculated in 10 ml of LB containing 
appropriate antibiotic. Culture was incubated overnight at 37 ºC with shaking at 200 
rpm. Plasmid DNA was isolated from E. coli culture using HiYield Plasmid Mini Kit 
(Yestern Biotech, Taiwan) according to manufacturer’s instructions. In general, 1.5 ml 
of overnight culture was transferred into a microcentrifuge tube and centrifuged at 
14,000 × g for 1 minute and supernatant was discarded. Pellet was resuspended in 200 
µl of PD1 buffer by vortex. Then, 200 µl of PD2 buffer was added to the suspension 
and mixed gently by inverting the tube 10 times followed by incubation at room 
temperature for 2 minutes until the lysate was clear. Three hundred µl of PD3 buffer 
was added to neutralize the lysate and mixed by inverted the tube 10 times, followed by 
centrifugation at 14,000 × g for 3 minutes. Less than 800 µl of supernatant of the clear 
lysate was aspirated using pipette tip without disturbing the pellet and was then applied 
to the PD column placed in 2 ml collection tube. The spin column was centrifuged at 
6,000 × g for 30 seconds. The flow through in the collection tube was discarded and the 
spin column was placed back in the collection tube. Four hundred ul of W1 buffer was 
added to the PD column and centrifuged at 6,000 × g for 30 seconds. The flow through 
was discarded and 600 µl of W2 buffer was added to PD column and centrifuged at 
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6,000 × g for 30 seconds. The flow through was discarded and centrifuged at 14,000 × g 
for extra 2 minutes to dry the column matrix. Dried PD column was placed in a clean 
microcentrifuge tube and 50 µl of Elution buffer or sdH2O was added to the center of 
column matrix and let it stand for 2 minutes until Elution buffer or sdH2O was fully 
absorbed by the matrix. The plasmid DNA was then eluted by centrifugation at 14,000 × 
g for 2 minutes. The plasmid concentration and purity were determined using a 
nanospectrometer (IMPLEN, Germany). Plasmid DNA was then stored at -20 ºC. 
 
3.3.7 Determination of DNA concentration 
The concentration of extracted DNA was determined by using a 
nanospectrometer (IMPLEN, Germany). Concentration of double-stranded DNA (ng/µl) 
and single-stranded DNA (ng/µl) were calculated from the absorbance at 260 nm (A260), 
using the following equation (Sambrook & Russell, 2001):  
Concentration = A260 × 1 absorption unit at A260 × dilution factor 
One absorbance unit at 260 nm is equal to 50 ng/µl of double stranded DNA and 38 
ng/µl of single stranded DNA. Purity of DNA was determined by calculation the ratio of 
A260 to A280, and pure DNA has an A260/A280 ratio of 1.7-1.9.  
 
3.3.8 Gel electrophoresis 
3.3.8.1 Agarose gel electrophoresis 
Plasmid DNA, PCR products, and RE digested samples were electrophoresed on 
agarose gel (1 to 3 % w/v) stained with EtBr in 1× TBE buffer [90 mM Tris-borate, 2 
mM EDTA (pH 8)]. The DNA fragments were visualized under UV transilluminator 
and photographed using a gel documentary system (Major Science).  
 
 
CHAPTER THREE: MATERIALS AND METHODS 
 
 
80 
3.3.8.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie Blue 
protein staining 
SDS-PAGE was carried out using MiniProtean II apparatus (Bio-Rad). In 
general, protein sample was mixed with equal volume of 2× Laemmli sample buffer 
[0.125 M Tris-HCl, 4 % (w/v) SDS, 20 % (v/v) Glycerol, 0.02 % (w/v) Bromophenol 
Blue, pH 6.8]. There were two types of SDS-PAGE, i.e., reduced and non-reduced with 
presence or absence of reducing agent (β-mercaptoethanol) in sample buffer, 
respectively. The reduced sample was pre-heated at 95 ºC for 10 minutes and then 
cooled on ice immediately before loading, whereas, non-reduced sample was loaded 
directly into gel without pre-heat step.  
Generally, 10 µl of sample mixture was loaded per lane. The samples were 
electrophoresed on 12 % SDS-polyacrylamide separating gel [12 % (v/v) 
polyacrylamide ready-mix solution, 375 mM Tris-HCl (pH 8.8), 0.1 % (w/v) SDS, 0.08 % 
(w/v) APS, 0.8 % (v/v) TEMED] with upper stacking gel [4.5 % (v/v) polyacrylamide 
ready-mix solution, 125 mM Tris-HCl (pH 6.8), 0.1 % (w/v) SDS, 0.1 % (w/v) APS, 
0.001 % (v/v) TEMED] in 1× SDS electrophoresis buffer [50 mM Tris-base (pH 8.3), 
50 mM glycine, 0.02 % (w/v) SDS] at 150 V for 80 minutes. Spectra™ Multicolor 
Broad Range Protein Ladder (10 – 260 kDa) (Fermentas) was used as the molecular 
weight.   
Coomassie Blue staining process was performed in a small plastic container with 
gentle shaking on an orbital rotary (Major Sciences). The resolved polyacrylamide gel 
was rinsed three times in distilled water for 5 minutes to remove the excessive SDS and 
stained with Bio-Safe
TM
 Coomassie G-250 stain (Bio-Rad) for 1 hour, and then the stain 
was discarded. This was followed by destaining with distilled water for 30-60 minutes 
until the resolving protein bands on gel were clearly visible. The result was then 
documented using ImageScanner III (GE Healthcare).  
CHAPTER THREE: MATERIALS AND METHODS 
 
 
81 
3.3.9 DNA purification from gel 
The QIAquick gel extraction kit (Qiagen, Germany) was used to purify PCR 
amplified DNA. All reactions were performed as described by the manufacturer’s 
instructions.  
PCR amplified band of expected size was excised from the 1.5 % (w/v) agarose 
gel with a clean and sharp scalpel and the gel slice was weighed. Three volumes of QG 
buffer was added to one volume of gel excised (100 mg = ~ 100 μl) and incubated at 50 
ºC for 10 minutes accompanied with brief vortexing every 2 minutes to dissolve the gel. 
One volume of absolute isopropanol was added to the sample and mixed. The sample 
was then applied to the column that placed in a 2 ml collection tube and centrifuged at 
17,900 × g for 1 minute. The flow-through was discarded. An additional 0.5 ml of QG 
buffer was added and centrifuged for another 1 minute and the flow-through was 
discarded. A 0.75 ml of PE buffer was added to wash the column, centrifuged for 1 
minute and flow-through was then discarded. This was followed by centrifugation for 1 
minute to remove the residual of ethanol from buffer PE. Later, the column was placed 
into a clean 1.5 ml microfuge tube. Thirty μl of EB buffer (10 mM Tris-Cl, pH 8.5) was 
added to the center of the column and the column was left standing for 1 minute 
followed by centrifugation for 1 minute to elute the DNA. The purified DNA was then 
used in DNA cloning or stored at -20 ºC. 
 
3.3.10 PCR optimization 
PCR conditions were optimized with various modifications of reaction mixtures 
(MgCl2 concentration, dNTP mixture, primers concentration) and thermal cycling steps 
(denaturation, annealing, and extension times and temperatures). The PCR protocols 
(multiplex PCR, nested PCR, colony PCR etc.) were described in more detail in the 
related session.  
CHAPTER THREE: MATERIALS AND METHODS 
 
 
82 
3.3.11 DNA sequencing  
Purified DNA sample for sequence confirmation was prepared and sent out for 
sequencing service (First BASE Laboratories, Malaysia). DNA sequencing was 
performed using a Big Dye
®
 Terminator (version 3.1) Cycle Sequencing Kit (Applied 
Biosystems, USA) with an ABI PRISM
®
 3100 Genetic Analyzer (Applied Biosystems). 
 
3.4 Development of a single-step multiplex PCR detection assay for five human 
Plasmodium species  
3.4.1 Multiplex primers design 
The primers for the hexaplex PCR were designed to amplify the specific region 
of highly conserved 18S small subunit ribosomal RNA (ssu rRNA) gene of the five 
human Plasmodium species, based on multiple alignments of sequences available in 
GenBank databases (http://blast.ncbi.nlm.nih.gov/) (Table 3.1). Basically, nucleotide 
sequences for all five human parasites were aligned and analyzed for their differences 
and conserved regions using CLUSTAL W program (Thompson, Higgins, & Gibson, 
1994) and BioEdit version 7.0.9 software (Hall, 1999) to obtain the consensus 
sequences for primer design.  
Overall, primers were designed by using Primer Premier Software 5.0 
(PREMIER Biosoft International, CA). This software allows the secondary structure 
checking, e.g., the presence of hairpin and dimer structures, possible false-priming, as 
well as cross-dimmers formations, which might affect the overall sensitivity and 
specificity of the multiplex PCR system. The primers with the secondary structure were 
re-designed with slight modification. Finally, five forward species-specific primers and 
a single reverse genus-specific primer of human malaria parasites were designed for this 
multiplex PCR system. The primers were then designed and checked through a Basic 
Local Alignment Tool (BLAST) (Altschul, Gish, Miller, Myers, & Lipman, 1990), 
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using Nucleotide BLAST (BLASTN) search (http://www.ncbi.nlm.nih.gov/) to ensure 
no non-specific amplification from non-target gene. The expected species-specific 
fragment sizes are shown in Table 3.1.  
 
Table 3.1: Plasmodium species and GenBank accession numbers for the 18S ssu rRNA 
sequence. 
Plasmodium species Accession number Base pair 
P. vivax X13926 
U03079 
~ 215 
P. knowlesi DQ350260 
DQ350261 
DQ350262 
DQ350263 
~ 284 
P. ovale curtisi 
 
 
 
P. ovale wallikeri 
 
AB182489 
AB182490 
AF145337 
L48987 
AB182491 
AB182492 
~ 304 
P. cf. malariae 
 
P. malariae 
AF487999 
AF488000 
AB489195 
AB489196 
AF145336 
~ 341 
P. falciparum M19172 
JQ627149 
JQ627150 
JQ627151 
JQ627152 
~ 453 
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3.4.2 In silico PCR  
Multiple sequences of Plasmodium species 18S ssu rRNA available in GenBank 
and NCBI databases in FASTA format were exported to ‘in silico’ database in txt 
format (up to five sequences in each assay). Together with designed primers pair, in 
silico PCR (http://insilico.ehu.es/PCR/) was performed for prediction of amplicons.  
 
3.4.3 Multiplex PCR optimization 
To develop a multiplex PCR, optimization in the concentration of MgCl2, 
dNTPs, primers, as well as PCR cycling parameters (especially primers annealing 
temperature) are important to avoid unspecific amplification and to ensure that each of 
the selected targets was correctly amplified at about equal intensity. Basically, the PCR 
parameters in the present study were optimized step by step as described by Henegariu 
and colleagues (Henegariu, Heerema, Dlouhy, Vance, & Vogt, 1997). Initially, the 
primer pair was optimized under monoplex conditions. Next, all primers were mixed 
together to perform subsequence multiplex PCR optimization for the detection of five 
human malaria parasites. PCR amplification was performed using TaKaRa PCR 
Thermal Cycler Dice
TM
 (TAKARA BIO, Japan). Finally, a stable and consistent 
multiplex PCR condition was established.  
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3.4.4 Positive control 
Three sets of additional primers were designed, in which one of these primer set 
will subsequently be included into the optimized multiplex PCR system as positive 
control for the determination of successful DNA extraction procedure and PCR reaction 
in present multiplex system. The PCR condition of each of the primer set was 
experimental tested to validate the suitability as positive control in the present multiplex 
system. 
In first control set, pGEX4T1 plasmid DNA, an external DNA together with a 
pair of targeted primers, i.e., pGEX (F) and pGEX (R) were included into optimized 
multiplex PCR system.  
In the second control set, a single forward primer targeting both human and 
Plasmodium conserved region of 18S ssu rRNA genes as well as a single reverse primer 
targeting human conserved region of ssu rRNA gene were designed. The primers were 
able to amplify both human and Plasmodium ssu rRNA conserved gene, thus generated 
two additional amplicons for the system. 
In the third control set, a pair of human housekeeping β-hemoglobin primers was 
designed. This primer set was finally included as an internal positive control for the 
present multiplex system.  
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3.4.5 Multiplex PCR amplification 
Fifteen µl of PCR reagent mixture containing 20 mM of Tris-HCl, 20 mM of 
KCl, 5 mM of (NH4)2SO4, 3.0 mM of MgCl2, 0.2 µM of each dNTP, the empirically 
determined concentration of primers (0.6 µM of single reverse genus-specific, F453, 
M341, and O304 primers, 0.5 µM of K284 primer, 0.4 µM of V215 primer, and 0.25 µM of 
each β-hemoglobin primers), 1 U of Maxima® Hot Start Taq DNA polymerase 
(Fermentas, USA), and 1.5 µl (~10 ng) of template DNA were used in the detection 
study. The reactions were subjected to initial denaturation at 95 ºC for 5 min, 35 
amplification cycles at 95 ºC for 30 sec, 56 ºC for 30 sec, 65 ºC for 40 sec, followed by 
a final extension at 65 ºC for 10 min using TaKaRa PCR Thermal Cycler Dice
TM
 
(TAKARA BIO, Japan). The amplified products were visualized on 3 % (w/v) agarose 
gel (Promega) stained with ethidium bromide.  
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3.4.6 Nested PCR amplification 
Nested PCR amplification was performed as a molecular gold standard method 
for the identification of human Plasmodium species (Singh, et al., 1999; Snounou, et al., 
1993) (Appendix 3.1) to validate the sensitivity and specificity of the present multiplex 
PCR system. Nested PCR conditions with minor modification were done using TaKaRa 
PCR Thermal Cycler Dice
TM
 (TAKARA BIO, Japan).  
First nested PCR was performed in a final volume of 15 µl that consisted of 1× 
optimized Dream Taq
TM
 buffer, 0.3 mM of each dNTP, 0.3 µM of each rPLU1 and 
rPLU5 primers (Snounou, et al., 1993), 2.0 mM of MgCl2, 1.5 µl of DNA template, 1.0 
U Dream Taq
TM
 DNA polymerase (Fermentas, USA). PCR amplifications were carried 
out with an initial denaturation step at 95 ºC for 3 minutes; 30 repeated cycles of  95 ºC 
for 30 seconds,  60 ºC for 30 seconds, and 72 ºC for 1 minute 30 seconds, followed by 
an extension step at 72 ºC for 7 minutes. 
Second nested PCR contained 10 mM of Tris-HCl, 50 mM of KCl, 0.08 (v/v) of 
Nonidet P40, 1.5 mM of MgCl2, 0.2 mM of each dNTP, 0.3 µM of each pair of primers 
i.e., rFAL1/2, rVIV1/2, rMAL1/2, rOVA1/2, and Pmk8/Pmkr9 (Singh, et al., 1999; 
Singh, et al., 2004), 0.5 U of Taq DNA Polymerase (Fermentas, USA), as well as 0.5 µl 
of amplicons from first nested PCR was used as DNA template in a final volume of 15 
µl. The OVA1/2 primer pair only targeting ssuRNA gene of P. ovale curtisi but not for 
P. ovale wallikeri, therefore an alternative primer pair targeting both P. ovale curtisi and 
P. ovale wallikeri from multiplex PCR was added to the second nested PCR (Padley, 
Moody, Chiodini, & Saldanha, 2003). The PCR thermal cycling was the same as the 
first nested PCR except that the temperature was changed to 72 ºC for 30 seconds in the 
30 repeated cycles.  
First and second nested PCR products were visualized on 1 % and 2 % (w/v) 
agarose gel (Promega) stained with ethidium bromide respectively. 
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3.4.7 Plasmodium 18S ssu rRNA clones construction  
Approximately 1.6-1.7 kb DNA fragment of 18S ssu rRNA gene of five human 
Plasmodium species, i.e., P. falciparum, P. vivax, P. knowlesi, P. malariae, and P. ovale 
clones were amplified using rPLU1 and rPLU5 primers (Snounou, et al., 1993) using 
nested PCR technique. The PCR products were further gel purified using QIAquick gel 
extraction kit prior to being cloned into the pCR
®
II-Topo TA cloning system 
(Invitrogen Life Technologies, USA) and transformed into Top10 chemically treated 
competent E. coli host cells, accordingly to the manufacturer’s guidelines.  
In general, 6 µl of ligation mixture containing 1 µl of salt (200 mM of NaCl; 10 
mM MgCl2), 0.5 to 4.0 µl of purified PCR product, and 1 µl of pCR
®
II-TOPO vector 
[10 ng/µl plasmid DNA; 50 % (v/v) glycerol; 50 mM Tris-HCl, pH 7.4; 1mM EDTA; 1 
mM DTT; 0.1 % (v/v) Triton X-100; 100 µg/ml BSA; phenol red). The ligation mixture 
was gently mixed and incubated for 30 minutes at room temperature (22-23 ºC) and 
then placed on ice or kept overnight at -20 ºC until transformation step was carried out.  
The amount of DNA needed for the ligation reaction was calculated, e.g.: 
 
 
 
Two µl of the TOPO
®
 cloning reaction was added into 100 µl of chemically 
competent TOP10 E. coli and mixed by gently swirling followed by incubation on ice 
for 30 minutes. Next, heat-shock transformation of the E. coli cells for 30 seconds at 42 
ºC was carried out and immediately transferred to the ice and incubated for 2 minutes. 
Then, 500 µl of S.O.C medium was added to the cells and shook horizontally (200 rpm) 
at 37 ºC for 1 hour. Fifty and 100 µl of each transformation were spread onto the LB 
agar plates containing 100 ug/ml of ampicillin, 50 µg/ml IPTG and 40 µg/ml Xgal. The 
plates were incubated overnight at 37 ºC. 
 
    10 ng of vector × 1.7 kb of inserted DNA            3 
                ×       = ~ 13 ng of insert DNA 
   3.9 kb of vector                        1 
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3.4.7.1 Screening of positive clones by colony PCR 
In order to identify positive clones, approximately 20 white colonies were 
randomly picked from the master (transformation) plate and incubated overnight in 1 ml 
of LB broth containing 100 ug/ml of ampicillin. Putative transformations were further 
confirmed by colony PCR. The 15 µl reaction contained 1× Taq polymerase PCR buffer 
(10 mM Tris-HCl, 50 mM KCl, 0.08 (v/v) Nonidet P40), 1.5 mM of MgCl2, 0.2 mM of 
each dNTP, 0.1 µM of each pair of T7 promoter and SP6 primers, 0.5 U of Taq DNA 
Polymerase (Fermentas), and 5 µl of boiled supernatant as template (supernatant was 
prepared from 10 µl of culture boiled for 10 minutes and spun down at 14,000 ×g for 30 
seconds). The cycling reaction was set as follows: an initial denaturation at 94 ºC for 5 
minutes, followed by 30 cycles of denaturation at 94 ºC for 30 seconds, annealing at  60 
ºC for 30 seconds, extension at 72 ºC for 90 seconds and a final extension incubation at 
72 ºC for 7 minutes. The PCR products were then analyzed on 1 % (w/v) agarose gel.  
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3.4.7.2 Screening of positive clones by DNA sequencing 
The positive clone confirmed by colony PCR was further isolated from 1 ml of E. 
coli culture using HiYield Plasmid Mini Kit (Yestern Biotech, Taiwan), according to the 
manufacturer’s instructions prior to subjected to sequencing. The nucleotide sequence 
of the selected plasmids was sequenced with T7 promoter (F) and SP6 (R) universal 
primers by using a Big Dye
®
 Terminator (version 3.1) Cycle Sequencing Kit (Applied 
Biosystems, USA) with an ABI PRISM
®
 3100 Genetic Analyzer (Applied Biosystems) 
for subsequence clones confirmation. The gene sequence (electropherogram) obtained 
was then analyzed using BioEdit version 7.0.9 Software (Hall, 1999) and CLUSTAL-W 
program (Thompson, et al., 1994). The gene sequence of each of five constructs was 
then blast searched on NCBI (http://www.ncbi.nih.gov) for inter-species confirmation.  
All five Plasmodium clones were used as templates in analytical sensitivity and 
specificity validation, as well as serve as positive controls in the subsequent PCR 
amplifications. Individual clones were long term stocked at -80 ºC in LB broth 
containing 100 ug/ml of ampicillin and 15 % (v/v) glycerol. 
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3.4.8 Sensitivity and specificity tests   
Sensitivity and specificity tests that were used to describe the value of assays, 
i.e., analytical sensitivity and specificity, diagnostic sensitivity and specificity, and 
random blind test were carried out in the present study.  
 
3.4.8.1 Analytical sensitivity test 
The parasitemia of the five human Plasmodium species, i.e., P. vivax, P. 
falciparum, P. knowlesi, P. malariae, and P. ovale obtained from clinical samples were 
estimated (Session 3.3.2) and each of the DNA sample was extracted. The extracted 
DNA of each species was then 10-fold serially diluted (10
-1
 to 10
-7
) with human DNA 
(10 ng/µl) and one µl of the DNA mixture was used in PCR reaction in the sensitivity 
validation assay. The sensitivity of the present hexaplex system to five human 
Plasmodium species were compared with the nested PCR as the molecular gold standard, 
whereas the microscopic results were used as the reference for the presence of the 
Plasmodium species.  
In clinical mixed infections, the ratios between two or more parasite species can 
be vary substantially (Conway, 2007; Zimmerman, et al., 2004), therefore, the effect of 
DNA and primer competition was also tested for the present multiplex PCR system. 
Due to lack of natural mixed infections, three combinations of experimental mixtures, 
i.e., 100 pg/µl of P. vivax clone DNA and 1, 10 or 100 pg/µl of P. falciparum clone 
DNA were created to determine the sensitivity of this multiplex PCR. A total of 60 
mixtures were test, i.e., make-up of 12 different simulated mixtures of DNA using two 
out of five human Plasmodium species for each set and three DNA concentrations. 
There were 10 possible combinations of two species simulated mixed infections. 
Besides, to test whether these primers would improve the detection of clinical mixed 
infections, a total of 30 experimental random mixed infections were created using 
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clinical samples and screened using the present multiplex PCR system and nested PCR 
as molecular gold standard for identifying mixed infections.  
 
3.4.8.2 Analytical specificity test 
Analytical specificity is the assay’s ability to measure one Plasmodium species, 
rather than other organisms in the sample. To estimate the analytical specificity of the 
Plasmodium hexaplex assay, DNA samples of other non-Plasmodium, i.e., Toxoplasma 
species, Giardia species, Aeromonas species, Serratia species, Vibrio species, and hook 
worm were screened. Besides, DNA from 20 healthy individuals also tested for the 
specificity and possibility of unspecific fragment.  
 
3.4.8.3  Random blind test and clinical sample screening 
To validate the sensitivity and specificity of the present multiplex system in 
species determination, a random blind test on 50 DNA samples (randomly drawn from 
211 microscopy confirmed clinical samples) followed by a detection study on 226 
clinical samples were carried out together with nested PCR for comparison.  
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3.4.8.4 Diagnostic sensitivity and specificity tests 
The diagnostic sensitivity (true positive rate), specificity (true negative rate), 
positive predictive value (PPV) (probability that the diseases is present when the test is 
positive), and negative predictive value (NPV) (probability that the diseases is not 
present when the test is negative) of two species, i.e., P. vivax and P. falciparum were 
calculated as formulas stated below (Table 3.2), based on 226 microscopic-confirmed 
malaria samples collected from two medical centers as well as 20 healthy control donors, 
using nested PCR as the standard. The 95 % confidence interval (95 % CI) was also 
calculated using MedCalc-Diagnostic test evaluation (http://www.medcalc.org/calc/ 
diagnostic_test.php). The calculations were expressed as percentage for ease of 
interpretation.  
 
Table 3.2: Formulas used in diagnostic specificity and sensitivity tests. 
 
a = known positive; test result positive (true positive); b = known positive; test result 
negative (false negative); c = known negative; test result positive (false positive); d = 
known negative; test result negative (true negative). 
 
95 % CI = exp [ In (OR) ± 1.96      (1 / a) + (1 / b) + (1 / c) + (1 / d) ] 
                                 Nested PCR 
Multiplex PCR 
Positive Negative 
Positive a c  
Negative b d 
Sensitivity a/(a+b) 
Specificity d/(c+d) 
PPV a/(a+c) 
NPV d/(b+d) 
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Development of a multiplex PCR targeting 18S small subunit ribosomal RNA 
gene for human Plasmodium species 
 
3.4.9 Overview of the development of a multiplex PCR detection system for 
human Plasmodium species 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Sample collection: 
Clinical samples (n=226) 
Healthy controls (n=20) 
 
DNA extraction 
Microscopy examination and 
parasitemia estimation 
Nested PCR amplification  
Multiplex PCR optimization 
Clone construction: 
Plasmodium vivax 
Plasmodium knowlesi 
Plasmodium ovale 
Plasmodium malariae 
Plasmodium falciparum 
Primer designed and multiplex 
PCR development 
Random 
blind test 
(n=50) 
Diagnostic sensitivity and specificity 
 - Sensitivity 
 - Specificity 
 - 95 % confident interval (95 % CI) 
 - Positive predictive value (PPV) 
 - Negative predictive value (NPV)  
 
Analytical 
sensitivity and 
specificity 
 
Clinical 
screening 
(n=246) 
Single 
infection 
Mixed 
infections 
Inclusion of positive control 
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3.5 Identification of binding peptides for PkAMA1 and PvAMA1 using a phage 
display library 
3.5.1 Heterologous protein expression in prokaryotic system 
Protein expression was carried out using Profinity eXact
TM
 System (Bio-Rad) 
(Appendix 4), according to the manufacturer’s instructions. The expression system was 
initiated with heterologous expression of target proteins in E. coli, which involved the 
construction and cloning of the target protein sequences into an expression vector, i.e., 
pPAL7 (size 5,901 bp) followed by further recombinant protein isolation as well as 
affinity purification using Profinity eXact Mini Spin Column (small scale purification) 
and 1 ml or 5 ml Bio-Scale Profinity eXact Mini Cartridges (large scale purification).  
 
3.5.1.1 Construction of PkAMA1 and PvAMA1 clones  
Specific forward and reverse primers were designed with appropriate RE 
recognition sites to adapt the Plasmodium AMA1 ectodomain gene for precise insertion 
into expression vector, i.e., pPAL7 based on the multiple cloning site provided by 
manufacturer (Appendix 4). 
The currently available whole sequence of AMA1 of the P. vivax and P. 
knowlesi were blast searched using NCBI database, followed by subsequence multiple 
aligned using BioEdit and ClustalW softwares. Finally, two sets of PCR primers with 5’ 
SpeI upstream (sense) and 5’ BamHI downstream (anti-sense) RE sites were designed 
for the amplification of gene fragments encoding the whole ectodomain, i.e., domain I 
(DI), domain II (DII), and domain III (DIII) of AMA1 for P. knowlesi (PkAMA1) and P. 
vivax (PvAMA1) (Table 3.3). The compatibility of appropriate REs sites were 
confirmed by NEB cutter V2.0 (NEB; http://tools.neb.com/NEBcutter2/) to eliminate 
the possibility of RE digestion on the PCR amplicon. 
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Although all the apicomplexan parasites share a structural homology in AMA1 
protein, the coding DNA of AMA1 gene is relatively polymorphic among Plasmodium 
species. As genetic variations were noted in the sequence of AMA 1 gene among 
intraspecies of P. vivax adopted from NCBI database, degenerate primers were designed 
as in Table 3.3. In each of the reverse primer, a stop codon (anticodon; +/-), either TTA 
(STOPTAA), CTA (STOPTAG), or TCA (STOPTGA) was included after RE recognition 
sequence to terminate the expression of target protein.  
 
Table 3.3: Primer pairs used in protein expression of PkAMA1 and PvAMA1.  
 
* Bolded sequences indicate of the appropriate RE recognition site; underline-bolded 
sequences indicate a stop codon of the reverse primer.  
 
DNA fragments of PkAMA1 and PvAMA1 were amplified using TaKaRa PCR 
Thermal Cycler Dice
TM
 (TAKARA BIO, Japan) and KOD Hot Start DNA polymerase 
(Novagen, USA). The 30 µl reaction contained 1× optimized PCR buffer, 2.0 mM 
MgSO4, 0.3 mM of each dNTP, 0.5 mM of each forward and reverse primers, 1 U of 
KOD Hot Start DNA polymerase, as well as 3 ul (~ 20 ng) of template DNA.  The 
cycling reaction was performed as follows: an initial denaturation step at 95 ºC for 2 
minutes, followed by 35 repeated cycles at 95 ºC for 20 seconds,  annealing temperature 
for 10 seconds, and 70 ºC for 30 seconds, followed by a final extension step at 70 ºC for 
15 seconds. Annealing temperature of each of the primers set was differed with 48 ºC 
and 50 ºC for PkAMA1 and PvAMA1, respectively. 
Name Primer sequence (5’-   -3’) REs sites 
PkAMA1 
AGCTATACTAGTGGGCCTATCATTGAGAGAAGT 
AGACAAGGATCCTTATAGTAGCATCTTCTTCTTATG 
SpeI 
BamHI 
PvAMA1 
ATATATACTAGTGGGCCTACCGTTGAGAGRAGC 
AGACAAGGATCCTTATAGTAGCATCYGCTTGTTCGA 
SpeI  
BamHI 
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Both the PCR product (PkAMA 1 and PvAMA 1 fragments) and supercoiled 
pPAL7 plasmid (Bio-Rad) were double digested with two restriction enzymes, i.e., SpeI 
(5’- A/CTAGT-3’) and BamHI (5’-G/GATCC-3’) according to the manufacturer’s 
instructions. In general, double digestion was performed at 37 ºC for 5 minutes in PCR 
tube containing 1× FastDigest restriction buffer, 1 µl of each of FastDigest RE 
(Fermentas), and 200 ng of either PCR product or pPAL7 vector to a final reaction 
volume of 30 and 20 μl, respectively. The enzymatic digestion was inactivated by DNA 
gel purification (Session 3.3.9) prior to DNA ligation. 
The gel purified RE digested-PCR product as well as pPAL7 vector were ligated 
using Ready-To-GO
TM
 T4 DNA Ligase (Amersham Biosciences). The vector:insert 
molar ratio used here was 3:1 as described in Sambrook and Russell (2001) for optimal 
sticky end ligation. Generally, 100 ng of REs-digested pPAL7 vector and ~ 70 ng of 
REs-digested PCR product were added to the lyophilized Ready-To-GO
TM
 T4 DNA 
Ligase tube, and was then reconstituted to a final volume of 20 µl solution, which 
contained 6 U of FPLCpure
TM
 T4 DNA ligase, 66 mM Tris-HCl (pH 7.6), 6.6 mM 
MgCl2, 0.1 mM ATP, 0.1 mM spermidine, and 10 mM DTT. The ligation mixture was 
incubated at 16 °C for 45 minutes. The ligation reaction was heat inactivated by 
incubation at 70 ºC for 10 minutes using heat block (Major Sciences).  
Two µl of ligation mixture were added and mixed to each of the 100 µl aliquot 
of C-Max5α E. coli competent cells by stirring briefly using pipette tip and then 
incubated on ice for 30 minutes prior to heat shock transformation at 42 ºC for 30 
seconds. The E. coli was then incubated immediately on ice for another 2 minutes. One 
ml of SOC [2 % (w/v) Tryptone, 0.5 % (w/v) Yeast extract, 10 mM NaCl, 10 mM 
MgCl2, 20 mM glucose] media was added to the culture followed by incubation at 37 ºC 
with 200 rpm agitation for 2 hours. One hundred µl of the culture was used for plating. 
Positive clones were selected onto LB agar supplemented with 100 ug/ml of ampicillin 
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and 0.5 % (w/v) glucose. The plates were incubated overnight at 37 ºC.  
Successful clones were then confirmed by colony PCR using forward T7 
promoter and reverse T7 terminator universal primers as described in colony PCR 
(Session 3.4.7.1). A ~ 400 bp of PCR band indicative of negative insertion, while ~ 1.8 
kb PCR band indicative of successful clone with insertion of ~ 1,350 bp target gene. 
Plasmids from successful clones were then isolated (Session 3.3.6) and sent for 
sequencing for the further correct insertion confirmation using pPAL7 internal forward 
primer (5’-GTGCTTCAAATATGTAGACGCA-3’; designed for sequencing) and T7 
terminator reverse primers. 
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3.5.1.2 Subcloning of Plasmodium AMA 1 ectodomain 
The E. coli culture that carries desired plasmid confirmed by sequencing was 
grown overnight and the plasmid was extracted (Session 3.3.6) and re-transformed into 
protein expression host, BL21-Codon Plus (DE3)-RIL E. coli cells (Stratagene) as 
manufacturer’s instructions.  
In general, an aliquot of competent cells (100 µl) were thawed on ice and 2 µl of 
1:10 diluted XL10-Gold β-mercaptoethanol mixture provided by the kit was added to 
each of the 100 µl of cells. The content of the tube was mixed gently by swirling and 
incubated on ice for 10 minutes with gentle swirling in every 2 minutes. Then, 50 ng of 
expression plasmid DNA containing the target gene was added to the tubes and swirled 
gently using pipette tip. The reaction mixture was incubated on ice for 30 minutes, 
followed by transformation of cell using heat shock method.  
The successful clones were selected onto LB agar plates supplemented with 100 
µg/ml of ampicillin to select pPAL7 plasmid as well as 34 µg/ml of chloramphenicol to 
select pACYC-based plasmid that confers chloramphenicol resistance. The plates were 
incubated overnight at 37 ºC. Successful colonies were further confirmed by colony 
PCR using pPAL7 internal (F), T7 promoter (F), and T7 terminator (R). 
Colony that carried positive clone was then streaked on a LB plate containing 
100 µg/ml ampicillin, 34 µg/ml chloramphenicol and grown overnight at 37 °C.  A loop 
full of colony was then inoculated in 5 ml of LB broth containing appropriate antibiotics 
and the log phase cells were then harvested by centrifugation at 4,000 ×g. The cell pellet 
was then suspended in 2 ml of LB broth containing 100 µg/ml ampicillin, 34 µg/ml 
chloramphenicol and 15 % (v/v) glycerol and stored at -80 ºC in two aliquots. The clone 
stocks acted as starter culture in subsequence recombinant protein expression. 
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3.5.2 Protein induction  
Ten ml of LB agar supplemented with 100 µg/ml ampicillin and 34 µg/ml 
chloramphenicol was inoculated with 5 µl of frozen stock culture and grown to 
confluence overnight as seed culture.   
One ml of overnight seed culture was added to 100 ml of 2× YT medium 
containing 100 µg/ml ampicillin and 34 µg/ml chloramphenicol and incubated at 37 ºC 
with 225 rpm shaking for ~ 3 hours (till bacterial turbidity reached ~ 0.6 at OD600). The 
protein expression is under the transcriptional control of the lac operator, which cause 
the inhibition of the T7 promoter due to the lac repressor protein. The addition of IPTG 
leads to the inactivation of the repressor protein and subsequent protein expression. 
Therefore protein expression was induced by the addition of 0.5 mM IPTG to the 
culture and further incubation for another 3 hours at 25 ºC with vigorous agitation at 
250 rpm. The bacteria cells were harvested by the centrifugation at 4,000 ×g for 20 
minutes at 4 ºC. The cell pellet was lysed directly or kept at -80 ºC for up to one week 
for further recombinant protein isolation.  
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3.5.3 SDS-PAGE solubility screening 
Solubility and expression level of target protein were screened by SDS-PAGE 
prior to subsequence large scale purification. Basically, 1 ml of culture was centrifuged 
at 16,000 ×g for 1 minute at 4 ºC. Five hundred µl of lysis buffer (100 mM sodium 
phosphate, pH 7.2, 200 µg/ml lysozyme) was added to the pellet and the cells were 
disrupted by vortexing for 1 minute. Twenty µl of lysate was collected in PCR tube and 
served as total sample (T) in SDS-PAGE analysis. The total lysate was then centrifuged 
at 16,000 × g for 5 minutes at 4 ºC and the supernatant served as soluble sample (S). 
The insoluble pellet was then resuspended in 500 ul of solubilization buffer (100 mM 
sodium phosphate, 4 M urea, pH 7.2), incubated for 1 hour at 4 °C, and then centrifuged 
at 16,000 × g for 5 minutes at 4 ºC. The supernatant served as insoluble protein (I). 
Twenty µl of T, S, and I samples were analyzed by SDS-PAGE and visualized by 
Coomassie Blue staining.  
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3.5.4 Western hybridization and colorimetric detection 
The expressed protein was further confirmed by colorimetric Western blotting 
assay using the anti-eXact monoclonal antibody (Bio-Rad).  
Proteins on SDS-PAGE gel was transferred to a membrane by electroblotting 
using, i.e., TE70 ECL Semi-dry Transfer Unit (Amersham Biosciences). After 
completion of SDS-PAGE, stacking gel of the polyacrylamide gel was removed and 
discarded. Separating gel was equilibrated in the Towbin transfer buffer for 15 minutes 
prior to Western blotting.  
For each gel, six pieces of blotting papers and 1 piece of Whatman Protran 
nitrocellulose transfer membrane (0.45 µm; Millipore) were cut to the same size as the 
gel or slightly smaller. The nitrocellulose membrane was soaked in dH2O for 5 minutes, 
then transferred and soaked in Towbin transfer buffer [25 mM Tris, 192 mM glycine, 
20 % (v/v) methanol, 0.1 % SDS; pH 8.3] for 5 minutes. Six pieces of blotting papers 
were also saturated in a dish filled with Towbin transfer buffer.  
The electrode plates was rinsed with dH2O and the transfer stack was assembled 
one by one in order from the lower plate (anode) to the upper plate (cathode) with three 
pieces of blotting paper, nitrocellulose membrane, gel, and followed by three pieces of 
blotting papers. Air pockets in each layer were removed by rolling a clean Falcon tube 
over the layer. After that, the lid of transfer unit was placed and the proteins were 
transferred at voltage limit to 30 V and current at 0.8 mA/cm
2
 for 1 hour. 
After blotting, the membrane was pre-stained with NOVEX
®
 Reversible 
membrane protein stain (Invitrogen) and then documented with ImageScanner III (GE 
Healthcare). The temporary stained was then removed according to the manufacturer’s 
instructions followed by immunodetection of target protein, as well as chromogenic 
visualization with horseradish peroxidase (HRP) using Opti-4CN substrate kit (Bio-
Rad).   
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All following steps were performed in a small plastic container on an orbital 
rocker. The membrane was air dried and washed twice with PBST for 5 minutes in each 
wash. After washing steps, the membrane was gently rocked in blocking buffer [PBST 
with 3 % (w/v) BSA] for 1 hour at room temperature, and then followed by two wash 
with PBST for 5 minutes each. After that, membrane was incubated with appropriate 
diluted primary antibody, i.e., anti-eXact monoclonal antibody (Bio-Rad) at dilution 
1:5,000 in an antibody dilution buffer [PBST, 1 % (w/v) BSA] for 1 hour and then 
followed by two wash with PBST for 5 minutes each. Next, the membrane was 
incubated with goat-anti-mouse-HRP conjugated secondary antibody in dilution 1:5,000 
for 1 hour at room temperature followed by another two washing steps with PBST for 5 
minutes each.  
Colorimetric reagent provided in Opti-4CN substrate kit was prepared according 
to the manufacturer’s instructions. Basically, one part of 10× Opti-4CN diluent 
concentrate was added with nine parts of sdH2O and 0.2 ml of Opti-4CN substrate was 
added per 10 ml of diluent. The reagent was mixed well and poured onto a membrane 
followed by gentle agitation for up to 30 minutes or until the desired band intensity was 
observed. The membrane was then washed in sdH2O for 15 minutes and allowed to air 
dry followed by membrane documentation with ImageScanner III (GE Healthcare). 
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3.5.5 Recombinant protein extraction from E. coli and insoluble inclusion body 
purification  
The cell pellet from the 100 ml of culture (Session 3.5.2) was resuspended in 5 
ml of B-PER
®
 in phosphate buffer (Pierce) in the presence of 1× Calbiochem
®
 Protease 
Inhibitor Cocktail Set I (Novagen) and 200 µg/ml of lysozyme (Novagen). The cells 
were disrupted by 20 pass through a 25 Guage syringe needle and followed by vortexed 
for a minute, and incubation at room temperature for 20 minutes with shaking at 40 rpm 
on an orbital rotary (Major Sciences). Ten U/ml of Benzonase (Novagen) was added 
after that and incubated for another 20 minutes to reduce the cell lysate viscosity. After 
incubation, 20 µl of total lysate was kept for SDS-PAGE analysis (labeled as T indicates 
of total lysate). The total lysate was centrifuged at 16,000 × g for 15 minutes at 4 ºC. 
The supernatant containing the soluble protein was collected in clean Falcon tube and 
20 µl of supernatant was kept for gel analysis (labeled as S).  
The pellet containing insoluble proteins or known as inclusion body (IB) was 
resuspended in 5 ml of wash buffer 1 [B-PER
 
buffer, 200 µg/ml lysozyme, 1 % (v/v) 
Triton X-100, 5 mM EDTA, 5 mM DTT, 1 M urea] by 20 pass through a 25 Guage 
syringe needle followed by incubation at room temperature for another 20 minutes with 
shaking at 40 rpm on an orbital rotary (Major Sciences). Twenty µl of suspension was 
kept for gel analysis and labeled as insoluble protein (I). Generally, the IB was washed 
with 1 M urea and 1 % Triton X-100 to remove E. coli cellular materials. Higher 
concentration of urea (more than 4 M) may result in partial solubilization of the 
recombinant protein, whereas Triton X-100 will not solubilize IB proteins, it was 
included to help extract lipid and membrane-associated proteins. Then, a total 15 ml of 
pre-chilled IB wash buffer 2 [1:10 diluted B-PER, 1 % (v/v) Triton X-100, 5 mM 
EDTA, 5 mM DTT, 1 M urea] was added to the suspension and mixed by vortexing for 
1 minute followed by centrifugation at 16,000 × g for 15 minutes at 4 ºC. Twenty µl of 
CHAPTER THREE: MATERIALS AND METHODS 
 
 
105 
supernatant was kept for gel analysis and labeled as insoluble supernatant (IS). The 
pelleted IB was then resuspended and washed with 15 ml of IB wash buffer 3 (1:10 
diluted B-PER) followed by centrifugation at 16,000 × g for 15 minutes at 4 ºC to 
remove excess Triton X-100 from the pellet. The washed IB becomes whiter as the 
purity increased.  
In every experiment, the protein fractions obtained during cells lysis and 
preparation of washed IB were analyzed with reduced SDS-PAGE. The purity of the IB 
can also be determined by comparing the intensities of the insoluble portion of total 
protein (I) as well as suspensions collected from each of the washing steps (W1 and 
W2). The suspension obtained from last washing step was designated as purified IB. 
Finally, the purified IB was then pelleted by centrifugation at 16,000 × g for 30 minutes 
at 4 ºC, which can be either processed directly for protein purification or long term 
stored at -80 ºC. 
 
3.5.5.1  Inclusion body solubilization 
Strong denaturant (urea) and reducing agent (DTT) were used to solubilize the 
purified IB. In general, purified IB was resuspended in IB solubilization buffer (100 
mM sodium phosphate, pH 7.2, 4 M urea, 5 mM DTT, 1 mM EDTA) and incubated 
either for at least 1 hour at room temperature (~ 25 ºC) or overnight at 4 ºC. Suspension 
of protein was then centrifuged at 15,000 × g for 30 minutes at 4 ºC. Supernatant 
containing denatured proteins was then collected and filtered through a 25 mm diameter 
0.45 µm pore size cellulose acetate membrane filter (Sartorius Stedim Biotech) prior to 
recombinant protein purification to prevent clotting of the Profinity eXact
TM
 purification 
cartridge (Bio-Rad). The sample was then diluted to a final concentration of 2 M urea 
and then kept at 4 ºC or on ice until further affinity purification. 
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3.5.6 Affinity protein purification under denatured conditions and fusion-tag 
removal 
The solubilized pPAL7-PkAMA1 and pPAL7-rPvAMA1 proteins were purified 
using 1 ml or 5 ml Bio-Scale Mini Profinity eXact
TM 
cartridges pre-packed with 1 or 5 
column volumes (CV) settled resin (Bio-Rad), respectively, using low pressure 
peristaltic pump system (Heildolph, Germany). Generally, the denatured purification 
protocol was adapted from manufacturer’s instructions that based on soluble protein 
purification, with inclusion of 4 M urea (denaturant) in both bind/wash and elution 
buffers along purification procedures.  
Cartridge was equilibrated with 10 CV of 100 mM sodium phosphate (pH 7.2) 
buffer at 3 ml/min to remove storage buffer containing 0.02 % (w/v) sodium azide. 
Chilled and filtered protein sample (~ 10 ml) was loaded at 1 ml/min. The cartridge was 
then washed with 15 CV of pre-chilled bind/wash buffer (4 M urea, 100 mM sodium 
phosphate, pH 7.2) at 3 ml/min. Another 10 CV of stringency wash (4 M urea, 100 mM 
sodium phosphate, 200 mM sodium acetate, pH 7.2) was performed to reduce the 
nonspecific and electrostatic binding of fusion protein. After that, the cartridge was then 
pumped with 5 CV of elution buffer (4 M urea, 100 mM sodium phosphate, 100 mM 
sodium fluoride, pH 7.2) at 0.1 ml/min at room temperature and the eluted target protein 
was collected in clean microcentrifuge tubes (1 ml each). Purified protein was stored at 
-80 ºC. The purity of the protein was determined using reduced SDS-PAGE and the 
concentration was estimated using Bradford Protein Assay (Bio-Rad).  
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3.5.7 Protein concentration determination using Bradford protein assay 
Concentration of the protein in solution was determined using Quick Start 
Bradford Protein Assay (Bio-Rad). The concentration of unknown protein was 
estimated using mean value of the triplicate readings obtained from the binding activity 
of Coomassie Brilliant Blue G250 dye to the protein standards, i.e., seven pre-diluted 
Bovine Serum Albumin (BSA) standard set (Bio-Rad) in final concentrations of 2,000 
µg/ml, 1,500 µg/ml, 1,000 µg/ml, 750 µg/ml, 500 µg/ml, 250 µg/ml, and 125 µg/ml, 
respectively. A protein blank was included to the test.  
Generally, an aliquot of well mixed 1× Bradford dye reagent (Coomassie 
Brilliant Blue G-250 dye containing methanol and phosphoric acid) was removed from 
4 ºC storage and was left to thaw to ambient temperature. Twenty µ1 of each standard 
as well as unknown sample were added and mixed well with 1 ml of the 1× dye reagent 
in microcentrifuge tubes. The protein mixture was incubated at room temperature for 5 
minutes prior to spectrometrically determination at 595 nm (all reading must complete 
within 1 hour) using 1.5 ml disposable cuvette and NanoPhotometer
TM
 (IMPLEN, 
Germany). A standard curve was plotted at the absorbance 595 nm values (y-axis) 
versus the concentration in µg/ml (x-axis) with the r
2
 equal or near to 1 using 
NanoPhotometer
TM
. The concentration of unknown protein sample was then determined 
based on the standard curve.  
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3.5.8 Precipitation of recombinant protein and buffer exchange 
The eluted Profinity eXact purified target protein in elution buffer (4 M urea, 
100 mM sodium phosphate, 100 mM sodium fluoride, pH 7.2) was quite diluted, 
therefore sample collected from several purifications were pooled and concentrated, 
followed by buffer exchanged into refolding buffer (4 M urea, 50 mM Tris phosphate 
buffer, pH 8) using Vivaspin 20 concentrator fitted with 5,000 MWCO PES membrane 
(Sartorius Stedim Biotech). The buffer exchange steps were performed as 
manufacturer’s instructions and the diluted target protein was then further concentrated 
into final concentration of approximately 2 mg/ml, confirmed by Bradford protein assay. 
The Vivaspin 20 enables concentration of solution in excess of 100×.  
Generally, concentrator was pre-rinsed with 15 ml of buffer solution or sdH2O to 
remove the trace amounts of glycerine and sodium azide on the membranes and decant 
the filtrate before sample processing. Samples collected from several small scale 
extractions were pooled and applied into the concentrator. The pooled sample was 
concentrated by centrifugation at 4,000 × g at 4 ºC for 1 hour, and centrifugation 
repeated until final volume of ~ 500 µl. This was followed by three subsequence buffer 
exchanged steps with 15 ml concentrator exchange buffer (4 M urea, 50 mM Tris 
phosphate, pH 8). The centrifugation was continued until the concentration of 
contaminating microsolute was sufficiently reduced (three wash cycles able to removed 
99 % of initial salt content). Once the desired concentration was reached (~ 1.5 ml), the 
assembly was moved and the sample was collected using pipette tip. The final 
concentration of target protein was determined using Bradford Protein Assay (Bio-Rad) 
and diluted to ~ 1 mg/ml target protein. A 1× of Calbiochem
®
 Protease Inhibitor 
Cocktail Set I (Novagen) was added to the concentrated sample solution and sample 
was aliquot into small volume (500 µl) in microcentrifuge tube to prevent several 
freeze-thaw cycles, and then stored at -80 ºC.  
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3.5.9  Protein renaturation 
3.5.9.1  Reduction of the target protein 
A 5 mM of DTT (reducing agent) was added to the concentrated protein solution 
(4 M urea, 50 mM Tris phosphate buffer, pH 8) prior to refolding to keep all cysteine 
residues in the reduced state and break all possible intramolecular disulfide bonds 
presented in entire ectodomain of Plasmodium AMA1 protein, and 1 mM of EDTA was 
added as the metal chelator. Generally, fresh prepared DTT was used to prevent air 
oxidation of the DTT stock solution, whereas EDTA was diluted from 0.5 M stock. The 
protein sample was then incubated at room temperature for 1 hour.  
 
3.5.9.2  Desalting and buffer exchange 
The reducing agent, DTT must be removed prior to refolding. The reduced 
protein sample (1 mM EDTA, 5 mM DTT, 4 M urea, 0.1 M Tris phosphate, pH 8) was 
buffer exchanged using 10 kDa MWCO Zeba Desalting Column (Pierces Thermo 
Scientific). Column was washed once with 5 ml of sdH2O to remove the trace amount of 
NaN3 and then pre-equilibrated three times with desalting buffer (4 M urea, 50 mM Tris 
phosphate, pH 8) by centrifuged at 1,780 × g for 1 minute in each step. Two ml of 
protein sample was loaded onto the center of resin and centrifuged at 1,780 × g for 1 
minute at 4 ºC. The eluted protein was collected in a clean Falcon tube and the protein 
concentration was then determined using Bradford protein assay. 
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3.5.9.3  Protein refolding by dialysis 
The native PkAMA1 and PvAMA1 contain eight disulfide bonds, therefore the 
refolding has to be supplemented with a redox system. The addition of a mixture of 
reduced and oxidized forms of low molecular weight thiol at a ratio of 4:1 usually 
provides the appropriate redox potential to allow formation and reshuffling of disulfide 
bonds. For instance, 1 mM reduced glutathione (GSH) and 0.25 mM oxidized 
gluthathione (GSSG) were added to desalted rPkAMA1 and rPvAMA1.  
In general, protein refolding was performed by dialysis method using 3 ml Slide-
A-Lyzer Dialysis Cassettes with 10 kDa MWCO (Pierces Thermo Scientific). The 
membrane of the cassette was hydrated by immersing the cassette attached with a buoy 
into the dialysis buffer for 2 minutes prior to dialysis process. Then, the cassette was 
removed from buffer and excess liquid was removed by taping the edge of the cassette 
gently on paper towel.  
Approximately 2 ml of the concentrated protein sample (1 mg/ml in 50 mM Tris 
phosphate, pH 8, 4 M urea, 1 mM EDTA, 1 mM GSH, 0.25 mM GSSG, and 1 × 
Calbiochem Protease Inhibitor Cocktail set 1) was loaded into the cassette using syringe 
fitted with 18-gauge needle by carefully penetrating the gasket through one of the 
syringe ports at the corner of the cassette with needle and the sample was then injected 
into the cassette cavity slowly to prevent the formation of bubble at high concentration. 
Next, the excess air was withdrawn by slightly pulling up the plunger. The syringe was 
then removed and the gasket was sealed automatically, and the membrane cavity has no 
air in direct contact with sample. The cassette was slipped into the grove of buoy and 
the assembly was floated in the dialysis solution and the sample was dialyzed at 4 °C 
with gentle stirring at the bottom using a magnetic stirrer (Eppendorf).  
Protein sample in the cassette was dialyzed against two changes of 400 ml of 
dialysis buffer (50 mM Tris phosphate, 0.4 M L-arginine, 1 mM EDTA, pH 8) with 
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stepwise decreases of urea concentration, i.e., 2 M and 1 M at 4 °C with stirring for four 
hours in each change, which allows the protein to refold optimally. After the last change, 
the protein solution was further dialyzed (buffer exchanged) overnight at 4 °C against 
sample buffer without urea (25 mM Tris phosphate, 50 mM NaCl, pH 8), which is 
compatible to downstream application, i.e., biopanning.  
To remove the refolded sample from cassette, the syringe fixed with needle was 
filled with a volume of air equal to sample volume. The gasket was penetrated with the 
needle through unused syringe guide port and the air was discharged into cassette cavity 
to separated membrane. Then, the unit was turned down so that needle was on the 
bottom, and the dialyzed sample was withdrawn and stored in clean microcentrifuge 
tube. 
 
3.5.9.4  Analysis of folding reactions 
 Refolding screening was assessed by determining the turbidity of the solution 
where protein aggregation has occurred by visual inspection of aggregates formation 
and quantification of turbidity changes by measuring changes in absorbance at 390 nm. 
Generally, turbidity of the refolded rPkAMA1 and rPvAMA1 protein samples was 
assessed by measuring the OD at 390 nm using NanoPhotometer
TM
 (IMPLEN) and the 
turbidity was determined by subtracting the apparent OD reading of the sample solution 
to the blank sample buffer (25 mM Tris phosphate, 50 mM NaCl, pH 8) and the protein 
was taken to be soluble at OD < 0.05. Refolded sample proteins were then further 
investigated using reduced and non-reduced SDS-PAGE (Session 3.3.8.2). 
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3.5.10 Protein identification by LC-MS/MS 
Recombinant PkAMA1 and PvAMA1 ectodomain were electrophoresed using 
10 % SDS-PAGE under non-reduced conditions followed by staining with Coomassie 
Blue. The bands of interest were excited from the gel and sent for reduced (20 mM 
Tributylphosphine), alkylated (40 mM Iodoacetamine), in-gel trypsin digestion, and 
liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis (Monash 
University Malaysia) for protein identification. The LC-MS/MS was performed using 
Agilent 6520 Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, USA). 
Peptide ions were analyzed with GPS Explorer software (Applied Biosystems) using 
MASCOT
TM
 Database. 
 
3.5.11    Phage display and M13 general methods 
3.5.11.1  Bacteria stain maintenance 
The ER2738 E. coli from the supplied glycerol culture was streaked out onto LB 
plate containing 20 µg/ml of tetracycline and incubated overnight at 37 ºC. The cultured 
plate was then wrapped with parafilm and kept at 4 ºC in the dark until needed for a 
maximum of one month. The E. coli culture for phages infection and propagation were 
prepared freshly by inoculating a single colony of ER2738 into LB broth containing 20 
µg/ml of tetracycline and incubated at 37 ºC with a vigorous shaking at 250 rpm until 
desired OD600. 
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3.5.11.2  Phage titering and plaques forming unit (pfu/ml) determination 
Phage titering was performed to calculate the input and output of phage particles 
in biopanning. The measurement was determined experimentally by infecting E. coli 
(ER2738) in a petri dish and then evaluated by quantifying the number of plaque-
forming units (cfu) left overnight on the bacterial lawn. 
Ten ml of LB broth containing 20 µg/ml of tetracycline was inoculated with a 
single colony of ER2738 culture and incubated with a vigorous shaking at 250 rpm for 
4-8 hours until OD600 ~ 0.5 (mid-log phase). While cells were growing, Top agar was 
melted in microwave oven and the molten Top agar was kept at 50 ºC until subsequent 
used. LB plates containing 40 µg/ml of Xgal as well as 50 µg/ml of IPTG (designated 
here as LB/IPTG/Xgal), which will be used in phage titering were pre-warmed at 37 ºC 
for at least one hour prior to spreading of diluted phage. Basically, one LB/IPTG/Xgal 
plate per each dilution was prepared.  
One µl of phage was serially diluted to appropriate dilutions in LB broth, 
ranging from 10 to 10
4
-fold for unamplified phages as well as 10
8
 to 10
11
 for amplified 
phages. To each dilution step, diluted phage was mixed by vigorous vortex for 10 
seconds followed by brief spun before preceded to next dilution step. Two hundred µl of 
a mid-log phase E. coli culture was dispensed into microcentrifuge tubes and 10 µl of 
each diluted phage was then added into microcentrifuge tube (one tube/dilution). The 
phage infections was performed by brief vortexed of the mixture, followed by incubated 
at room temperature for 5 minutes. The infected cells were then transferred into 5 ml 
disposable sterile culture tube and 3 ml of pre-warmed (~ 50 ºC) molten Top agar was 
then added to each of dilution tube. The samples were mixed and immediately poured 
onto a pre-warmed LB/IPTG/Xgal plate, and the plate was tilted gently to ensure even 
distribution. The plates were cooled for 5 minutes at room temperature and then 
incubated overnight at 37 ºC.  
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Plaques on the plate that have ~ 100 plaques were calculated, then the number of 
plaques was multiplied with dilution factor to determine the plaque forming units (pfu) 
per 10 µl. Usually, the titer of phage was expressed in unit of cfu/ml. 
 
3.5.11.3  Phage amplification and precipitation  
A single colony of ER2738 was inoculated in 20 ml of LB broth using 250-ml 
Erlenmeyer flask and incubated at 37 ºC with vigorous shaking. The growth of the 
culture was monitored carefully so that the culture did not grow beyond early log phase 
(OD600 0.01-0.05) or alternatively, an overnight culture of ER2738 was 1:100 diluted in 
20 ml LB. Approximately 80 µl of eluate phage (unamplified) from each of the 
biopanning step was added to the culture and incubated with vigorous shaking (250 rpm) 
for 4.5 hours at 37 ºC. 
Cell culture was then transferred to a 50-ml Falcon tube and centrifuged for 20 
minutes at 4,000 ×g at 4 ºC. Supernatant was transferred to a new tube and re-spun, 
whereas the pellet was discarded. After that, 16 ml (80 %) of the upper supernatant was 
transferred to a fresh tube and 4 ml of 20 % (w/v) PEG/2.5 M NaCl was added. 
Subsequently, the amplified phages were allowed to precipitate at 4 ºC for at least 2 
hours, preferably overnight.  
Subsequently, PEG precipitation was centrifuged at 12,000 ×g for 15 minutes at 
4 ºC and the supernatant was discarded. Then, the tube was re-centrifuged briefly and 
the remaining residual supernatant was removed with a pipette. Phage pellet is likely a 
white finger print sized smear on the side of the tube. The pellet was suspended in 1 ml 
TBS and transferred to a microcentrifuge tube and spun at maximum speed (18,700 × g) 
for 5 minutes at 4 ºC to pellet residual cells. Supernatant was transferred to a fresh 
microcentrifuge tube and re-precipitated by adding 200 µl of 20 % (w/v) PEG/2.5 M 
NaCl and then let it incubated on ice for 15-60 minutes. The sample solution was 
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centrifuged at 18,700 × g for 10 minutes at 4 ºC. The supernatant was then discarded 
and the tube was re-spun briefly to remove the residual supernatant with a pipette. The 
pellet was resuspended in 200 µl of TBS and incubated at room temperature for 1 hour. 
After that, the phage suspension was centrifuged at full speed for an additional 1 minute 
to pellet any remaining insoluble material and the supernatant (amplified phage) was 
then transferred to a fresh tube and can be stored for up to three weeks at 4 ºC or long 
term storage at -20 ºC under equal volume of glycerol. 
 
3.5.11.4  Storage of phage 
Eluted phage (in 0.2 M Glycine-HCl, pH 2.2 and neutralized with 1 M Tris-HCl, 
pH 9.1) as well as amplified phage (0.1 M TBS; either by adding of 0.02 % (w/v) NaN3 
or incubated at 65 ºC for 15 minutes to kill the residual of E. coli) can be kept for up to  
several weeks at 4 ºC. For long term storage, phage stock was diluted 1:1 with sterile 
glycerol and 0.02 % (w/v) NaN3 and stored at -20 ºC. The phage stored at -20 ºC was 
recovered by re-amplification from phages stock prior to further experiments (e.g., 
biopanning, phage ELISA). 
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3.5.12 Biopanning of the phage display library 
Biopanning was carried out using Costar high binding, flat bottom 96 well 
microtiter plate (Corning Incorporated, USA) accordingly to the direct target coating 
method described in Ph.D.
TM 
Phage Display Libraries instruction manual. The following 
method can be used to immobilize target protein by hydrophobic adsorption on 
polystyrene plate whereby the target protein was coated onto the plate and then excess 
target was removed.  
In general, 150 µl of target solution (50 µg target/ml of 0.1 M NaHCO3, pH 8.6) 
was added to each of the microtiter well and swirled repeatedly until the surface of each 
well was completely coated with the target solution. This was followed by incubation of 
the plate overnight at 4 ºC in a humidified container.  
On the following day, the coating solution from each well was poured off and 
firmly slapped face down onto a clean paper towel to remove residual solution. After 
that, each of the well was completely filled with 200 µl of blocking buffer [0.5 mg/ml of 
BSA, 0.1 M NaHCO3, pH 8.6, 0.02 % (w/v) NaN3] and incubated at 4 ºC for at least one 
hour. The blocking buffer was discarded as described in the above steps and washed 
with 300 µl of TBST [TBS plus 0.1 %  (v/v) Tween 20 for the first round of panning 
and TBS plus 0.5 % (v/v) Tween 20 for the subsequence rounds of panning experiment] 
with vigorous pipetting steps. The washing solution was poured off and the plate was 
slapped face down onto a clean paper each time. The washing steps were repeated for 
six times. Next, a total of 1 µl of phage (original library) was diluted with 100 µl of 
TBST [TBS plus 0.1 % (v/v) Tween 20] and dispensed into coated well and rocked 
gently at 15 rpm for 60 minutes at room temperature using a waver shaker (Major 
Sciences). The non-binding phage was then discarded and the plate was slapped face-
down onto a clean paper towel. The well was washed thoroughly with PBST for 10 
times as described before. The bound phages were eluted by pH shift with 0.2 M 
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glycine-HCl (pH 2.2) supplemented with 1 mg/ml BSA. The plate filled with elution 
buffer was rocked gently for 20 minutes and the eluate was aspirated into fresh 
microcentrifuge tube using pipette tip, and neutralized with 15 µl of 1 M Tris-HCl, pH 
9.1. One µl of the eluate was titered as described in general M13 phage titering protocol. 
The rest of the eluate was then amplified and precipitated as above protocol (Session 
3.5.11.3).  
Basically, the amplified eluates from previous round of biopanning were used 
for subsequent round of selection. In general, three biopanning were performed in 
typical epitopes mapping assay. Phage titering was carried out after each round of 
biopanning experiment not only to determine the concentration of bound/amplified 
phage but also used to calculate an appropriate input volume corresponding to the input 
titer in subsequent round of biopanning process. The input phage titer must be as little 
as10
9 
pfu for succeeding rounds of biopanning process.  
Basically, after a third round of biopanning, a serial dilution ranging from 10
1
 to 
10
5
 was carried on the unamplified eluate as described in general phage titering method 
and the diluted phages were then incubated overnight on LB/IPTG/Xgal plates at 37 ºC 
no longer than 18 hours, as deletions may occur if plates were grown longer. Plaques 
from this titering were picked and amplified as following protocol for subsequence 
phage ELISA assay and sequencing. 
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3.5.13 Post panning protocols: Mini preparation of phage amplification for 
sequencing and peptide binding assays 
After third round of biopanning, 20 phage clones were randomly selected and 
identified by DNA sequencing. The binding specificity of phage can be confirmed by 
phage ELISA and Western blot binding assays. In both cases, it was necessary to 
amplify phage either from individual plaques or from the eluted pools, to obtain 
sufficient quantities to work with those assays. 
An overnight ER2738 culture was 1:100 diluted in LB broth and dispensed 1 ml 
each into the 2 ml disposable culture tubes (one phage/tube). Approximately 10-20 of 
well separated form of blue colonies were randomly picked from a 1-3 days old, stored 
at 4 ºC, and have less than 100 plaques titering plate using sterile pipette tip, and 
transferred to a tube containing 1 ml of diluted culture (one phage/tube). The tubes were 
then incubated at 37 ºC with shaking at 250 rpm for 4.5 hours. The cultures were then 
spun at 18,700 × g for 30 seconds and the supernatant was then transferred to a fresh 
tube and re-spun. Using pipette, 800 µl of the upper supernatant was transferred to a 
new tube and this was the amplified phage stock and can be stored at 4 ºC for several 
weeks until further single stranded DNA isolation for sequencing or peptide binding 
assays.  
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3.5.13.1  Phage single-stranded DNA (ssDNA) isolation and sequencing 
Single stranded bacteriophage M13 phagemid DNA was isolated from 500 µl of 
amplified phage stock obtained from above amplification procedures. Generally, 200 µl 
of 20 % (w/v) PEG/2.5 M NaCl was added to the 500 µl of amplified phage stock and 
mixed by inverting the tube for several times, and let it to stand for 20 minutes at room 
temperature. After that, the precipitate phage solution was centrifuged at 18,700 × g for 
10 minutes at 4 ºC, and the supernatant was discarded. Basically, pellet may not be 
visible in such concentration. The remaining supernatant was re-centrifuged briefly and 
then aspirated carefully using pipette. The pellet was suspended thoroughly in 100 µl of 
iodide buffer by vigorous tapping the tube. Then, 250 µl of absolute ethanol was added 
to phage solution and was left to incubate for 20 minutes at room temperature. Short 
incubation at room temperature enhance the precipitated of phage ssDNA, while leaving 
most of phage protein in solution. After that, the microcentrifuge tube was centrifuged 
at 18,700 × g for 10 minutes at 4 ºC and the supernatant was discarded. The pellet was 
then washed with 500 µl of 70 % prechilled (-20 ºC) ethanol, re-spun at 18,700 × g for 
10 minutes at 4 ºC. The supernatant was discarded and the pellet was air-dried overnight 
at room temperature. Finally, the pellet was suspended in 30 µl of TE buffer and stored 
at -20 ºC.  
The concentration and purity of phage ssDNA were measured using 
NanoPhotometer
TM
 (IMPLEN, Germany) as well as 1 % (w/v) agarose gel. In agarose 
gel electrophoresis, 5 µl of phage ssDNA should give a band of comparable intensity to 
0.5 µg of purified single-stranded M13mp18 DNA ladder (NEB). Ten µl of ssDNA of 
each phage was sequenced using a -96gIII sequencing primer (5’-
CCCTCATAGTTAGCGTAACG-3’). The nucleotide sequence of the phages were 
aligned with BioEdit version 7.0.9 Software (Hall, 1999) and a consensus sequences 
were compared to the sequence of original construct to obtain the translation 
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polypeptide sequence expressed by each of the individual phage. 
 
3.5.13.2  Phage ELISA binding assay 
The binding affinity of the selected phages to the target Plasmodium AMA1 
ectodomain was determined using ELISA binding assay. This assay was essential to 
distinguish the true target binding from binding to the plastic support in the direct 
coating method of panning. 
Each clone to be characterized after confirmation by sequencing was amplified 
as steps in phage amplification and precipitation (Session 3.5.11.3). In general, 5 µl of 
each phage stock was added to the 20 ml of ER2738 culture (OD600 0.01 - 0.05) and 
incubated with vigorous aeration at 250 rpm for 4.5 hours at 37 ºC. The amplified phage 
was finally suspended in 50 µl of TBS and titer as general M13 method and the titer 
should be ~ 10
14 
pfu/ml. The phage stock can be either stored at 4 ºC up to several 
weeks or long term stored at -20 ºC in presence of 50 % (v/v) glycerol and 0.02 % (w/v) 
NaN3.  
The wells of the microtiter plate (every phage clone to be assayed per well) were 
coated (100 µg/ml of Plasmodium AMA1 in 0.1 M NaHCO3, pH 8.6) and blocked [0.1 
M NaHCO3, 0.5 mg/ml BSA, 0.02 % (w/v) NaN3] as biopanning step. Another row of 
uncoated wells per phage clone to be assayed were also blocked to test for binding of 
each selected sequence to BSA-coated plastic (background binding). One hundred µl of 
each of the phage (~ 10
9
 in TBST) was filled respectively into one target-coated and one 
uncoated (blocked) wells and incubated at room temperature for 2 hour with agitation 
and washing similar to biopanning steps.  
The HRP-conjugated anti-M13 monoclonal antibody (GE Healthcare) was 
1:5,000 diluted in blocking buffer [0.1 M NaHCO3, 0.5 mg/ml BSA, 0.02 % (w/v) 
NaN3]. Two hundred µl of diluted conjugate was added into each well and incubated at 
CHAPTER THREE: MATERIALS AND METHODS 
 
 
121 
room temperature for 1 hour with agitation. The diluted conjugate was shaken out and 
washed the plate 6 times with TBST. One hundred µl of ABTS
Tm 
Chromophore 
substrate solution (Calbiochem) was added to each well and incubated at room 
temperature for up to 30 minutes. The reaction was stopped by adding 100 µl of 0.5 M 
H2SO4 to the wells and mixed properly, and the absorbance was read at 405 nm using 
ELISA iMark
TM
 microplate reader (BioRad). For each phage colony, the signals 
obtained with and without target protein were compared and the folds of binding were 
calculated by dividing the absorbance obtained from target protein to the absorbance 
obtained from BSA. 
 
3.5.13.3  Western blot binding assay 
Binding phages were further confirmed by Western blot as described in Western 
hybridization (Session 3.5.4). In general, rPkAMA1 and rPvAMA1 proteins (10 µg/well) 
were electrophoresed on 12 % SDS-PAGE under non-reducing condition and then 
blotted onto a nitrocellulose membrane. The location of AMA1 protein was confirmed 
using NOVEX® Reversible membrane protein stain (Invitrogen). The blot was then cut 
into individual strips. The location of target protein was marked and then destained 
properly prior subjected to Western blot binding assay.  
The membrane strips were air dried and blocked with 3 % (w/v) BSA for 1 hour 
at room temperature and then wash twice with PBST for 5 minutes in each wash. After 
that, protein strip was then incubated with each individual phage (10
9 
phage particles) 
for 1 hour at room temperature followed by two washing steps with PBST for 5 minutes 
each. The binding affinity of the each individual phage to rPkAMA1 and rPvAMA1 
were determined using 1:2,500 HRP-conjugated anti-M13 monoclonal antibody (GE 
Healthcare) in antibody dilution buffer [PBST, 1 % (w/v) BSA] and Opti-4CN (Bio-Rad) 
as the substrate. The results obtained were captured with a digital camera.  
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3.5.14 Protein sequence and bioinformatic analysis 
The whole genome of AMA1 of P. knowlesi and P. vivax were searched using 
BLASTN and aligned with BioEdit version 7.0.9 Software (Hall, 1999). Consensus 
motifs between the various peptide sequences were determined with ClustalW 
(Thompson, et al., 1994). The inserted coding frame of AMA1 ectodomain as well as 
phage displayed binding peptides was confirmed by Translate tool accessed via the 
ExPASy interface (http://au.expasy.org; Gasteiger, et al., 2003). Compute pI/MW tool 
(http://web.expasy.org/compute_pi/) was used to determine the theoretical isoelectric 
point (pI) and molecular mass. The solubility of the Plasmodium AMA1 ectodomain 
recombinant proteins assuming the protein is being overexpressed in E. coli was 
predicted based on the amino acids composition using Recombinant Protein Solubility 
Prediction statistical tool (http://biotech.ou.edu/; Wilkinson & Harrison, 1991). 
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Identification of binding peptides for PkAMA1 and PvAMA1  
using a phage display library 
Tag-free recombinant protein: 
rPkAMA1 
rPvAMA1 
 
3.5.15 Overview of the identification of binding peptides for PkAMA1 and 
PvAMA1 using a phage display library 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 PCR amplification:  
- PkAMA1 ectodomain 
- PvAMA1 ectodomain   
Restriction enzymes digestion:  
- SpeI and BamHI 
Gel purification 
Protein expression: 
Profinity eXact Fusion-Tag system 
(Bio-Rad) 
pPAL7 supercoiled vector 
restriction enzymes digestion  
(SpeI and BamHI) 
T4 DNA ligation 
Transformation into selection 
host: 
C-Max5αTM E.coli 
 
Transformation into 
expression host: 
BL21-Codon Plus-RIL E. coli 
(Strategene) 
Recombinant protein 
expression  
(IPTG induction) 
Protein isolation 
and purification: 
1 ml or 5 ml 
Profinity eXact 
cartridge (under 
denatured 
conditions) 
Protein refolding:  
Dialysis 
Biopanning:  
Ph.D.
TM
-12-phage display 
peptide library (NEB) 
Colony PCR and 
sequencing 
confirmation 
Plasmid isolation 
and subcloning 
Peptides 
identification by 
sequencing  
Peptide binding assays 
- Phage ELISA  
- Western blot 
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CHAPTER FOUR: RESULTS 
4.1 Clinical sample collection and DNA extraction 
A total of 226 suspected malaria blood samples and 20 healthy control samples 
were collected during 2008 to 2010. In specificity validation of the multiplex PCR 
system, DNA from bacteria strains, i.e., Aeromonas aquariorum, Aeromonas caviae, 
Aeromonas hydrophila, Aeromonas veronii, Vibrio harveyi, Vabrio parahaemolyticus, 
and Serratia species were extracted. Besides that, DNA from other non-malaria 
parasites, i.e., Toxoplasma gondii, Giardia duodenalis, and hookworm (i.e., Necator 
americanus and Ancylostoma duodenale) were also obtained. 
  
4.2 Identification of malaria by microscopic examination  
A total of 211 malaria samples were positive by microscopic examination, in 
which 203 samples were single infection samples with 83, 63, 38, and 6 samples were 
identified as P. vivax, P. falciparum, P. malariae, and P. knowlesi respectively, whereas 
13 samples were identified as either P. malariae or P. knowlesi samples. None of P. 
ovale infection was detected. Eight samples were examined as mixed infections, i.e., 
two were P. vivax mixed with P. falciparum, three were P. vivax mixed with P. 
malariae, one was P. vivax mixed with P. knowlesi, and two were P. falciparum mixed 
with P. malariae.  
Of the positive samples, 91 cases (43 %) were scored as + category, 23 cases 
(11 %) were ++, 31 cases (15 %) were +++, and 66 cases (31 %) were ++++. Whereas 
another 15 blood samples obtained from patients with clinical malaria symptoms and 20 
healthy control samples were negative via microscopic examination.  
 Table 4.1 summarized the distribution of Plasmodium species by cases and 
parasitemia scores via microscopic examination. 
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Table 4.1: Distribution of Plasmodium species and parasitemia obtained from 
microscopic examination. 
                    Parasitemia 
 
Microscopy result 
Plus system (Parasites/µl) 
Total (%) + ++ +++ ++++ 
4-40 41-400 401-4,000 > 4,000 
P. vivax 38 7 13 25 83 (39) 
P. falciparum 23 6 11 23 63 (30) 
P. malariae 11 10 7 10 38 (18) 
P. knowlesi 6 0 0 0 6 (3) 
P. malariae or P. knowlesi 13 0 0 0 13 (6) 
P. ovale 0 0 0 0 0 (0) 
P. vivax & P. falciparum 0 0 0 2 2 (1) 
P. vivax & P .malariae 0 0 0 3 3 (1) 
P. vivax & P .knowlesi 0 0 0 1 1 (1) 
P. falciparum & P. malariae 0 0 0 2 2 (1) 
Total (%) 91 (43) 23 (11) 31 (15) 66 (31) 211 (100) 
Suspected malaria case 
(microscopy negative) 
15 
Healthy control     
(microscopy negative) 
20 
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4.3 Nested PCR 
A primer pair of genus-specific, rPLU1 and rPLU5 for first nested PCR 
(Snounou, et al., 1993) as well as five pairs of species-specific primers for second 
nested PCR (Singh, et al., 1999; Singh, et al., 2004), targeting to 18S ssu rRNA gene of 
five of human Plasmodium species were synthesized (Appendix 3.1). Due to the 
inability of currently available nested PCR in identifying P. ovale wallikeri (variant 
type), which has some genetic differences with P. ovale curtisi (classic type), a primer 
pair targeting to both P. ovale subtypes (Padley, et al., 2003) was included into the 
nested PCR assay (Appendix 3.1). Hence, a total of seven separate monoplex PCR was 
performed in the identification of five human Plasmodium species.  
DNA fragment of first nested PCR targeted to 18S ssu rRNA gene was 
approximately 1.7 kb. The second nested PCR DNA fragment with sizes of 117 bp for 
P. vivax, 144 bp for P. malariae, 153 bp for P. knowlesi, 205 bp for P. falciparum, and 
787 bp and 375 bp (alternative primer pair) for P. ovale.  
Figure 4.1 shows the positive clinical samples for five human Plasmodium 
species in nested PCR assay. 
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Figure 4.1: Nested PCR results. First nested PCR targeting genus conserved region of 
18S ssu rRNA gene of Plasmodium species and second nested PCR targeting species 
conserved region were used in Plasmodium species determination.  
Lanes, 
1 :  100 bp plus DNA ladder (Fermentas) 
2 & 11 :  First nested PCR; sample with Plasmodium species infection (~ 1.7 kb) 
3 :  First nested PCR; sample absent of Plasmodium species infection 
4 & 10 :  50 bp DNA ladder (Fermentas) 
5 :  P. ovale curtisi (787 bp) 
6 :  P. falciparum (205 bp) 
7 :  P. knowlesi (153 bp) 
8 :  P. malariae (144 bp) 
9 :  P. vivax (117 bp) 
12 :  P. ovale (375 bp) [Alternative primer pair from Padley, et al., 2003] 
1       2       3      4       5       6      7       8       9      10    11     12 
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4.4 18S ssu rRNA plasmids construction 
A total of nine clones were constructed in the present study, i.e., two for each 
species, P. vivax, P. knowlesi, P. malariae, P. falciparum, and one for P. ovale based on 
availability of clinical samples. In general, PCR was performed using rPLU1 and 
rPLU5 primers as described in the first nested PCR that generated PCR amplicons with 
a size of ~ 1.7 kb. PCR product was then gel purified prior to cloning into pCR
®
II-
TOPO vector (4.0 kb). Escherichia coli Top10 competent cells used here were prepared 
from stock culture to ensure that the transformation efficiencies in cloning experiments.  
The putative positive clones were selected from white colonies from 
LB/IPTG/Xgal/ampicillin plates and then further confirmed by colony PCR and 
sequencing using T7 and SP6 promoter primers encompassing ~ 186 bp TA cloning site, 
which resulted in ~ 1.9 kb PCR amplicon, indicative of positive clone. The inserted 
DNA for each construct was sequenced and checked with BLASTN 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) for further clone confirmation. Finally, five 
human Plasmodium species clones were developed successfully and served as positive 
controls in the subsequence PCR amplifications as well as templates for sensitivity and 
specificity validation.  
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4.5 Development of a single step multiplex PCR detection assay for five human 
Plasmodium species  
4.5.1 Multiplex PCR primers design and PCR optimization  
The challenge of multiplex PCR development is to make the designed primers 
have similar annealing temperature while amplification products should be 
distinguishable in size in a single reaction when analysis is performed using agarose gel 
electrophoresis. For instance, primers in the present multiplex system is able to generate 
PCR fragments ranged between 200 to 500 bp, i.e., ~ 453 bp for P. falciparum, ~ 341 
bp for P. malariae, ~ 304 bp for P. ovale, ~ 284 bp for P. knowlesi, and ~ 215 bp for P. 
vivax, after PCR (Figure 4.2).  
The selected primers were tested through BLASTN search 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and in silico PCR amplification 
(http://insilico.ehu.es/PCR/index.php) for the amplicon prediction. There was no any 
other nonspecific amplification from nontarget gene. Finally, single step multiplex PCR 
system utilizing five forward species-specific primers and a single reverse genus-
specific primer targeting 18S ssu rRNA gene sequences from five human Plasmodium 
species was successful established.  
PCR conditions and reaction mixture for each of the primer pairs were 
optimized individually and then mixed together to perform a multiplex PCR for the 
detection of five human malaria parasites. Regarding the PCR conditions, 
thermocycling conditions was initially optimized based on primer annealing 
temperatures ranging from 52 ºC to 62 ºC. The PCR bands of each primer pair in 
individual assay became invisible after 60 ºC, therefore, the final multiplex PCR 
annealing temperature was set at 56 ºC, which showed shaper and clearer bands in all 
five primer pairs. Due to relatively high AT-content in the Plasmodium DNA, lower 
extension temperature of 65 °C was selected and the extension time for 40 seconds was 
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sufficient to amplify all target genes.   
Initially, equimolar primer concentration of 0.4 µM each were used in the 
multiplex PCR, but there were inconsistent amplifications, with some of the larger 
fragments barely visible if compared to smaller fragments even after the reaction was 
optimized for the PCR conditions. To overcome this problem, the proportions of 
primers were changed, i.e., increase in the amount for the weak binding primers and a 
decrease in the amount for the strong binding primers. The final concentration of each 
primer (ranged between 0.4 to 0.6 µM) varied considerably was established empirically.  
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Figure 4.2:  Pentaplex PCR results. All Plasmodium species primers target the 18S ssu 
rRNA gene of Plasmodium species resolved in 3 % (w/v) agarose gel stained with 
ethidium bromide.  
Lanes, 
1 & 7 :  50 bp DNA ladder (Fermentas, USA),  
2 :  P. vivax (~ 215 bp) 
3 :  P. knowlesi (~ 284 bp) 
4 :  P. ovale (~304 bp) 
5 :  P. malariae (~ 341 bp) 
6 :  P. falciparum (~ 453 bp) 
8 :  Ladder for five human Plasmodium species 
9 :  P. vivax mixed P. falciparum  
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4.5.2 Positive control 
In the present multiplex PCR development, positive control was included as 
indicative of successful DNA extraction procedure as well as functionality of the PCR 
reaction mixture for amplification of the target DNA. Generally, three additional primer 
pairs were designed and tested individually on optimized pentaplex PCR system. The 
external positive control is an external DNA source spiked into test specimen, whereas 
an internal positive control is a nontarget DNA sequence occurring naturally in the test 
specimen, which is simultaneously extracted and co-amplified in the same tube together 
with the target DNA (Hoorfar, et al., 2004). The procedures of each of the positive 
control and the observations based on screening of 50 clinical samples were described. 
 
4.5.2.1 The pGEX4T1 plasmid DNA  
Inclusion of pGEX4T-1 plasmid DNA as external positive control DNA as well 
as a pair of pGEX-targeted primers, i.e., pGEX 5’ (5’-GGGCTGGCAAGCCACGTTT 
GGTG-3’) and pGEX 3’ (5’-CCGGGAGCTGCATGTGTCAGAGG-3’) to primary 
optimized pentaplex PCR conditions generated a DNA fragment with a size of ~ 173 bp.  
Due to high amount and integrity of the plasmid DNA compared to Plasmodium 
DNA, therefore the multiplex PCR system tends to favor the plasmid DNA 
amplification. This consequently led to the competition for PCR reagents and thus 
impairing the detection sensitivity in the present pentaplex system. The PCR selection 
phenomenon is referred to as competition inhibition. Even though the concentration of 
plasmid DNA was reduced to 50 pg and primers to 0.1 µM, the competition effect still 
pose a problem, especially to samples with low parasitemia, thus limiting the 
applicability as positive control in the present multiplex PCR system. Figure 4.3 shows 
the PCR results with the inclusion of a pGEX4T1 plasmid DNA and its primer pair into 
clinical samples, which have a high parasitemia average. 
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Figure 4.3:  Multiplex PCR results with an external positive control, pGEX4T plasmid 
DNA. 
Lanes, 
1 & 10 : 50 bp DNA ladder (Fermentas, USA),  
2 :  P. vivax  
3 :  P. knowlesi  
4 :  P. ovale 
5 :  P. malariae 
6 :  P. falciparum 
7 :  P. vivax and P. falciparum  
8 :  pGEX4T-1, external positive control (~ 173 bp) 
9 :  DNA blank 
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pGEX4T-1 
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positive control 
(~ 173 bp) 
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4.5.2.2 The human and Plasmodium 18S ssu rRNA genes 
The inclusion of a human and Plasmodium 18S ssu rRNA conserved primer as 
forward primer (HP-F) and a human 18S ssu rRNA conserve reverse primer (HR155) to 
the pentaplex system generated two additional DNA fragments in pentaplex PCR 
system (Figure 4.4). Of which, the larger DNA fragment with a size range between 580 
bp and 630 bp indicated the presence of Plasmodium species, whereas the smaller 
fragment DNA with a size of ~ 155 bp indicated human DNA that served as internal 
positive control of the multiplex PCR system. The human 18S ribosomal RNA gene is 
one of the common housekeeping genes in molecular studies and the primers designed 
in the present study was referred to the gene sequence deposited in GenBank (i.e., 
accession number NR_003286.2). 
Based on the screening results of 50 clinical samples, the human control band 
appeared consistently in all clinical samples; however, the appearance and intensity of 
Plasmodium genus-specific and species-specific bands were different. Some PCR 
intensities denoted favor either genus-specific amplification or species-specific 
amplification, whereas some other showed similar intensities. The reason for the 
biasness in the multiplex PCR was not further tested in the present study. The 
inconsistencies of results in species determination limit this format as an internal 
positive control. 
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Figure 4.4:  Multiplex PCR results with human internal positive control, Plasmodium 
genus-, and species-specific primers are both targeting 18S ssu rRNA gene.  
Lanes, 
1 & 10 : 50 bp DNA ladder (Fermentas, USA),  
2 :  P. vivax  
3 :  P. knowlesi  
4 :  P. ovale 
5 :  P. malariae 
6 :  P. falciparum 
7 :  P. vivax mixed P. falciparum  
8 :  Human internal positive control (~ 155 bp) 
9 :  DNA blank 
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4.5.2.3 The human β-hemoglobin gene 
The inclusion of primer pair targeting human β-hemoglobin gene, i.e., β-
hemoglobin (F) (5’-CACAACTGTGTTCACTAGC-3’) and β-hemoglobin (R) (5’-
CAACTTCATCCACGTTCACC-3’) into primary optimized pentaplex system 
generated an addition of PCR amplicon with a size of ~ 109 bp in all human samples. 
This human β-hemoglobin gene is a common human housekeeping gene in molecular 
studies. The primers design was referred to a gene sequence deposited as GenBank 
accession number of NM_000518.4.  
The concentration of primers used in PCR was fully optimized in present 
detection system, therefore no significant reduction of the sensitivity in the 
identification of five human Plasmodium species. The inclusion of this primer pair as 
internal positive control targeting heterologous gene gave a very consistence results in 
Plasmodium species determination that showed 100 % concordance to the results 
obtained from nested PCR. Finally, a hexaplex PCR detection system for identification 
of five human Plasmodium species together with a β-hemoglobin internal control was 
established. Figure 4.5 shows the hexaplex PCR results tested on six clinical samples.  
The primers in this detection system were patented under reference no: PI 2010 
003802 and currently is commercialized under Reszon Diagnostics International 
(http://www.reszonics.com/product-Malaria.html). 
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Figure 4.5:  Hexaplex PCR results with a human internal positive control targeting β-
hemoglobin gene. All Plasmodium species primers targeting 18S ssu rRNA gene of 
Plasmodium species. 
Lanes,  
1 & 10 : 50 bp DNA ladder (Fermentas) 
2 :  P. vivax  
3 :  P. knowlesi  
4 :  P. ovale 
5 :  P. malariae 
6 :  P. falciparum 
7 : Healthy control sample  
8 : DNA blank  
9 : Hexaplex DNA ladder 
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4.5.3 Analytical sensitivity and specificity analyses 
4.5.3.1 Sensitivity in single infection 
The starting parasitemia levels of the blood samples were 25,000 parasites/µl for 
P. vivax, 25,250 parasites/µl for P. knowlesi, 26,500 parasites/µl for P. ovale, 26,980 
parasites/µl for P. malariae, as well as 15,000 parasites/µl for P. falciparum. The final 
detectable limit of the hexaplex PCR can be as low as 0.025 parasites/µl (10
-6
) for P. 
vivax, 0.25 parasites/µl (10
-5
) for P. knowlesi, 0.027 parasites/µl (10
-6
) for P. ovale, 0.27 
parasites/µl (10
-5
) for P. malariae, and 0.15 parasites/µl (10
-5
) for P. falciparum (Figure 
4.6).   
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.6: Detection limits of the hexaplex PCR system to five human Plasmodium 
species. Lane 1, 50 bp DNA ladder (Fermentas); Lanes 2-8, 10-fold dilutions of all five 
Plasmodium species DNA samples from malaria patients, using 10 ng/µl of human 
DNA. Dilution of Plasmodium DNA samples: lane 2, 10
-1
; lane 3, 10
-2
; lane 4, 10
-3
; 
lane 5, 10
-4
; lane 6, 10
-5
; lane 7, 10
-6
; lane 8: 10
-7
.  
 P. vivax (~ 215 bp)            P. knowlesi (~ 284 bp)     P. ovale (~ 304 bp)  
     P. malariae (~ 341 bp)         P. falciparum (~ 453 bp) 
1     2    3    4    5    6     7   8     1     2    3   4    5    6    7    8      1    2    3    4    5    6   7   8    
    
 
1     2    3    4    5    6    7    8       1     2    3    4    5    6     7    8    
    
 
0.15 parasites/µl 
0.027 parasites/µl 
0.025 parasites/µl 
0.25 parasites/µl 
0.27 parasites/µl 
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4.5.3.2 Sensitivity in mixed infections 
Sometimes, there is a possibility of more than one Plasmodium species infection 
occurring in a particular patient at the same time and this is recognized as mixed 
infections. In mixed infections, the ratios between the two or more parasite species can 
vary substantially in clinical samples (Conway, 2007; Mayxay, et al., 2004; 
Zimmerman, et al., 2004). Therefore, DNA and primer competition effects in mixed 
infections samples were also tested in the present study.  
Due to the lack of natural acquired mixed infections during the study period, 
three simulated mixtures, i.e., 100 pg/µl of P. vivax clone DNA and 1, 10 or 100 pg/µl 
of P. falciparum clone DNA, were experimentally created to determine the sensitivity 
of this hexaplex PCR. A serial dilution of the DNA mixtures was performed using DNA 
solution containing 10 ng/µl human DNA. This was taken into consideration due to the 
presence of large amount of human DNA in the actual clinical samples. In addition, a 
pair of human housekeeping primers was included as internal positive control in the 
present detection system.  
Subsequently, a sensitivity test with 12 different mixtures of DNA using two of 
the five human Plasmodium species for each set, together with another set of mixtures 
with all five Plasmodium species was performed as shown in Table 4.2. All mixed 
Plasmodium species DNA were successfully detected in the simulated mixtures (a total 
of 60 mixtures were tested) and the results are shown in Figure 4.7. A total of 10 
possible combinations of DNA to create two-species-simulated mixed infections with 
equal clone DNA concentration (100 pg/µl) are shown in Figure 4.8.  
 
 
 
 
CHAPTER FOUR: RESULTS 
 
 
140 
Table 4.2: Validation of sensitivity in simulated mixed infections using clone DNA.  
Abbreviations: 100 (A), 10 (B), and 1 (C) indicate concentrations of clone  DNA of 100 
pg/µl, 10 pg/µl, and 1 pg/µl, respectively, in which A, B, and C were linked to the 
labeling in Figure 4.7. 
 
 
 
 
 
 
pg/ul P. falciparum P. malariae P. ovale P. knowlesi P. vivax 
P. falciaprum 100 (A) 
100 (A) 100 (A) 100 (A) 100 (A) 
10 (B) 10 (B) 10 (B) 10 (B) 
1 (C) 1 (C) 1 (C) 1 (C) 
P. malariae 
100 (A) 
100 (A) 
100 (A) 100 (A) 100 (A) 
10 (B) 10 (B) 10 (B) 10 (B) 
1 (C) 1 (C) 1 (C) 1 (C) 
P. ovale 
100 (A) 100 (A) 
100 (A) 
100 (A) 100 (A) 
10 (B) 10 (B) 10 (B) 10 (B) 
1 (C) 1 (C) 1 (C) 1 (C) 
P. knowlesi 
100 (A) 100 (A) 100 (A) 
100 (A) 
100 (A) 
10 (B) 10 (B) 10 (B) 10 (B) 
1 (C) 1 (C) 1 (C) 1 (C) 
P. vivax 
100 (A) 100 (A) 100 (A) 100 (A) 
100 (A) 10 (B) 10 (B) 10 (B) 10 (B) 
1 (C) 1 (C) 1 (C) 1 (C) 
Total 
 
60  PCR samples 
50 without repeat 
10 mixed combinations 
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Abbreviation: F = P. falciparum; M = P. malariae; O = P. ovale; K = P. knowlesi; V = P. vivax;  
A = 100 pg; B = 10 pg; C = 1 pg 
Figure 4.7: Sensitivity assay of the hexaplex PCR system in two species mixed 
infections based on cloned DNA. 
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Figure 4.8: Hexaplex PCR results based on simulated mixture of clone DNAs. Ten 
possible combinations of two species mixed infections caused by five human 
Plasmodium species infection.  
Lanes, 
1 & 15 :  50 bp DNA ladder (Fermentas)              8 :  P. malariae & P. vivax  
2        :  P. falciparum & P. malariae         9  :  P. ovale & P. knowlesi  
3        :  P. falciparum & P. ovale        10  :  P. ovale & P. vivax  
4          :  P. falciparum & P. knowlesi        11 :  P. knowlesi & P. vivax  
5        :  P. falciparum & P. vivax        12 :  Healthy control sample 
6          :  P. malariae & P. ovale        13  :  DNA blank 
7         :  P. malariae & P. knowlesi        14  :  Hexaplex DNA ladder 
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4.5.3.3  Simulated clinical mixed infections 
To test whether these primers could improve the detection of clinical mixed 
infections, a total of 30 experimental random mixed infections (two to three 
Plasmodium species) were created using clinical samples, and these were screened 
using the present hexaplex PCR and a nested PCR, the molecular gold standard for 
comparison study. All mixed Plasmodium species infections were successfully detected 
in all the simulated clinical samples. Figure 4.9 shows the hexaplex PCR results based 
on simulated clinical mixed infections using three of the most prevalent Plasmodium 
species in our local scenario, i.e., P. vivax, P. falciparum, and P. knowlesi.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9:  Hexaplex PCR results based on simulated clinical mixed infections. Lanes 
1 and 9: 50 bp DNA ladder (Fermentas), Lane 2 to 7: Random mixed infections of two 
Plasmodium species. Lane 8: Random mixed infections of three Plasmodium species. 
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4.5.3.4 Specificity analysis 
To estimate the specificity of the Plasmodium hexaplex PCR assay, DNA 
samples obtained from two isolates of bacterial strains, i.e., Aeromonas aquariorum, 
Aeromonas caviae, Aeromonas hydrophila, Aeromonas veronii, Vibrio harveyi, Vabrio 
parahaemolyticus, and Serratia species, as well as non-malaria parasites, i.e., 
Toxoplasma gondii, Giardia duedenalis, and hook worms (Necator americanus and 
Ancylostoma duodenale) were screened. DNA samples from 20 healthy individuals 
were also tested for the specificity and possibility of non-specific fragments. None of 
the Plasmodium PCR product was detected by the hexaplex PCR assay when the DNA 
was obtained from all non-Plasmodium samples. Only an approximately 109 bp band 
that represented the human β-hemoglobin gene in human samples was visualized on the 
gel. 
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4.5.4 Random blind test and clinical screening 
The present hexaplex system demonstrated the specificity of the PCR primers to 
their target species. High sensitivity and specificity also were detected for at least two-
species detection based on experimentally created mixed-infections without any 
significant diagnostic constrains. Both the hexaplex and nested PCR gave concordant 
results for species identification in all 50 samples in random blind test as well as 226 
clinical samples suspected to have malaria.  
Among the 211 microscopy confirmed malaria samples, the hexaplex PCR 
assays indicated that there were only two cases (1 %) of mixed infections (both caused 
by P. falciparum and P. vivax infections) another 201 (95 %) malaria samples showed 
single infection. PCR based species identification showed 39 % (83/211) of the samples 
were P. vivax, 28 % (60/211) were P. falciparum, 26 % (55/211) were P. knowlesi, 1 % 
(2/211) were P. malariae, as well as an imported P. ovale case, which was 
misdiagnosed as P. vivax by microscopy (Lim, et al, 2010) . The rest of the eight (4 %) 
malaria samples were negative by both nested and hexaplex PCR assays, with only the 
human positive control DNA amplicon observed.  
Among 15 microscopy negative clinical malaria samples, five samples were 
diagnosed positive with single Plasmodium species, i.e., one P. falciparum, one P. vivax, 
and three P. knowlesi infections. The results were further confirmed by nested PCR 
with similar results obtained. Table 4.3 summarizes the results of hexaplex PCR and the 
comparison of results for the identification of Plasmodium species by hexaplex PCR 
and microscopy. 
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4.5.5 Diagnostic sensitivity and specificity 
The sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) with 95 % confidence interval (95 % CI) of the microscopic 
examination as well as hexaplex PCR were evaluated using nested PCR as gold 
standard for all two modalities. The diagnostic sensitivity and specificity assays in P. 
vivax and P. falciparum determinations were calculated based on 246 samples 
(including two cases of P. vivax and P. falciparum mixed infections confirmed by PCR 
and 20 healthy controls) using MedCalc-Diagnostic test evaluation 
(http://www.medcalc.org/calc/diagnostic_test.php). 
 
Table 4.4: The sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) of the hexaplex PCR and microscopy were compared to a 
standard nested PCR. 
Nested PCR as gold standard 
                 Species 
Test 
P. vivax P. falciparum 
Positive Negative Positive Negative 
H
ex
a
p
le
x
 P
C
R
 
Positive 86 0 63 0 
Negative 0 160 0 183 
 
Percentage 
(%) 
95 % CI      
(%) 
Percentage 
(%) 
95 % CI      
(%) 
Sensitivity 100 95.76 to 100.00 100 94.26 to 100.00 
Specificity 100 97.70 to 100.00 100 97.98 to 100.00 
PPV 100 95.76 to 100.00 100 94.26 to 100.00 
NPV 100 97.70 to 100.00 100 97.98 to 100.00 
                 Species 
Test 
P. vivax P. falciparum 
Positive Negative Positive Negative 
M
ic
ro
sc
o
p
y
 
Positive 82 7 58 8 
Negative 4 153 5 175 
 
Percentage 
(%) 
95 % CI      
(%) 
Percentage 
(%) 
95 % CI      
(%) 
Sensitivity 95.35 88.51 to 98.69 92.06 82.43 to 97.34 
Specificity 95.62 91.19 to 98.22  95.63 91.57 to 98.09 
PPV 92.13 84.46 to 96.77 87.88 77.50 to 94.60 
NPV 97.45 93.60 to 99.29 97.22 93.63 to 99.08 
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4.6 Heterologous expression of PkAMA1 and PvAMA1 ectodomain proteins 
4.6.1 Plasmodium strain used in plasmid construction  
Plasmodium knowlesi strain H (GenBank accession no:  DQ350263) as well as P. 
vivax strain Sal-1 (GenBank accession no: U03079) were selected for recombinant 
protein expression study.  
 
4.6.2 Construction of pPAL7-PkAMA1 and pPAL7-PvAMA1 plasmids 
The entire gene of PkAMA1 and PvAMA1 ectodomains were successfully 
amplified with the REs digestion sites, i.e., SpeI (upstream RE) and BamHI 
(downstream RE) to 5’ and 3’ of PCR amplicon (~ 1.34 kb), respectively allowed the 
creation of PCR amplicon with specific restriction sites for directional DNA ligation to 
the compatible multiple cloning sites of pPAL7 vector (~ 5.9 kb).  
In general, both of the pPAL7 vector (~ 5.9 kb) and Plasmodium AMA1 PCR 
amplicon (~ 1.34 kb) were double digested with SpeI and BamHI and followed by gel 
purification prior to ligation step. The AMA1 coding DNA (cDNA) fragments of P. 
knowlesi and P. vivax were ligated in-frame respectively with the pPAL7 vector codes 
for a Profinity eXact tag on N-terminal end of the protein and generated DNA size with 
~ 7.2 kb. The efficiency of REs digestion and DNA ligation were checked using 1 % 
(w/v) agarose gel (Figure 4.10A).  
The pPAL7-PkAMA1 and pPAL7-PvAMA1 were initially transformed into C-
Max5α E. coli (cloning host) and plated on LB agar containing 100 µg/ml of ampicillin 
to select the pPAL7 clones. The transformation efficiency of cloned DNA was 
confirmed by colony PCR using T7 promoter and T7 Terminator primers. Positive 
clone was indicated by a PCR fragment with ~ 1.75 kb. Bacterial colonies containing 
desired recombinant clone were picked and grown in LB broth and the plasmid of each 
clone was isolated and the inserted sequence was further confirmed by DNA sequencing 
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using T7 promoter, pPAL7 internal, and T7 Terminator primers.  
Figure 4.10 shows the example of successful construction of pPAL7-PvAMA1 
clone confirmed by RE digestions and colony PCR. 
 
          A) DNA ligation/RE digestion           B) Colony PCR 
    
 
 
 
 
 
 
Figure 4.10: Confirmation of pPAL7-PvAMA1 construct by restriction enzyme 
digestion and colony PCR. (A) Increases of the size of pPAL7 vector indicated the 
successful of DNA ligation: Lane 1, Gel purified SpeI and BamHI digested PvAMA1 
PCR amplicon (~ 1.34 kb); Lane 2, Spe1 digested pPAL7 DNA (~ 5.9 kb); and Lane 3, 
Spe1 digested pPAL7-PvAMA1 (~ 7.2 kb). (B) Colony PCR with T7 promoter and T7 
Terminator primers generated an ~ 1.75 kb DNA fragment indicating successful DNA 
transformation. L1kb is 1kb DNA ladder (Fermentas) and L100 is 100 bp plus DNA 
ladder (Fermentas). Similar way was done for construction of pPAL7-PkAMA1. Due to 
similar in fragment size of PCR amplicon (~ 1.34 kb) for PkAMA1 and both of digested 
pPAL7 plasmid and pPAL7-PkAMA1 DNA, therefore, only the figure for construction 
of pPAL7-PvAMA1 clone is showed here.  
   1        L100       2         3       L1kb               4         5       L100 
              ~ 5.9 kb  ~ 7.2 kb 
 
 
~ 1.34 kb 
~ 1.75 kb 
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4.6.3 Sequencing and BLAST search of PkAMA1 and PvAMA1 
The sequencing results indicated that both of the pPAL7-PkAMA1 and pPAL7-
PvAMA1 (Figure 4.11) constructed clones carried an inserted DNA of 1,338 bp length. 
The clones were 99 % concordance with the published mRNA of the AMA1 
ectodomain gene of P. knowlesi (GenBank ref. no.: XM_002259303; Appendix 5.1) as 
well as P. vivax (GenBank ref. no.: FJ785007; Appendix 5.2). 
The nucleotide sequences were then translated into amino acid sequences 
(Figure 4.12) using ExPASy Translate tool (http://web.expasy.org/translate/) and then 
searched against the protein database using NCBI protein BLAST (BLASTP; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). The results indicated that both of the inserted 
coding sequences were in-frame with 446 amino acid residues of AMA1 ectodomain, 
encompassing entire region of domain I-II-III. The recombinant PkAMA1 (rPkAMA1) 
was 100 % identical with P. knowlesi H strain AMA1 protein (PKH_093110) deposited 
in GenBank with accession number XP_002259339 (corresponding to amino acids 42 
to 487, number commencing from the first residue of the signal peptide; Appendix 5.3), 
whereas recombinant PvAMA1 (rPvAMA1) was identical with P. vivax AMA1 protein 
with accession number ACY68841 (corresponding to amino acids 42 to 487; Appendix 
5.4). 
Only E. coli carrying the clone with correct coding sequence and orientation (in-
frame translation) confirmed by sequencing was further grown in LB broth and the 
plasmid was extracted and then re-transformed into BL21-CodonPlus (DE3)-RIL E. coli, 
a codon-optimized expression host, which carried an additional pACYC plasmid. This 
ColE1-compatible, pACYC-based plasmid containing extra copies of the argU, ileY, 
and leuW tRNA genes is suited for heterologous expression of recombinant protein 
consisted of AT-rich genome, i.e., Plasmodium DNA, as well as an additional 
chloramphenicol resistance (Cam
r
) gene to maintain the selection of pACYC plasmid. 
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Thus, only transformed E. coli colonies that carried recombinant clone were selected on 
LB plate containing 100 µg/ml of ampicillin and 34 µg/ml of chloramphenicol. Selected 
clones were further verified by colony PCR, REs digestion, and sequencing as 
mentioned above.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Plasmodium AMA1 coding DNA inserted into pPAL7 vector. Both 
PkAMA1 (A) and PvAMA1 (B) clones consist of 1,338 bp inserted AMA1 ectodomain 
gene. 
(A) Inserted PkAMA1 gene 
GGGCCTATCATTGAGAGAAGTATACGAATGAGTAACCCATGGAAAGCCTTCATGGAAAAGTATGATT
TAGAGAGAGCACACAATTCCGGGATTAGAATTGATTTAGGGGAAGATGCAGAAGTGGGAAATTCCAA
GTATAGAATACCAGCTGGAAAATGTCCAGTTTTTGGAAAGGGTATCGTTATAGAAAATTCTAACGTT
AGCTTCTTAACACCCGTAGCTACAGGAGCTCAAAGGTTGAAGGAAGGAGGTTTCGCCTTCCCCAATG
CAGATGACCACATTTCCCCTATAACAATAGCAAACCTTAAAGAGAGGTATAAAGAAAATGCAGATTT
GATGAAATTAAATGATATAGCCTTGTGTAAAACGCATGCAGCCAGCTTTGTCATTGCAGAGGATCAA
AATACATCTTACAGACATCCAGCTGTTTATGACGAAAAGAATAAAACATGTTACATGTTGTATTTGT
CAGCGCAAGAAAATATGGGTCCACGATACTGTAGCCCAGATTCACAAAATAAAGACGCCATGTTTTG
CTTCAAGCCAGATAAAAATGAAAAATTTGACAACCTGGTGTATTTAAGCAAAAACGTAAGTAATGAT
TGGGAAAACAAGTGCCCGCGTAAAAATTTAGGAAACGCAAAATTTGGATTATGGGTGGATGGGAACT
GTGAAGAAATACCATACGTTAATGAAGTGGAGGCAAGGAGCCTACGGGAATGCAACCGAATCGTTTT
CGAAGCTAGCGCTTCAGATCAACCACGTCAGTACGAAGAAGAACTGACAGATTATGAAAAAATACAA
GAGGGATTTAGACAAAATAATCGGGACATGATTAAAAGTGCCTTTCTTCCAGTGGGTGCATTTAACT
CAGACAATTTTAAGAGTAAAGGAAGAGGATATAACTGGGCAAATTTCGATTCTGTAAATAATAAGTG
TTACATTTTTAATACCAAACCTACGTGTCTCATTAATGACAAAAATTTTTTTGCAACAACAGCGTTA
TCTCACCCTCAAGAAGTAGACAATGAATTTCCATGCAGCATATACAAAGATGAAATTGAAAGAGAAA
TTAAGAAACAGTCGAGAAATATGAATCTGTACAGTGTTGATAAGGAACGGATTGTCTTGCCAAGGAT
ATTTATCTCCACCGATAAGGAGAGTATCAAATGTCCATGTGAGCCTGAACACATTTCCAATAGTACC
TGCAACTTTTACGTTTGTAACTGTGTAGAGAAGAGAGCAGAAATTAAGGAAAATAACGAAGTTATCA
TAAAGGAAGAATTTAAGGAGGATTATGAAAATCCGGACGGCAAACATAAGAAGAAGATGCTACTA 
 
(B) Inserted PvAMA1 gene  
GGGCCTACCGTTGAGAGGAGCACACGAATGAGTAACCCCTGGAAAGCGTTCATGGAAAAATACGACA
TCGAAAGAACACACAGTTCTGGGGTTCGAGTGGATTTAGGGGAAGATGCAGAAGTGGAAAATGCAAA
GTACAGAATTCCAGCTGGAAGATGTCCTGTTTTTGGAAAGGGTATCGTCATAGAGAATTCCGCTGTT
AGCTTCTTAAAACCTGTGGCTACAGGAGATCAGAGGCTGAAGGATGGAGGTTTCGCCTTCCCCAATG
CGAATGACCATATCTCCCCCATGACAATAGCGAACCTTAAGGCAAGGTATAAAGACAATGTAGAGAT
GATGAAGTTAAACGATATAGCTTTGTGCAGAACCCACGCAGCTAGCTTTGTCATGGCAGGGGATCAA
AATTCGTCCTACAGACACCCAGCTGTATACGACGAAAAGGAAAAAACATGCCACATGTTGTATTTAT
CAGCGCAGGAAAATATGGGTCCGAGGTACTGCAGCCCAGATGCACAAAATAGAGATGCCGTGTTCTG
CTTCAAGCCAGATAAAAATGAAAGCTTTGAAAACCTGGTGTATTTGAGCAAAAATGTGCGTAATGAT
TGGGATAAAAAATGCCCCCGTAAAAATTTAGGAAACGCCAAGTTCGGATTATGGGTGGATGGGAACT
GCGAAGAAATTCCATACGTTAAAGAAGTGGAGGCAAAGGATCTGCGCGAATGCAACCGAATCGTTTT
CGAAGCGAGTGCCTCAGATCAACCAACTCAGTATGAAGAAGAAATGACGGATTATCAAAAAATACAA
CAAGGGTTTAGACAAAACAACCGAGAGATGATTAAAAGTGCCTTTCTTCCAGTGGGTGCATTCAACT
CGGATAATTTCAAAAGTAAAGGAAGAGGATTTAACTGGGCAAATTTCGATTCTGTAAAAAAGAAGTG
TTACATCTTTAATACCAAACCGACTTGCCTCATTAATGACAAAAATTTTATTGCAACAACGGCGTTA
TCTCACCCACAAGAAGTAGACCCGGAGTTCCCCTGCAGCATATATAAAGACGAAATTGAAAGAGAAA
TTAAGAAACAATCGAGGAACATGAATCTGTACAGTGTTGATGGGGAACGCATTGTCCTGCCGAGGAT
ATTTATCTCCAACGATAAGGAGAGTATCAAATGTCCCTGCGAACCTGAGCACATTTCCAACAGTACC
TGCAACTTTTACGTTTGTAACTGTGTAGAGAAAAGGGCGGAAATTAAGGAAAATAACCAAGTTGTTA
TAAAGGAAGAATTTAGGGATTATTACGAAAATGGGGAGGAAAAATCGAACAAGCAGATGCTACTA 
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Figure 4.12: Protein sequences of the construct for rPkAMA1 and rPvAMA1 comprised 
446 amino acids residues. The rPkAMA1 sequence was 100 % in concordance with P. 
knowlesi strain H (NCBI reference sequence: XP_002259339), whereas rPvAMA1 
sequence was 100 % in concordance with P. vivax strain Sal-1 (NCBI reference 
sequence: ACY68841). The Plasmodium AMA1 sequences are given the following 
domain colour coding: domain I in green, domain II in red, and domain III in blue.  
 
 
(A) Recombinant PkAMA1 (rPkAMA1) 
GPIIERSIRMSNPWKAFMEKYDLERAHNSGIRIDLGEDAEVGNSKYRIPAGKCPVF
GKGIVIENSNVSFLTPVATGAQRLKEGGFAFPNADDHISPITIANLKERYKENADL
MKLNDIALCKTHAASFVIAEDQNTSYRHPAVYDEKNKTCYMLYLSAQENMGPRYCS
PDSQNKDAMFCFKPDKNEKFDNLVYLSKNVSNDWENKCPRKNLGNAKFGLWVDGNC
EEIPYVNEVEARSLRECNRIVFEASASDQPRQYEEELTDYEKIQEGFRQNNRDMIK
SAFLPVGAFNSDNFKSKGRGYNWANFDSVNNKCYIFNTKPTCLINDKNFFATTALS
HPQEVDNEFPCSIYKDEIEREIKKQSRNMNLYSVDKERIVLPRIFISTDKESIKCP
CEPEHISNSTCNFYVCNCVEKRAEIKENNEVIIKEEFKEDYENPDGKHKKKMLL 
 
(B) Recombinant PvAMA1 (rPVAMA1) 
GPTVERSTRMSNPWKAFMEKYDIERTHSSGVRVDLGEDAEVENAKYRIPAGRCPVF
GKGIVIENSAVSFLKPVATGDQRLKDGGFAFPNANDHISPMTIANLKARYKDNVEM
MKLNDIALCRTHAASFVMAGDQNSSYRHPAVYDEKEKTCHMLYLSAQENMGPRYCS
PDAQNRDAVFCFKPDKNESFENLVYLSKNVRNDWDKKCPRKNLGNAKFGLWVDGNC
EEIPYVKEVEAKDLRECNRIVFEASASDQPTQYEEEMTDYQKIQQGFRQNNREMIK
SAFLPVGAFNSDNFKSKGRGFNWANFDSVKKKCYIFNTKPTCLINDKNFIATTALS
HPQEVDPEFPCSIYKDEIEREIKKQSRNMNLYSVDGERIVLPRIFISNDKESIKCP
CEPEHISNSTCNFYVCNCVEKRAEIKENNQVVIKEEFRDYYENGEEKSNKQMLL 
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4.6.4 Protein sequence and bioinformatic analysis 
The theoretical isoelectric point (pI) and molecular weight (MW) of the 
rPkAMA1 and rPvAMA1 were estimated from their respective amino acids sequences 
using ExPASy interface, the Compute pI/MW tool (http://web.expasy.org/compute_pi/). 
The theoretical pI/MW of rPkAMA1 and rPvAMA1 were 5.85/51343.86 and 
6.28/51275.85, respectively. The Recombinant Protein Solubility Prediction tool 
(http://biotech.ou.edu/; Wilkinson & Harrison, 1991) estimated that 71.3 % of 
rPkAMA1 and 72.5 % of rPvAMA1 probably to be overexpressed in E. coli system in 
an insoluble form that mainly localized in an inclusion body (IB).  
 
4.6.5 Induction of protein expression  
A fraction of pre- and post-induction crude culture samples were collected to 
check the expression level of the recombinant protein. In general, the expression level, 
protein purity, and solubility of fusion protein were analyzed using Coomassie-stained 
12 % SDS-PAGE under reduced conditions (Session 4.6.5.1). The solubility of each 
fusion proteins was further confirmed using Western blot assay (Session 4.6.5.2).  
 
4.6.5.1 SDS-PAGE quick solubility screening 
The AMA1 ectodomain of P. knowlesi and P. vivax were expressed in the form 
of fusion protein with N-terminal Profinity eXact-tag (8.2 kDa) and yielded a protein 
fragment with molecular weight of ~ 60 kDa from E. coli lysate after induction with 
IPTG. Generally, the solubility of recombinant protein was determined by analyzing 
fractions of the supernatant and pellet samples after centrifugation, on 12 % SDS-PAGE 
under reduced conditions. Reduced SDS-PAGE result shows that both the pPAL7-
PkAMA1 and pPAL7-PvAMA1 proteins were found to be overexpressed as insoluble 
fraction of the cell lysate as IB by comparing the band of target protein at ~ 60 kDa in 
total, soluble, and insoluble fractions collected after 3 hour of induction (Figure 4.13).  
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Figure 4.13: Fractionation profile of the supernatant and pellet after centrifugation, on 
reduced 12 % SDS-PAGE. SDS-PAGE analysis of E. coli produced recombinant 
PkAMA1 (left) and recombinant PvAMA1 (right) with N-terminal Profinity eXact-tag. 
The pPAL7-PkAMA1 and pPAL7-PvAMA1 proteins were expressed in molecular 
weight of ~ 60 kDa. Lanes T were total proteins contained of both soluble and insoluble 
proteins; Lanes S contained only soluble protein; Lanes I contained only insoluble 
protein; Lanes IS contained solubilized cellular contaminants after washed with W1 
buffer containing additional treatment with 1 % (v/v) Triton X-100, 1 M urea, 1 mM 
EDTA, and 5 mM DTT; Lanes IB were purified inclusion bodies in W2 buffer; Lane M 
was protein marker (Fermentas).  
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4.6.5.2  Detection of the expression by Western blot analysis 
Western hybridization assay using anti-Profinity eXact monoclonal antibody 
(Bio-Rad) also showed that two of current expressed recombinant proteins, i.e., pPAL7-
PkAMA1 and pPAL7-PvAMA1 were localized in an insoluble IB. None of these 
proteins was detected in a soluble form in Western blot assay (Figure 4.14).  
Alterations in induction temperature (16 ºC, 25 ºC, and 37 ºC), induction time 
(OD600 to 0.6, 1.0, 1.5, and 2.0), as well as IPTG inducer concentration (0.1 mM, 0.5 
mM, 1.0 mM, and 2.0 mM) did not improve the expression of soluble target protein. 
Therefore, both of the recombinant proteins used in phage display biopanning assay 
were isolated and purified from insoluble IBs. 
 
 
 
  
 
 
 
Figure 4.14: Western blot analyzed the expression level of pPAL7-PkAMA1 (A) and 
pPAL7-PvAMA1 (B) using anti-Profinity eXact monoclonal antibody (Bio-Rad).  
Lanes, 
SP : Induced protein on 12 % SDS-PAGE (Insoluble lysate) 
Pre- : Pre-induce E. coli whole cell extract 
S : Soluble protein lysate (S) 
T : Total lysate (T) 
I : Insoluble lysate (I) 
IB : Purified inclusion body (IB) 
(A) pPAL7-PkAMA1                (B) pPAL7-PvAMA1 
 SP      Pre-     S       T        I        IB         SP      Pre-     S        T        I       IB            
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4.6.6  Recombinant protein extraction from E. coli and IB purification  
Basically, insoluble, unfolded, functional inactive IB is frequently formed upon 
overexpression of recombinant protein in transformed E. coli. The IB is accumulated in 
the cytoplasm of host cell, which contain the recombinant protein in high yield that can 
be isolated by solid/liquid separation, i.e., centrifugation. 
 
4.6.6.1 Cell lysis and IB purification 
Prior to protein isolation, E. coli cells were lysed so that the target protein can be 
purified from other cell components. In the present study, total proteins were extracted 
from bacterial cells with a combined disruption method to break down the cell walls or 
membranes, i.e., chemical and enzymatic disruptions (using B-PER
®
 reagent and 200 
µg/ml of lysozyme) as well as incorporation of mechanical disruption using 25 Guage 
syringe needle followed by vigorous vortexing. After centrifugation, IB was settled 
down with bacteria debris to form a pellet. The pellet was washed twice with B-PER 
buffer containing low concentration of chaotropic agent (1 M urea) and detergent (1 % 
Triton X-100) to solubilize the protein contaminants, e.g., outer membranes and 
proteins (proteases) from E. coli. Finally, a purified IB was obtained.  
Figure 4.15 and Figure 4.16 show the protein components isolated from E. coli 
crude culture collected during pre-induction and after 3 hours of post-induction (total, 
soluble, insoluble), as well as recombinant protein obtained from washed and purified 
IB.  
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Figure 4.15: Profinity eXact-tagged PkAMA1 protein expression and IB purification. 
Lanes, 
1 : Pre-induced E. coli whole cell extract 
2 : Induced E. coli whole cell extract- total lysate (T)  
3 : Soluble (S) fraction  
4 : Insoluble (I) fraction  
5 : Insoluble supernatant (IS) 
6 : Washed inclusion body (W1)  
7 : Purified inclusion body (IB) 
8 : Protein marker (Fermentas) 
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Figure 4.16: Profinity eXact-tagged PvAMA1 protein expression and IB purification. 
Lanes, 
1 : Protein marker (Fermentas) 
2 : Pre-induced E. coli whole cell extract 
3 : Induced E. coli whole cell extract- total lysate (T)  
4 : Soluble (S) fraction  
5 : Insoluble (I) fraction  
6 : Insoluble supernatant (IS) 
7 : Washed inclusion body (W1)  
8 : Purified inclusion body (IB)  
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4.6.6.2  Inclusion bady solubilization 
The IB is dense, insoluble aggregates of denature and unfolded proteins that 
need to be solubilized under denaturing condition using a high concentration of 
denaturant such as 4-8 M urea or 6 M guanidine-HCl. However, the ion Cl
-
 present in 
guanidine-HCl may trigger the cleavage of fusion protein therefore urea was chosen as 
denaturant for IB solubilization in this study. For some IB, very high concentration of 
denaturant, i.e., 8 M urea is required to facilitate the solubilization, otherwise protein 
might not be dissolve in a solution and keep deposited in insoluble pellet, which will 
inhibit further affinity purification procedure using column. Therefore the 
concentrations of minimal urea requirement for IB solubilization were empirically 
tested from range of 2 M to 8 M (Figure 4.17). Purification of target protein from IB 
with Profinity eXact resin can be run with urea concentration up to 2 M without 
affecting binding capacity or column performance, while protein solubilization with 
more than 4 M urea may lower the yield and affect the protein purity; therefore 
concentrations above 4 M are not recommended. IB solubilization buffer (0.1 M sodium 
phosphate, 5 mM DTT, 1 mM EDTA) with 4 M urea was sufficient to dissolve whole 
IB after incubation overnight at 4 °C. 
 
 
 
 
 
 
 
Figure 4.17: Optimization of concentrations of urea (2 M to 8 M) used in IB 
solubilization buffer. Loading samples were supernatant of solubilized protein 
centrifuged at 15,000 × g for 30 minute. 
 pPAL7-PkAMA1                              pPAL7-PvAMA1  
 IB  8M  7M   6M  5M  4M   2M            IB  8M  7M  6M  5M  4M   2M             
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4.6.7 Affinity protein purification and fusion-tag removal   
The Profinity eXact technology enable a single step on-column affinity 
purification of fusion protein followed by cleavage release of purified recombinant 
protein with a native N-terminus triggered by 100 mM sodium fluoride (elution buffer). 
In general, solubilized IB protein sample was centrifuged and the supernatant was 
filtered and then diluted in 2 M urea prior to load into a Profinity eXact cartridge. The 
tagged recombinant protein was bound to the mutant subtilisin protease (S189), a ligand 
immobilized to the support matrix. The host protein contaminants and excessive 
unbound target protein were then collected in the flow-through fraction. After two 
subsequent column washes, a tag-free recombinant protein was collected into five 
elutions (0.1 ml/minute). The apparent molecular masses of two constructs were ~ 50 
kDa, in accordance with theoretical mass calculated from their respective amino acid 
sequences. The Profinity eXact cartridge can be regenerated using 0.1 M phosphoric 
acid and the collected fraction contains an 8.2 kDa mass of Profinity eXact tag that has 
an apparent electrophoretic mass of ~ 12 kDa in SDS-PAGE as reported in product 
bulletin (Figure 4.18 and Figure 4.19, Lane 11).  
SDS-PAGE results show that the Profinity eXact tag-free recombinant proteins, 
i.e., rPkAMA1 (Figure 4.18) and rPvAMA1 (Figure 4.19) were purified and eluted at 
the end of the affinity purification protocol under denatured conditions. The protein 
fractions along the isolation and purification procedures were analyzed by reduced 
SDS-PAGE. 
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Figure 4.18: Profinity eXact tag-free rPkAMA1 purified and eluted using a 1 ml Bio-
Scale Mini
TM
 Profinity eXact cartridge under denatured and reduced conditions.  
Lanes, 
1 : Solubilized IB crude protein (centrifuged and filtered) 
2 : Flow-through fraction (excessive target protein and host protein contaminants)   
3 : Host protein contaminants from column wash 
4 : Host protein contaminants from stringency wash 
5 : Protein marker (Fermentas) 
6 : Eluted tag-free rPkAMA1 (elution 1, 1 ml) 
7 : Eluted tag-free rPkAMA1 (elution 2, 1 ml) 
8 : Eluted tag-free rPkAMA1 (elution 3, 1 ml) 
9 : Eluted tag-free rPkAMA1 (elution 4, 1 ml) 
10 : Eluted tag-free rPkAMA1 (elution 5, 1 ml) 
11 : Cleaved Profanity eXact fusion-tag (column regeneration) 
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Figure 4.19: Profinity eXact tag-free rPvAMA1 purified and eluted using a 5 ml Bio-
Scale Mini
TM
 Profinity eXact cartridge under denatured and reduced conditions.  
Lanes, 
1 : Protein marker (Fermentas) 
2 : Solubilized IB crude protein (centrifuged and filtered) 
3 : Flow-through fraction (excessive target protein and host protein contaminants)   
4 : Host protein contaminants from column wash 
5 : Host protein contaminants from stringency wash 
6 : Eluted tag-free rPvAMA1 (elution 1, 5 ml) 
7 : Eluted tag-free rPvAMA1 (elution 2, 5 ml) 
8 : Eluted tag-free rPvAMA1 (elution 3, 5 ml) 
9 : Eluted tag-free rPvAMA1 (elution 4, 5 ml) 
10 : Eluted tag-free rPvAMA1 (elution 5, 5 ml) 
12 : Cleaved Profanity eXact fusion-tag (column regeneration) 
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4.6.8 Analysis of folding reactions 
 The efficiency of refolding conditions were monitored by measuring the protein 
aggregation by simple visual inspection and turbidity analysis (Session 4.6.8.1), as well 
as reduced/non-reduced SDS-PAGE (Session 4.6.8.2). 
 
4.6.8.1 Aggregation measurement 
Instant visual inspection is often used as the first line to monitor the refolding 
process. When refolding conditions are not optimized; the protein aggregation is clearly 
seen. In addition to visual inspection, the turbidity of the sample solution (aggregation) 
was further performed by measuring the optical density at 390 nm subtracted from the 
apparent absorbance readings due to solution turbidity without the protein sample. In 
the present study, the refolded rPkAMA1 and rPvAMA1 ectodomain proteins were 
taken to be soluble as both of the apparent OD reading for sample solution subtracted to 
blank sample buffer was less than 0.05. This solubility assay basically accounts for 
protein solubility and not for protein folding. 
After completion of refolding, the sample solutions were then centrifuged at 
14,000 × g for 1 hour. Neither of visually aggregates nor pellet was observed in both 
rPkAMA1 and rPvAMA1 sample solutions (non-denaturing buffer).  
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4.6.8.2 Reduced and non-reduced SDS-PAGE 
Evidence of successful protein refolding was further analyzed through SDS-
PAGE under reducing and non-reducing conditions in the presence or absence of β-
mercaptoethanol, respectively in the protein loading buffer.  
Correctly folded (native) AMA1 protein is known to contain eight disulfide 
bonds (Hodder, et al., 1996). Generally, unsuccessful refolding results in an increased 
fraction of high molecular weight inter-molecular disulfide-linked multimeric AMA1 
agrregates, i.e., dimers, trimers, and multimers. Refolding in some circumstances may 
also produce monomeric misfolded AMA1 that might co-migrate with refolded AMA1 
on non-reduced SDS-PAGE. However, this monomeric misfolded AMA1 variants 
could be detected by the examination of band diffuseness on non-reducing SDS-PAGE. 
Under non-reducing conditions, the apparance of more fuzzy band or diffused band are 
due to differentially folded AMA1 variants (Gupta, et al., 2005).  
For instance, the more diffuse and multimeric AMA1 aggregates were observed 
in pre-refold samples (Figure 4.20, Lanes 1 and 2). After refolding, both the refolded 
products (rPkAMA1 and rPvAMA1) were close to apparent homogeneity in a 
molecular mass of ~ 50 kDa (Lanes 3 and 4). Furthermore, there were disappearance of 
most disulfide-bonded aggregates in post-refold samples and none of dimmers, 
trimmers, and multimers was observed in both of the post-refolded rPkAMA1 and 
rPvAMA1 (Figure 4.20, Lanes 3 and 4). Besides that, the resulting non-reduced bands 
(Lane 3) were not diffuse and virtually identical to the reduced bands (Lane 4) 
indicating most material was refolded successfully. Figure 4.20 also shows the refolding 
evidence of the rPkAMA1 and rPvAMA1, where the refolded and non-reduced proteins 
(Lane 3) exhibit a faster mobility than refolded and β-mercaptoethanol-treated proteins 
(Lane 4). Shift in mobility upon reduction showed that β-mercaptoethanol treatment 
reduced the expected intramolecular disulfide bonds in the refolded protein and thus 
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suggested that rPkAMA1 and rPvAMA1 produced in this study also contained 
reduction-sensitive, disulphide-bonded, tertiary structures. 
 
     
 
 
 
 
 
 
 
 
 
Figure 4.20: Reduced and non-reduced SDS-PAGE analysis of refolding of rPkAMA1 
and rPvAMA1 ectodomain proteins. Pre-refold and post-refold fractions of rPkAMA1 
(A) and rPvAMA1 (B) were analyzed under non-reducing (Lanes 1 and 3) and reducing 
(Lanes 2 and 4) conditions using 12 % SDS-PAGE. Non-reduced proteins exhibited 
overall a faster mobility than reduced proteins suggested that recombinant proteins 
produced in present study contained reduced-sensitive intramolecular disulfide bonds. 
More diffused and fuzzy band as indication of misfolded AMA1 variants were observed 
in both of the pre-refold rPkAMA1 and rPvAMA1 samples as compared to the post-
refold samples, in both of the non-reduced and reduced conditions. The disappearance 
of most multimers and disulfide-bonded aggregates in post-refold showed that these 
proteins were successfully refolded.  
 
 
     A                rPkAMA1            B       rPvAMA1 
          Pre-refold   Post-refold     Pre-refold          Post-refold 
      1        2       M         3        4      M              1        2     M         3        4       M 
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4.6.9 Protein identification by LC-MS/MS 
The identity of rPKAMA1 and rPvAMA1 were further confirmed by LC-
MS/MS (Table 4.5). Matched peptides are shown in Appendix 6. 
 
Table 4.5: LC-MS/MS spectrum mill analysis of PkAMA1 and PvAMA1. 
Spectra 
Distinct 
peptides 
MS/MS 
search 
score 
% AA 
coverage
* 
Database 
accession 
Protein ID 
Recombinant PkAMA1 
47 25 426.00 38 P21303 
Merozoite receptor PK66 
OS=Plasmodium knowlesi 
(strain nuri) GN=PK66 
PE=2 SV=2 
Recombinant PvAMA1 
40 25 424.99 48 
62738184 
PDB: 
1W81
** 
b|1W81|A Chain A, 
Crystal Structure Of 
Apical Membrane Antigen 
1 From Plasmodium vivax 
40 25 424.99 48 
62738193 
PDB: 
1W8K
** 
b|1W8K|A Chain A, 
Crystal Structure Of 
Apical Membrane Antigen 
1 From Plasmodium vivax 
 
*  Indicates the percentage of amino acids coverage in LC-MS/MS results compared 
with entire region of Plasmodium AMA1, including prosequence, ectodomain 
(domain I, II, and III), transmembrane region, and cytoplasmic domain deposited in 
reference database. 
** Protein Data Bank (PDB): http://www.wwpdb.org/ 
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4.7 Identification of PkAMA1 and PvAMA1 binding peptides using a phage 
display library 
In order to isolate phage that displayed peptides with specific to PkAMA1 and 
PvAMA1 proteins, a phage display peptide library with a diversity of ~ 2 × 10
9
 phage 
particles was employed. This Ph.D.-12 phage display library was purchased from NEB. 
The rPkAMA1 and rPvAMA1 were used as target proteins conducted on two 
independent affinity selections. Three consecutive rounds of biopanning were carried 
out in order to identify the peptides binding to PkAMA1 as well as PvAMA1 proteins. 
The pool of selected phages that displayed polypeptides with high binding affinity 
towards the target protein was enriched prior to the subsequence round of biopanning.   
The titer of phage library was determined by infecting E. coli ER2738 with the 
ten-fold serial dilutions of phage in LB broth, i.e., with dilution ranging from 10 to 10
4
 
for unamplified biopanning eluates (Figure 4.21B) and 10
8
 to 10
11
 for amplified phage 
culture supernatants (Figure 4.21C).  
In general, the blue plaques are recombinant phages from phage library that 
carried the lacZ gene, while the white plaques are due to wily-type phage contamination. 
During the three rounds of biopanning and phage amplification, none of white plaque 
was observed. This quality control was essential due to vanishingly small levels of 
contaminating wild-type phage will completely overtake the pool of phage library used 
in subsequent round of biopanning. 
 
 
 
 
 
 
CHAPTER FOUR: RESULTS 
 
 
168 
 
A) Titering plate with blue plaques resulted from the lysed of E. coli by phage 
 
 
 
 
 
 
 
B) Serial dilutions of phage for unamplified biopanning eluates 
 
 
 
 
10
-1
              10
-2
            10
-3
         10
-4 
C) Serial dilutions of phage for amplified phage culture supernatants 
 
 
 
 
10
-8
              10
-9
           10
-10
         10
-11 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Phage titering. Example of typical results obtained from titering of phage 
sample. Serial dilutions of phage as indicated were mixed with Escherichia coli 
ER2738 cells and incubated on LB/IPTG/Xgal agar plates overnight at 37 °C. 
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4.7.1 Biopanning of phage library to PkAMA1 and PvAMA1 
Generally, ~ 2 × 10
11
 of the input phage library was used as initiation of 
biopanning. The titer of output phage was determined, amplified, and then diluted to the 
desired titer as the input for the subsequence round of biopanning procedure. The titer 
of input and output phage during three rounds of biopanning was listed in Table 4.6. 
 
 Table 4.6: Phage titers obtained following each round of biopanning of rPkAMA1 and 
rPvAMA1. 
 
 
4.7.2 Sequence analysis of phage clones selected from panning with PkAMA1 and 
PvAMA1 
Peptides that bound to PkAMA1 and PvAMA1 have been identified from 
random peptide library expressed on the surface of phage. Twenty plaques were 
randomly selected and amplified from the third round of biopanning. Single-stranded 
DNA of each phage isolate was extracted and sequenced to determine the inserted 
coding DNA. The sequence of the inserted coding DNA was then translated into amino 
acid sequence using ExPASy Translate tool (http://web.expasy.org/translate/).  
Figure 4.22 shows an example of the identification of a binding peptide selected 
from biopanning against PkAMA1. 
Number of phage particles 
rPkAMA1 First Second Third 
Input 2.0 × 1011
 
2.0 × 10
10  4.0 × 1010 
Output 4.5 × 102
 
6.8 × 10
2 
2.2 × 10
4 
rPvAMA1 First Second Third 
Input 2.0 × 1011 1.0 × 1011 4.0 × 1010 
Output 2.8 × 102
 
5.5  × 10
2 2.0 × 103
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A. Phage amplification 
 
 
 
 
 
 
 
 
 
B. Single-stranded DNA isolation 
 
 
 
 
 
 
C. DNA sequencing and binding peptide identification 
 
 
 
 
 
 
 
 
5’- TCT CAC TCT TGG CAT TGG GGT CTT CTG TAT CCT GCG AGT GCT AAT GGT GGA GGT 
N’- Ser His Ser Trp His Trp Gly Leu Leu Tyr Pro Ala Ser Ala Asn Gly Gly Gly 
   W   H   W   G   L   L   Y   P   A   S   A   N 
 
DNA sequence encoded 12-mer peptide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
Figure 4.22: Amplification and sequencing of a phage clone selected from biopanning 
of rPkAMA1. Following elution of interacting peptides in phage display, the copy 
number can be increased by bacterial infection (phage amplification), as these peptides 
are displayed on M13 bacteriophage (A). Interacting phage displayed peptides can then 
be isolated and their sequence can be identified (B). In turn, these codons can be 
translated to determine the amino acid sequences of the interacting phage-derived 
peptides (C). Red box indicates a DNA sequence encoded for 12-mer peptide. The rest 
of binding peptides were identified in similar way (Appendix 8 and Appendix 9). 
Individual 
phage 
selected from 
biopanning of 
PkAMA1 
Phage 
amplification Phage-
displayed 
peptide 
Phage clone DNA 
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Overall, 4 and 3 phage peptide variants that bound to rPkAMA1 and rPvAMA1 
respectively were identified from 20 random picked phage isolates in the third round of 
biopanning. Twenty sequences of the inserted DNA were obtained for rPkAMA1 while 
16 were obtained for rPvAMA1, this was due to two clones were failed in sequencing 
and another two clones showed lack of inserted DNA. The overall results are listed in 
Table 4.7. Interesting, one of the peptide sequence, WHWSWWNPNQLT (designated 
as PdK3 and PdV2) was identified in both of the biopanning against rPKAMA1 and 
rPvAMA1. 
 
Table 4.7: Peptide sequences obtained in the third round of each biopanning against 
PkAMA1 and PvAMA1. 
Target protein: rPkAMA1 
Phage clone Peptide sequences Frequency (n=20)* Percentage (%) 
PdK1 GGSIAASELEYY 6 30 
PdK2 WHWGLLYPASAN 10 50 
PdK3 WHWSWWNPNQLT 1 5 
PdK4 HSQAMPSMLHQA 3 15 
Target protein: rPvAMA1 
Phage clone Peptide sequences Frequency (n=16)*
 
Percentage % 
PdV1 DLTFTVNPLSKA  8 50 
PdV2 WHWSWWNPNQLT 7 44 
PdV3 TSVSYINNRHNL 1 6 
 
* Frequency and percentage indicate the total number of observations of a specified 
phage variants identified in third round of biopanning. 
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4.7.3 Consensus sequences determination 
The presence of consensus motifs in the binding peptides with affinity to 
rPkAMA1 and rPvAMA1 were investigated using ClustalW (Thompson, et al., 1994) 
(Figure 4.23). 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Amino acid sequences alignment of selected dodecapeptides obtained after 
three rounds of biopanning against rPkAMA1 (A) and rPvAMA1 (B). The color bar 
represented the consensus amino acids located at the same position of consensus motif.  
 
 
 
 
 
 
 
 
A. Peptide sequences obtained from biopanning against rPkAMA1 
PdK1         --GGSIAASELEYY 
PdK2         WHWGLLYPASAN-- 
PdK3         WHWSWWNPNQLT-- 
PdK4         -H-SQAMPSMLHQA 
 
B. Peptide sequences obtained from biopanning against rPvAMA1 
PdV1         -DLTFTVNPLSKA 
PdV2         WHWSW-WNPNQLT 
PdV3         TSVSYINNRHNL- 
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4.7.4 Analysis of binding affinity of selected peptides to PkAMA1 and PvAMA1 
4.7.4.1 Phage ELISA binding assay 
The binding affinity of each selected peptide clone to rPkAMA1 as well as 
rPvAMA1 was validated using phage ELISA binding assay, a useful method for 
qualitative determination of relative binding affinities for a number of selected clones in 
parallel. The binding of respective phage with target protein, i.e., rPkAMA1 or 
rPvAMA1 and BSA as the negative control were determined and the binding signals of 
each of the individual phage with target protein and BSA were then compared. The bar 
charts in Figure 4.24 and Figure 4.25 show the comparative results obtained from phage 
ELISA binding assay with comparison of binding affinities of individual phage clone to 
the rPkAMA1 and rPvAMA1, respectively.  
Finally, only two out of four of phage clones show strong binding signal to 
rPkAMA1, i.e., PdK1 (GGSIAASELEYY) and PdK2 (WHWGLLYPASAN) with 8.3× 
and 22.6×, respectively, whereas PdK3 (WHWSWWNPNQLT) and PdK4 
(HSQAMPSMLHQA) peptides show weak binding signal with 2.1×. Three phage 
clones selected from biopanning on rPvAMA1, i.e., PdV1 (DLTFTVNPLSKA), PdV2 
(WHWSWWNPNQLT), and PdV3 (TSVSYINNRHNL) show positive binding signal 
with 12.1×, 3.5×, and 3.1×, respectively. 
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  rPkAMA1 (+) 
 
BSA (-) 
 
Phage clone 
 
 
 
 
 
 
 
 
 
 
Figure 4.24: Phage ELISA binding assay for peptides selected from biopanning against 
rPkAMA1. Upper wells of microplate were coated with 100 µg/ml of rPkAMA1, 
whereas lower wells were coated with BSA. Negative (Neg.) indicates none of phage 
clone was tested. Phage binding signals were determined using HRP-conjugated anti-
M13 antibody and ABTS as the HRP-substrate. The folds of binding are shown in the 
table. 
 
 
 
Phage clone 
Absorbance 405 nm 
Fold of binding 
BSA  
(-) 
rPkAMA1 
 (+) 
Neg. 0.101 0.103 - 
PdK1 0.094 0.779 8.3× 
PdK2 0.093 2.106 22.6× 
PdK3 0.106 0.225 2.1× 
PdK4 0.106 0.224 2.1× 
N
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  rPvAMA1 (+) 
 
BSA (-) 
 
Phage clone 
 
 
 
 
 
 
 
 
 
 
Figure 4.25: Phage ELISA binding assay for peptides selected from biopanning against 
rPvAMA1. Upper wells of microplate were coated with 100 µg/ml of rPvAMA1, 
whereas lower wells were coated with BSA. Negative (Neg.) indicates none of phage 
clone was tested. Phage binding signals were determined using HRP-conjugated anti-
M13 antibody and ABTS as the HRP-substrate. The folds of binding are shown in the 
table.  
 
 
 
Phage clone 
Absorbance 405 nm 
Fold of binding 
BSA 
(-) 
rPvAMA1 
(+) 
Neg. 0.141 0.141 - 
PdV1 0.134 1.616 12.1× 
PdV2 0.550 1.949 3.5× 
PdV3 0.122 0.377 3.1× 
N
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P
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4.7.4.2  Western blot binding assay 
The binding characteristics of the phage peptides were further examined by 
Western blot analysis. The results obtained were captured with a digital camera (Figure 
4.26).  
The phage clones PdK1 and PdK2 showed positive signal to rPkAMA1, whereas 
no signals were being observed on strips PdK3 and PdK4. On the other hand, clear 
signal was observed in PdV1 to rPvAMA1, while weak binding signals were being 
observed in strips PdV2 and PdV3. 
 
 
 
 
 
 
 
 
 
Figure 4.26: Western blot assay for peptides binding to rPkAMA1 and rPvAMA1.   
   PdK1          PdK2       PdK3       PdK4                 PdV1          PdV2          PdV3 
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CHAPTER FIVE: DISCUSSION AND CONCLUSION 
5.1 Diagnosis of malaria 
Malaria is a serious global health challenge and the disease may turn severe if 
the patient is left untreated especially for P. falciparum and P. knowlesi infections. 
Plasmodium vivax is considered a benign infection and rarely causes death, however, 
there have been increasing severe vivax malaria reported elsewhere (Karyana, et al., 
2008; Kochar, et al., 2005; Rogerson & Carter, 2008; Tjitra, et al., 2008). Severe vivax 
malaria was frequently reported in young children and debilitated patients after 
repeating infections (Mueller, et al., 2009; Rogerson & Carter, 2008). Furthermore, P. 
vivax gametocytes develop early in the infection and can be seen in the peripheral 
circulation before or at the beginning of clinical symptoms. The asymptomatic infection 
in yet untreated individual might serve as potential reservoir to transmit the infection to 
mosquitoes (Mueller, et al., 2009). Basically, most of the severe malaria may actually 
have been associated with mixed infections as well as multidrug resistance (Karyana, et 
al., 2008; Kochar, et al., 2005; Rogerson & Carter, 2008; Tjitra, et al., 2008). 
Thus far, effective malaria vaccines are still unavailable (malERA Consultative 
Group on Vaccines; Richards & Beeson, 2009), therefore a rapid, accurate, species-
sensitive/-specific and economically-efficient diagnostic tool is crucial to increase the 
effectiveness of targeted treatment for infected individuals and control management. 
Accurate diagnosis of malaria is necessary to prevent the disease from progressing and 
eliminating malaria death, besides avoiding the unnecessary use of antimalarial agents. 
The improper drug prescription not only may lead to drug-related adverse effects but 
also contribute to unnecessary drug pressure, thereby enhance the existence of drug 
resistance Plasmodium stains. 
Most of the currently available malaria diagnostic tools are focused on parasites 
circulated in the erythrocytic cycle, which are responsible for the appearance of clinical 
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symptoms in human. To date, available diagnostic tools include microscopic 
examination of Giemsa stained thin and thick blood smears, immunochromatographic 
dipstick assay, and molecular PCR assays.  
 
5.1.1 Microscopic examination 
Giemsa stained blood smears are the most widely used approach for malaria 
diagnosis. Although this method is effective and inexpensive, it is laborious, time-
consuming, and is challenging for Plasmodium species identification, especially when 
infections are at low parasitemia below the threshold of microscopy detection, i.e., 
below 40 parasites/µl of blood, as well as in mixed-species infection cases. Generally, 
the detection limit can vary among microscopists. The routine detection level usually 
exceed 50 parasites/µl (Mayxay, et al., 2004; Moody, 2002) and can be down to 
approximately 5-10 parasites/µl for an expert (Zimmerman, et al., 2004). Microscopic 
examination permits the determination of the infecting species as well as the stage of the 
circulating parasites. In addition, it also allows quantification of Plasmodium parasites, 
assessing the disease severity, as well as monitoring the response to antimalarial therapy. 
Moreover, malaria blood smears also provide a permanent record for quality assessment 
of the microscopy diagnosis.  
Although microscopic examination has long served as a gold standard for 
routine malaria diagnosis, multiple morphological appearances of parasites remain the 
major concern in malaria diagnosis in both cases of the single- as well as in multiple-
species infections. Morphological confusion in blood stages of some Plasmodium 
species to others is one of the major challenges in malaria diagnosis (Moody, 2002). For 
example, P. knowlesi morphologically resembles P. falciparum in the early ring 
trophozoite stage and to P. malariae in the later erythrocytic stages (mature trophozoite, 
schizont, and gametocyte). This has made it difficult for the speciation of Plasmodium 
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via microscopy (Lee, et al, 2009). Besides that, five human malaria parasites exhibit 
high morphological similarity in young ring-forms; therefore, species differentiation can 
also be difficult if the circulating stages are in immature erythrocytic stage, especially in 
mixed infections.  
Unrecognized and underestimation of mixed infections are common in malaria 
cases diagnosed based on microscopy alone. The hallmark features of P. falciparum 
infection for severe malaria include mature parasites cytoadhere to a variety of receptors 
and become sequestered in the deep vasculature of various tissues and organs. Parasite 
sequestration could be the reasons for the absence of mature asexual blood stage forms 
of parasites in blood circulation, unless in severe cases with very high parasitemia 
(Zimmerman, et al., 2004). Other than sequestered parasite, undetectable of P. vivax and 
P. ovale parasites that exhibit hypnozoite forms (dormant stage) in the liver, as well as 
delayed appearance of one cryptic species might consequently lead to the difficulties in 
featuring the exact infectious species and parasitaemia in mixed infections (Mayxay, et 
al., 2004).  
Mixed infections certainly have worst clinical outcome compared to single 
infection. Failure to detect mixed infections could result in inadequate or incorrect 
treatment. For example, missed diagnosis of P. falciparum and P. knowlesi within 
mixed infections could result in the risk of developing subsequence severe and possibly 
fatal disease; whereas, missed diagnosis of P. vivax and P. ovale infections could result 
in repeated debilitating relapses in the blood due to the reactivation of dormant liver-
stage hypnozoite. Missed diagnosis of vivax malaria during pregnancy could also result 
in the birth of low-birth-weight infants that increases the risk death in newborn (Mayxay, 
et al., 2004; Desai, et al., 2007; Steketee, et al., 2001). Basically, the therapeutic 
regimens will differ in mixed infections and immediate drug treatment is priority 
recommended for treatment of P. falciparum infection in malaria cases with mixed 
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infections as the consideration of severe disease and even fatal complications in 
falciparum malaria (WHO, 2000). 
 
5.1.2 Rapid diagnostic tests (RDTs) 
The RDTs offer the possibility of rapid (required 15-20 minutes assay time) and 
nonmicroscopic methods for malaria diagnosis based on the principle of 
immunochromatographic lateral-flow-strip technology. The dipstick format RDT 
enables the capture of the parasitic antigen from peripheral blood using Plasmodium 
specific monoclonal antibodies that are immobilized on the surface of a nitrocellulose 
membrane. Despite the low sensitivity (require > 100 parasites/µl of blood) and most of 
commercial available kits are only specific to P. falciparum detection, the RDTs have 
been implemented as an adjunct to microscopic examination in many diagnostic 
laboratories and also widely used in remote areas across the world, whereby lack of 
well-equipped diagnostic facilities is common (Moody, 2002; Murray, et al., 2008). 
However, antigenemia may persist in plasma a few weeks beyond the actual infection, 
leading to the possibility of false positive results (Moody, 2002). 
 
5.1.3 Molecular PCR diagnosis 
In malaria epidemiological studies, correct estimates for the global burden of 
species-specific Plasmodium infections require better diagnostic methods. Therefore, a 
more sensitive and specific diagnostic assay is urgently needed. The detection of low 
level asymptomatic and mixed species infections with conventional light microscopy 
and RDTs are limited. Misdiagnosis of Plasmodium species, especially in overlooking 
lethal Plasmodium species will have a significant negative impact on the effectiveness 
of treatment, control measures and prognosis of patients (Moody, 2002; malERA 
Consultative Group on Diagnoses and Diagnostics, 2011). Essentially, this will 
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definitely stifle the global malaria eradication efforts.  
The molecular detection for Plasmodium diagnosis using PCR has been proven 
to be relatively more sensitive and specific to detect asymptomatic carries, prepatent 
patients, and people recently exposed to Plasmodium infections. Conventional PCR 
assays, such as nested PCR (Singh, et al., 1999; Singh, et al., 2004; Snounou, et al., 
1993), semi-nested  PCR (Rubio, et al., 1999), and multiplex PCR (Padley, et al., 2003), 
as well as real-time PCR (Mangold, et al., 2005; Perandin, et al., 2004; Rougemont, et 
al., 2004; Safeukui, et al., 2008), have shown to improve the sensitivity and specificity 
over microscopic evaluations or RDTs in many cases, as they can detect parasitemia 
levels of < 5 parasites/µl, and as low as 0.004 parasites/µl for P. ovale (Padley, et al., 
2003). 
Real-time PCR is also known as a quantitative PCR (qPCR) due to its ability in 
quantifying the parasite DNA copy numbers, i.e., estimation of parasite densities in 
malaria. The real-time PCR is a rapid assay, and the result obtained is in a more 
straightforward format based on completion of amplification without any downstream 
analysis through gel electrophoresis such as in conventional PCR assays. Furthermore, 
the closed system can also minimize the probability of cross-contamination inherent in 
conventional PCR. However, the cost of reagents, consumables, and equipment are 
much higher than any conventional PCR assays.  
Most recently, a simplest molecular method using loop-mediated isothermal 
amplification (LAMP) assay was first described by Han and colleagues in the diagnosis 
of four human malaria parasites (except P. knowlesi) (Han, et al., 2007). Generally, six 
distinct regions on a target gene (i.e., 18S rRNA gene) are amplified under constant 
temperature of 60 - 65 °C using either two to three sets of primers and a Bst DNA 
polymerase with high strand displacement activity in addition to a replication activity. 
The corresponding release and precipitation of magnesium pyrophosphate as by-product 
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of LAMP reaction will result in visible turbidity, which allows easy visualization by the 
naked eye or real-time turbidimeter (Han, et al., 2007). Although this method is rapid 
and simple, however further evaluation of this method is necessary to determine its 
utility for malaria diagnosis in the field.  
Among the PCR assays, a single-step multiplex PCR seems to be the most ideal 
assay in the diagnosis of malaria in terms of costing and duration of time needed to 
obtain the results. The main advantage of multiplex PCR is the ability to simultaneously 
identify more than two targets in a single tube reaction; this is an attractive option for 
routine malaria diagnosis, since mixed infections can be detected in a single step. 
However, there are limited studies in this area due to the difficulties in primer design 
and the cumbersome optimization procedures that are needed to establish a highly 
sensitive and specific assay. The use of various couples of primers which have different 
characteristics, especially for primers annealing and melting temperatures are the main 
technical constraints in multiplex PCR development. Furthermore, there is no standard 
protocol in optimizing multiplex PCR, all primers designing and optimum reaction 
conditions need to be tested empirically. 
To the best of our knowledge, only two multiplex PCR assays based on 
conventional PCR technology, i.e., a semi-nested PCR (Rubio, et al., 1999) and a single 
tube multiplex PCR (Padley, et al., 2003) that can detect up to four species, excluding P. 
knowlesi, have been described. In light of the emergence of the potentially fatal human 
infections with P. knowlesi, which was previously considered as a zoonotic parasite, a 
straightforward single-step multiplex PCR for simultaneously identification of five 
human malaria parasites was developed in the present study. 
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5.2 Multiplex PCR system for identification of five human Plasmodium species 
Multiplex PCR is one of the research priorities for future malaria diagnosis 
(malERA Consultative Group on Diagnoses and Diagnostics, 2011). With the WHO 
malaria eradication programs back on the global health agenda, it is of paramount 
significance that a rapid, accurate, species-sensitive/species-specific, and economically 
efficient system be made available for the institution of effective treatment management 
and control. Essentially, with a highly effective diagnosis system, the ultimate aim is to 
increase the chances for patient recovery and survival, hence reducing morbidity and 
eliminating mortality due to malaria.  
 
5.2.1 The significance of 18S ssu rRNA gene in species determination 
18S ssu rRNA gene is a highly conserved and pivotal gene in the phylogenetic 
studies that universally existed in all eukaryotic cells. Thus far, most of the molecular 
characterization of different plasmodia has widely relied on sequencing and analyzing 
of 18S ssu rRNA genes (Leclerc, Hugot, Durand, & Renaud, 2004). The highly 
conserved and variable regions of 18S ssu rRNA gene not only provide important 
information for the relationship among species, it can also be used as the biological 
identification marker in PCR screening (Conway, 2007). In general, rRNA gene 
sequences are easy to be used as universal primers due to their highly conserved regions. 
Furthermore, the repetitive arrangement within the genome provides excessive amounts 
of template DNA for PCR. At least five copies of the 18S ssu rRNA gene are dispersed 
on separate chromosomes throughout the Plasmodium genome (Carlton, et al., 2008; 
Gardner, et al., 2002; Pain, et al., 2008), which certainly will enhance the sensitivity of 
PCR assay. Therefore, the 18S ssu rRNA gene of five human Plasmodium parasites was 
chosen as the target in the current multiplex PCR development.   
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5.2.2 Clinical samples and negative controls 
In the present study, a total of 246 whole blood samples were collected in EDTA 
tubes, and further aliquot into three portions, i.e., for routine laboratory tests, such as 
microscopic examination and immunochromatographic test (ICT), DNA extraction for 
PCR assays, and the remaining portion was kept at -70 ºC for long term storage. The 
226 samples were from patients suspected with malaria, and 20 healthy controls were 
from volunteer group with no history of malaria and negative by microscopy.  The DNA 
samples served as templates in specificity validation.  
 
5.2.3 18S ssu rRNA plasmids construction  
Plasmodium parasites have structurally and functionally different paralogous 
copies of the 18S ssu rRNA gene, which could be expressed during the different 
developmental stages. Thus far, three types of 18S ssu rRNA have been reported, they 
are asexual- (A-), sporozoite- (S-), and oocyst- (O-) types that are expressed in asexual, 
sporozoite, and oocyst stages, respectively (Leclerc, et al., 2004; Nishimoto, et al., 
2008). However, based on the NCBI database records, the S-type of 18S ssu rRNA gene 
sequences of P. knowlesi are referred as putative sexually transcribed form, both of 
which were isolated from patient’s blood samples reported in Malaysia Borneo (Singh, 
et al., 2004). 
The primers used in nested PCR and DNA clone construction, i.e., rPLU1 
(forward) and rPLU5 (reverse) are universally targeting genus-specific of all types of 
18S ssu rRNA gene of Plasmodium species, based on the variably expressed during the 
parasite life cycle. The O-type gene expression is only restricted in oocyst stage in the 
mosquito, while the sporozoite-type gene is expressed during liver stage replication. 
Therefore, there are two possibilities of gene amplifications (either asexual- or sexual-
types) and further randomly clone into E. coli cells when PCR using human blood 
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samples, due to unsynchronized stages of parasites in blood. In general, most of 
molecular studies, such as phylogenetic and molecular PCR analyses, are emphasizing 
only on the A-type gene (Leclerc, et al., 2004; Nishimoto, et al., 2008). 
 In the present study, the amplicon from the first nested PCR (~ 1.7 kb) was gel 
purified and further cloned into TOPO cloning vector, followed by transformation into 
competent cells. The successful clones were confirmed by colony PCR and sequencing. 
Only the clones carrying the representative gene types (either asexual- or sexual- types) 
were selected and kept as positive controls in multiplex PCR development. Generally, 
asexual-type primers were designed to identify four human Plasmodium species, 
excluding P. knowlesi. Given that the majority of human P. knowlesi 18S ssu rRNA 
gene sequences deposited in GenBank are in sexually transcribed form, therefore, a 
sexual-type primer was designed to identify P. knowlesi. The single reverse primer used 
in multiplex PCR system was conserved in both of the A-type and S-type genes. 
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5.2.4 Primer design and multiplex PCR optimization 
All the five species-specific forward primers as well as single reverse genus-
specific primer were successfully designed with the aid of Primer Premier software 
(PREMIER Biosoft International). Basically, the primers were designed and selected 
based on the following parameters: homology of primers with their target nucleic acid 
sequences, primer length, product length, product location, minimal hairpin and dimer 
formations, the GC content, and annealing temperature. Ideally, all the primers in 
multiplex PCR should allow similar amplification efficiencies for respective target. This 
may be achieved through the utilization of primers with nearly identical optimum 
annealing temperatures. Furthermore, primers should not display significant homology 
either internally or to one another, to avoid the secondary structures (hairpin and dimer 
structures) and possibility of self-priming, false priming, and cross dimer formation.  
In 2010, Sutherland and coworkers reported that there were two nonrecombining 
sympatric forms of P. ovale with dimorphism of genetic haplotypes, i.e., P. ovale curtisi 
(classic type) and P. ovale wallikeri (variant type), and only P. ovale curtisi can be 
identified by nested PCR based on the primers targeting ssu rRNA gene (Sutherland, et 
al., 2010). For this reason, an alternative PCR primer pair specific to both P. ovale 
subspecies (Padley, Heath, Sutherland, Chiodini, & Baylis, 2008) was also included to 
the second nested PCR (Figure 4.1). In the present study, this was taken into 
consideration by designing a degenerate P. ovale primer that covers both the classic and 
variant types of P. ovale. However, due to sample limitation, the detection of both P. 
ovale variants could only be tested through in silico PCR. In this study, the 18S ssu 
rRNA of the only P. ovale clinical sample was cloned and further confirmed as P. ovale 
curtisi through sequencing (Lim, et al., 2010).  
The multiplex PCR conditions, such as, primers concentration, PCR reagent 
mixture, amplification conditions etc, were fully optimized using DNA extracted from 
CHAPTER FIVE: DISCUSSION 
 
 
 
187 
blood samples in this study.  
 
5.2.5 Positive control 
In a PCR without a positive control, a negative result obtained showing there 
was no target sequence present in the reaction, but it can also mean the reaction was 
inhibited due to malfunction of the thermal cycler, PCR mixture, or presence of 
inhibitory substances in the reaction mixture. Conversely, in a PCR with positive 
control, a control band should always be produced even though there is no target 
sequence present for disease specific primer pair. Therefore absent of control band can 
directly reveal the failure of a PCR.  
In the present study, three types of positive controls targeting different sources 
of DNA (either external or internal control) as well as genes were tested on the 
pentaplex PCR system (Figure 5.1). The selection of positive control to be included in 
the multiplex PCR system was based on the observation of the PCR results from 50 
malaria DNA samples.  
In the first set of positive control (Figure 5.1A), inclusion of external positive 
control, pGEX4T1 plasmid DNA and pGEX4T1 primer pair (i.e, pGEX 5’ and pGEX 3’) 
posed a serious competition on Plasmodium PCR amplification, thus this set of control 
was excluded in the present multiplex PCR system. In contrast to external positive 
control, another two positive controls were considered as the internal amplification 
control, whereby control DNA sequence was present in the same specimen, which can 
be co-amplified simultaneously with the target sequence. Generally, internal positive 
control can be further subdivided into two formats in a diagnostic PCR assay, either to 
be used competitively or noncompetitively (Hoorfar, et al., 2004).  
The inclusion of the second set of positive control, i.e., Plasmodium and human 
conserved primers to the multiplex PCR system is a typical type of competitive PCR, 
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where the target and control are amplified with a common set of primers under the same 
conditions in a PCR tube (Figure 5.1B). Simultaneous amplifications of two different 
Plasmodium DNA fragments flanked by the same primers sites can result in competition 
of both products as a phenomenon seen in the present study. The inconsistency in PCR 
amplifications could be explained by three possibilities. Firstly, primer-template 
competitions could have occurred in this multiplex PCR system, due to multiple 
forward primers to a single reverse primer. Secondly, there are variations in the binding 
affinity of each forward and reverse primer pairs targeting homologous gene. Thirdly, 
constrains of reaction mixture (dNTPs, Mg
2+
, Taq polymerase, etc) due to at least three 
DNA fragments, i.e., human genus-specific, Plasmodium genus-specific, and 
Plasmodium species-specific 18 ssu rRNA genes must present in a single species 
infection case.  
In the third design (Figure 5.1C), a noncompetitive primer pair targeting human 
β-hemoglobin gene was designed and finally selected, which served as an internal 
positive control, indicative of a successful DNA extraction procedure and PCR. There 
was no significant reduction of sensitivity and specificity of pentaplex PCR system with 
the inclusion of the β-hemoglobin primer pair. In contrast, PCR selection (competitive 
inhibition) was observed in another two positive control candidates. PCR selection is 
defined as a mechanism which inherently favors the amplification of certain templates 
due to the target concentrations or properties of the target. The amplification biasness 
may also be due to the primers itself, such as high or low amplification efficiency.  
Finally, a rapid and single-step hexaplex PCR system for the identification of 
five human Plasmodium species with an internal positive control targeting β-
hemoglobin gene was developed. 
Figure 5.1 illustrates an overview of the three positive controls tested in the 
present multiplex PCR system.  
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Figure 5.1: Schematic of the multiplex PCR amplification for identification of five 
human Plasmodium species with a positive control. (A) The pGEX4T-1 plasmid served 
as external positive control. (B) Both genus-specific of Plasmodium and human genes 
served as internal positive controls. (C) β-hemoglobin gene served as an internal 
positive control. The dark blue arrows represent the primers used in multiplex PCR; 
purple box represent positive control. 
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5.2.6 Sensitivity and specificity analyses 
5.2.6.1 Sensitivity and specificity in single infection 
The present hexaplex PCR revealed high sensitivity with all five human 
Plasmodium parasites detectable below 0.5 parasites/µl of blood sample in the 
sensitivity validation, i.e., 0.025 parasites/µl for P. vivax, 0.027 parasites/µl for P. ovale, 
0.15 parasites/µl for P. falciparum, 0.25 parasites/µl for P. knowlesi, and 0.27 
parasites/µl for P. malariae.  
A study conducted on the validation and comparison of the detection limits of 
three conventional PCR detection systems, i.e., nested PCR (Singh, et al., 1999; 
Snounou, et al., 1993), semi-nested PCR (Rubio, et al., 1999), and multiplex PCR 
(Padley, et al., 2003) in the detection of four human Plasmodium species (excluding P. 
knowlesi), using a series of known parasitemia samples as well as experimentally mixed 
infections, noted that nested PCR was the only method that consistently and accurately 
diagnosed mixed infections and subclinical infections when compared with semi-nested 
PCR and multiplex PCR (Mixson-Hayden, Lucchi, & Udhayakumar, 2010).  
Overall, optimized nested PCR in our laboratory was able to detect Plasmodium 
species at a low titer, with an average of 0.01 parasites/µl, which is more sensitive than 
nested PCR reported by Mixson-Hayden study, i.e., 0.4 parasites/µl (Mixson-Hayden, et 
al., 2010), semi-nested PCR, i.e., 0.1 parasites/µl (Rubio, et al., 1999), and the present 
hexaplex PCR system, i.e., less than 0.3 parasites/µl. However, this single-round 
hexaplex PCR results showed 100 % concordance with the results obtained through 
nested PCR. Furthermore, five missed malaria infections were successfully detected 
from 15 microscopy negative clinical samples. This may have been due to the fact that 
our tested samples had a parasitemia level above the detection limits of both approaches.  
The only limitation of the present study was unable to further evaluate the 
sensitivity and specificity of P. malariae and P. ovale due to limited samples in this 
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study period. However, the current hexaplex PCR had been validated on sufficient 
numbers of clinical malaria samples, especially on three most prevalent malaria agents 
in our local area, i.e., P. vivax, P. falciparum, and P. knowlesi, which have multiple 
ranges of parasitemia counts. Most significantly, the system successfully and 
consistently picked up the two most potential fatal infectious agents, i.e., P. falciparum 
and P. knowlesi.  
 
5.2.6.2 Sensitivity and specificity in mixed infections 
In mixed infections, primer binding competition effect can contribute to result 
inconsistencies in most of the multiplex PCR assays. However, this problem did not 
exist in the present newly developed multiplex PCR. The only limitation in the 
evaluation of the present multiplex PCR is the lack of naturally acquired mixed 
infections. However, in the mixtures of two parasite species in the 60 experimentally 
simulated mixed infection tests using clones DNA with different DNA ratios (Figure 4.7) 
and 30 clinical samples, Plasmodium species were accurately identified in all the 
samples, confirming that this hexaplex PCR system is robust and capable of detecting 
mixed-infections at least up to two-species level without any diagnostic constrain. The 
triple-species mixed infections, i.e., P. falciparum, P. vivax, and P. knowlesi were also 
randomly created using clinical samples with various parasitemia scores, and all three 
mixed-species were successfully detected by multiplex PCR as shown in Figure 4.9 
(Lane 8). Due to sample limitation, the simulated clinical mixed infections were not 
performed on P. malariae and P. ovale. 
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5.2.6.3 Random blind test and clinical screening 
A random blind test based on 50 DNA samples was conducted, and no cross-
reactions among the five species-specific primers were observed. This assay was further 
validated with 226 clinical samples, and the results demonstrated 100 % concordance 
with the results obtained through nested PCR, the current molecular gold standard. 
There were only two cases of P. vivax-P. falciparum mixed infections detected by PCR 
among 211 microscopy confirmed samples in the present study; one was microscopy 
identified to be mixed infections and one was microscopy identified as P. vivax single 
infection. Another 201 samples were single-species infections, including another seven 
samples identified by microscopy as mixed infections; one case of P. vivax mixed with 
P. falciparum, three cases of P. vivax mixed with P. malariae, as well as one case of P. 
vivax mixed with P. knowlesi (as identified by microscopy) were actually single 
infection of P. vivax, while another two cases of P. falciparum mixed with P. knowlesi 
were single infection of P. knowlesi. Neither Plasmodium species was detected in both 
nested PCR and multiplex PCR in the rest of the eight clinical samples. Only clear β-
hemoglobin fragment (~ 109 bp) was visualized in multiplex PCR assay in these eight 
samples. Based on microscopy results, seven of these samples scored in the + category 
(two P. vivax, three P. falciparum, one P. knowlesi, and one P.malariae/P. knowlesi) 
and one P. falciparum was scored in the ++ category. Due to high sensitivity of 
molecular PCR detection assays (concordance results obtained in both nested PCR and 
multiplex PCR) over microscopy assay, the present study therefore postulated that these 
samples might be considered as false positive cases by microscopy. Furthermore, 
appearances of the internal positive control fragment in these cases are indicative of 
successful DNA extraction procedure and PCR.   
Interesting, only two samples were PCR confirmed as P. malariae infection 
(4 %) among the 51 samples identified with microscopy as either P. malariae or P. 
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malariae/P. knowlesi infection. This finding was similar to the study done by Singh and 
colleagues in 2004, indicating that most microscopy-diagnosed P. malariae infections 
turned out to be P. knowlesi infections based on nested PCR assay (Singh, et al., 2004). 
Both findings further support the sensitivity and specificity of molecular PCR assays 
over microscopic examination for the diagnosis of malaria, especially for P. knowlesi 
cases.  
 
5.2.6.4 Diagnostic sensitivity and specificity 
Due to samples limitation in P. ovale and confusing results in microscopic 
examination between P. malariae and P. knowlesi, therefore only the sensitivity, 
specificity, PPV, and NPV of the present developed multiplex PCR system in diagnosis 
of both P. falciparum and P. vivax were estimated and there were 100 % concordance 
with the results of nested PCR as gold standard. While the overall decreases on these 
values were observed in microscopy assay. The present study can therefore propose that 
multiplex PCR is as reliable as nested PCR in clinical detection of these two species of 
malaria parasites, as reported here for P. falciparum and P. vivax.  
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5.2.7 Advantages of multiplex PCR over others molecular diagnostic assays   
Some of the main advantages of the present novel hexaplex PCR over available 
semi-nested (Rubio, et al., 1999) and nested PCR (Singh, et al., 1999; Singh, et al., 2004; 
Snounou, et al., 1993) assays include the hexaplex PCR system being less labor-
intensive and rapid (reduced hands-on time) due to its single-step PCR, compared to at 
least two and/or six PCRs which are need to be conducted for the semi-nested and 
nested-PCR assays, respectively, in the identification of all five Plasmodium species. 
The fewer steps reduce the usage of PCR reagents and disposable consumables. The 
time required for this single-step hexaplex PCR is only three hours, versus 
approximately six hours for semi-nested PCR and about twenty hours for nested PCR, 
including time for PCR preparation, conducting the PCR and agarose gel 
electrophoresis. Thus, the current hexaplex PCR significantly shorten the time for 
diagnosis. In addition, a single-tube reaction is also recommended, as it avoids the risk 
of carryover and possible external contamination during the transfer of PCR amplicons 
from primary to secondary PCR mixture and agarose gel electrophoresis for the 
detection of PCR products. However, this contamination can be avoided if good 
laboratory practice for molecular amplification techniques is followed. 
Currently, ordinary multiplex PCR technique is widely applied in rapid 
diagnosis of many infectious diseases (Khamrin, et al., 2011; Padley, et al., 2003; Teh, 
Chua, & Thong, 2010; Thong, Lai, Teh, & Chua, 2011). With well-designed primers 
used under fully optimized conditions, most of the multiplex systems have shown high 
sensitivity and specificity. For instance, the results from the present hexaplex PCR and 
nested PCR assays were in agreement. Multiplex PCR is an ideal and affordable method 
in most of the laboratories or field settings, especially in developing countries or 
countries with lower economic resources, since the conventional PCR thermal cycler 
and agarose gel electrophoresis system remain the cheapest molecular assay if 
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compared with the real-time PCR assay, which utilizes expensive reagents (probes), 
consumables, and equipment. In addition, multiplex PCR assay also allows large-scale 
screening of samples within a short period, especially in malaria hyperendemic regions, 
where there is a lack of clinical personnel and experienced microscopists. The workflow 
in microscopic examination can be very burdensome and time-consuming when huge 
sample size must be handled.  
Despite nested PCR assay being considered as molecular gold standard in the 
diagnosis of malaria, there are increasing issues that affect the usefulness of nested PCR 
in Plasmodium species discrimination recently. For instance, several studies carried out 
in different countries of Southeast Asia reported that the P. knowlesi-primers (i.e., Pmk8 
and Pmkr9) developed for nested PCR (Singh, et al., 2004), have been shown to give 
possible cross-hybridization with sequences of P. vivax, and thus lead to false positive 
results (Imwong, et al., 2009; Jiang, et al., 2010; Sulistyaningsih, et al., 2010; Van den 
Eede, et al., 2009). In addition, the P. ovale wallikeri (a variant type of P. ovale) was 
undetectable by current nested PCR (Sutherland, et al. 2010). This situation emphasizes 
a need to improve and establish a more reliable PCR-based method for routine diagnosis 
of malaria and the present multiplex offers a good option or alternative, which has been 
fully optimized for the identification of the five human Plasmodium species.  
On the other hand, LAMP assay is claimed to be the simplest molecular 
approach for disease diagnosis, however only qualitative results can be obtained through 
LAMP and there is no specific indicator to determine whether it is a true-positive or 
false-positive result due to potential contamination. Furthermore, multiple primer pairs 
are required in the identification of a single species infection, therefore large scale 
screening efforts using LAMP are still under assessment. In addition, no reports have 
been published on multiplex-LAMP assays. 
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5.2.8 Future perspectives 
As there were only one P. ovale and two P. malariae infections detected during 
the study period, more samples will be obtained in future from other countries 
(especially African countries) to carry out further sensitivity and specificity tests, 
especially for the case of  P. ovale wallikeri infection.  
The present hexaplex PCR have been validated with DNA extracted from whole 
blood samples, which gave 100 % concordance results with nested PCR. However, 
when handling with malaria disease, preserving the fingerprick blood sample by spotted 
on filter paper and/or in blood smear formats are the common practice, especially in 
field setting and rural areas that are lack of infrastructures and facilities. Therefore, 
hexaplex PCR system might be tested onto these two preserved formats as well.  
The lack of consistency in the current standard operating procedures and 
diagnostic approaches among different laboratories is the major constrain in malaria 
epidemiology studies. This problem has made it difficult for results from distinct 
diagnostic approaches to be compared. To reconcile the differences between the 
management and the diagnosis of malaria, it is important to develop a diagnostic 
standard or parameter that facilitates inter-laboratories results comparisons. A good 
example is the development of the first WHO International Standard for P. falciparum 
DNA nucleic acid amplification technique (NAT)-based assay. This assay was 
calibrated in an international collaborative study involving 14 laboratories from 10 
different countries and can be used to consistently access P. falciparum detection 
methods (Padley, et al., 2008). It is hoped that similar standard for other Plasmodium 
species will be developed in the near future to accommodate implementation of 
consistency for multiplex assays among laboratories. 
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5.2.9 Conclusion 
Overall, the present hexaplex PCR system highlighted in the present study 
provides a set of primers which are sensitive and specific for simultaneous detection of 
single infection as well as mixed infections. Screening of Plasmodium species with this 
assay has proven to be rapid, beneficial and could significantly improve detection 
procedures. The availability of this system may indeed facilitate the efforts in the global 
malaria eradication programs. With a rapid and highly effective diagnostic system such 
as this, evaluation of malaria morbidity and mortality will be more accurate. In addition, 
this tool can also be used for future global molecular epidemiological studies to produce 
consistent and reliable data in malaria distribution, including asymptomatic and 
subclinical cases.  
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5.3 Identification of binding peptides for human Plasmodium species 
5.3.1 Merozoite surface antigens and host cell invasion 
Plasmodium is an obligate intracellular parasite and the ability of this parasite to 
invade and replicate within host cells, i.e., hepatocyte and erythrocyte are thought to 
play critical role in pathogenesis of the malaria disease. Generally, the host cell invasion 
is rapid and thought to be a fundamental strategy in immune evasion of these parasites 
and the sequential mechanism is controlled exclusively by the parasite itself (Tyler, et 
al., 2011). The invasion of erythrocytes by Plasmodium parasites is highly complex and 
multi-steps involvement is dependent on a cascade of specific molecular interactions 
and mostly species-specific.  
 
5.3.1.1 AMA1 as invasion property of Plasmodium species 
Nowadays, numerous proteins have been implicated in the parasite invasion. 
AMA1 is the most prominent and best-characterized molecule among malarial surface 
antigens that is responsible for attachment and entry into host cells, i.e., sporozoite into 
hepatocyte (Silvie, et al., 2004) and merozoite into erythrocyte (Triglia, et al., 2000).  
AMA1 is the first discovered invariant merozoite surface antigen in P. knowlesi 
(previously known as Pk66) (Deans, et al., 1982; Deans, Thomas, Alderson, & Cohen, 
1984; Thomas, Deans, Mitchell, Alderson, & Cohen, 1984), and subsequently in P. 
falciparum (previously known as Pf83) (Peterson, et al., 1989), and then it was 
identified in all characterized Plasmodium species (Waters, et al., 1990). In general, 
AMA1 primary structure exhibits a conserved architecture throughout Plasmodium 
parasites, which is highly specialized for host cells invasion and maintaining parasite 
growth. The conservation of all 16 invariant cysteine residues within the ectodomain 
indicates that there is a structural constraint on the AMA1 molecule and underlying the 
importance of the disulfide bonds in defining the polypeptide fold (Chesne-Seck, et al., 
CHAPTER FIVE: DISCUSSION 
 
 
 
199 
2005; Hodder, et al., 1996).  
Although precise biological role of AMA1 in host cell invasion remain 
uncharacterized, much evidence have suggested a receptor-binding functions. The 
crystal structure indicates that DI and DII of AMA1 ectodomain exhibit the 
plasminogen-apple-nematode (PAN) folding motifs, which is generally found in an 
array of adhesive proteins that are involved in the binding to protein or carbohydrate 
receptors or ligands (Chesne-Seck, et al., 2005; Pizarro, et al., 2005). AMA1 is an 
essential component of moving junction (MJ), an irreversible multi-protein complex 
formed by tight interaction between a number of parasite receptors on the merozoite and 
host cell receptors on the erythrocyte membrane. The most recent study proved that 
binding of PfAMA1 with parasite rhoptry neck protein complex (RON2, RON4, and 
RON5) that spans the erythrocyte membrane, tight junction, and merozotes membrane 
triggers commitment to invasion (Richard, et al., 2010; Tyler, et al., 2011; Vulliez-Le 
Normand, et al., 2012).  
 
5.3.1.2 AMA1 as a potent antimalarial drug target and pivotal malaria vaccine 
candidate 
Although AMA1 is a low abundant malarial surface protein; it is thought to be 
the most prominent malarial surface antigen that has long served as a potent antimalarial 
drug target and pivotal malaria vaccine candidate (Macraild, et al., 2011; Remarque, 
Faber, Kocken, & Thomas, 2008). AMA1 elicits strong immune responses and most 
individuals exposed to malaria develop anti-AMA1 antibodies after relatively few 
exposures (Rodrigues, et al., 2005; Wickramarachchi, et al., 2006). There is strong 
evidence to suggest that anti-AMA1 antibodies are the primary mediators for acquired 
immunity in human infection, as demonstrated by a decrease in parasite density in 
children following passive transfer of antibodies from immune adults (Hodder, 
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Crewther, & Anders, 2001). Moreover, active immunization of animal models, i.e., 
experimental rodents (Anders, et al., 1998; Crewther, Matthew, Flegg, & Anders, 1996; 
Deans, et al., 1982) and primates (Collins, et al., 1994; Deans, et al., 1988; Stowers, et 
al., 2002) with either native or recombinant forms of AMA1 proteins has been shown to 
induce parasite-inhibitory responses. In addition, passive immunization of anti-AMA1 
antibodies can also facilitate protection (Anders, et al., 1998; Crewther, et al., 1996; 
Kennedy, et al., 2002; Narum, Ogun, Thomas, & Holder, 2000; Stowers, et al., 2002).  
The role of AMA1 in invasion can be interfered with by antibodies. Both 
monoclonal (Deans, et al., 1982; Thomas, et al., 1984) and polyclonal (Hodder, et al., 
2001) antibodies bind to AMA1 and block parasite invasion in vitro and thus reduce 
parasites multiplication substantially (Remarque, et al., 2008). Besides that, there is 
evidence of peptides derived from or with affinity for Plasmodium AMA1 can also 
inhibit invasion of erythrocyte by parasite in vitro (Harris, et al., 2005; Keizer, et al., 
2003; Li, et al., 2002; Urquiza, et al., 2000).  
Although there have been numerous AMA1-based vaccine approaches currently 
available (focused on P. falciparum), however none has yet been fully evaluated in 
clinical trials (mainly in phase I and few in phase II trials to date) and the efficacy of 
protective data are only available based on animal models and in vitro studies (Anders, 
et al., 2010; Remarque, et al., 2008; Richards & Beeson, 2009).  
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5.3.2 The significant of heterologous protein expression in Plasmodium studies 
The critical constrain of molecular and functional studies on Plasmodium 
parasites is the inability to maintain large scale in vitro cultivation of parasites 
(excluded P. falciparum) that exhibits complex and multistage life cycle. Since the 
established continuous in vitro cultivation of P. falciparum by Trager and Jensen in 
1976 (Trager, 1994; Trager & Jensen, 1976), the plasmodial proteome profiling across 
the life cycle that required high amounts of crude proteins is only focused on this 
species. Even though there are some progresses made in establishing cultivation 
methods of P. vivax (Golenda, Li, & Rosenberg, 1997) and P. malariae (Lingnau, 
Doehring-Schwerdtfeger, & Maier, 1994) in the laboratory, the difficulty in long term 
reproducible and maintaining these pathogens in vitro is the major obstacle for further 
research manipulations. Furthermore, a specific protein of interest can only in rare 
instances be isolated in sufficient amounts from natural host cell for downstream 
applications that require highly homologous and pure material. Therefore, heterologous 
expression of the selected protein is of paramount importance for providing sufficient 
amounts of recombinant protein for further downstream analysis, such as biochemical, 
biophysical, and molecular functional studies, as well as in several immunological 
applications, such as the production of recombinant antigens for the generation of 
research antibodies and immunogens or subunit vaccine antigens for vaccination. 
Besides that, recombinant expression also enabled the development of serodiagnostic 
tools in malaria, e.g., HRP-2 and aldolase antigens in dipstick assays (Birkholtz et al., 
2008; Fernandez-Robledo & Vasta, 2010).  
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5.3.2.1 Heterologous expression of plasmodial proteins in prokaryotic system 
Generally, heterologous protein expression is referred to the production of 
protein of interest in an organism that is different from the organism source of target 
protein. Even though heterologous protein production has now become a relatively 
routine endeavor for most proteins of diverse origins, the functional expression of 
soluble plasmodial proteins is highly problematic and thus slows down the progress in 
the discoveries of novel antimalarial drugs and potential vaccine candidates. The 
performances of heterologous expression systems in production of recombinant proteins 
from protozoan parasites have been reviewed and compared (Birkholtz, et al., 2008; 
Fernandez-Robledo & Vasta, 2010).  
If compared with other expression systems, the transfection and cultivation of E. 
coli is relatively more simple, rapid with high growth rate and high densities, and often 
inexpensive in fermentation processes. However, problems can arise when 
conformation and modification of recombinant proteins are important. This is because E. 
coli is a prokaryote and has different folding and modification patterns than eukaryotes, 
i.e., Plasmodium. Misfolding of recombinant protein can lead to solubility problems and 
the accumulation of heterologous proteins may also bring to toxicity effect on bacteria 
host cell and consequently reduce the level of expression.  
Malaria antigens are among the most difficult proteins to be expressed with in 
vitro methods, as reflected by the paucity of plasmodial protein structures available in 
the Protein Data Bank (PDB) (~ 205 till mid of 2013), if compared to over 5,000 cDNA 
available in whole genomes sequencing data. Besides that, the lack of expression is 
always observed in heterologous expression efforts and the expression of soluble 
proteins is also a relatively difficult task in malarial studies. A study that attempted 
high-throughput expression of functional molecules of P. falciparum discovered that 
only nine soluble proteins (~ 9 %) were produced, out of 95 purified proteins (Aguiar, et 
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al., 2004). Similar observation also reported that of the expression of 1,000 genes of P. 
falciparum, only 337 (~ 34 %) target proteins were expressed successfully using 
heterologous system, with only 63 (~ 6 %) targets generating soluble proteins (Mehlin, 
et al., 2006). Additionally, most of potential antigens are highly polymorphic and 
expression and correct folding of recombinant proteins can be difficult to achieve 
(Beeson & Crabb, 2007). Besides that, increasing of molecular weight and isoelectric 
point (pI) of protein also correlated with the expression problems (Mehlin, et al., 2006). 
During heterologous protein expression, low expression may attribute to the 
differences in synonymous codon usage between expression and natural hosts, which 
can be explained by codon bias. Codon bias is referred to the high frequency 
preferential use of a particular triplet codes for amino acids (codons, tRNA) within 
homologous organism. For instance, the genome of Plasmodium species have overall 
high AT content, i.e., 81 % in P. falciparum (Gardner, et al., 2002), 58 % in P. vivax 
(Carlton, et al., 2008), and 63 % in P. knowlesi (Pain, et al., 2008), whereas E. coli has 
only about 50 % (Baca & Hol, 2000). There is a high level of codon mismatch 
(difference in amino acid content) between the two organisms, particularly in P. 
falciparum and the codons that are preferentially used by Plasmodium in many instance 
are considered rarely used (definitely a low-usage codon) by E. coli for expression, thus 
it may impose a metabolic burden on the bacterial host during protein translation and 
consequently resulting in translation stalling and diminish the yields of recombinant 
protein (Baca & Hol, 2000; Birkholtz, et al., 2008; Chen & Texada, 2006). The codon 
usage of each organism can be referring to Codon usage database 
(http://www.kazusa.or.jp/codon/).  
There are two strategies to overcome the expression problems caused by rare 
codon. One of the most common strategy is by expanding the intracellular tRNA pool 
using co-expressed plasmids, which encoded rare tRNAs used in host cell, i.e., E. coli 
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(Baca & Hol, 2000). Nowadays, there are many bacterial cell lines which have the 
advantage of rare tRNA supplementation; BL21-CodonPlus (Stratagene) used in the 
present study and Rosetta (Novagen) E. coli strains are the two most common examples. 
Second strategy refers to the codon optimization. Codon optimization is a kind of 
nucleotide substitution, whereby the rare (low frequency used) codons in the expression 
host are replaced by synonymous optimal or other major (frequently used) codons 
(Birkholtz, et al., 2008; Chen & Texada, 2006). Generally, in order to highly express a 
foreign gene in E. coli, either one or both of the two strategies may be adopted (Chen & 
Texada, 2006). There are several reported enhancements in heterologous expression of 
recombinant antimalarial candidate vaccine targets in E. coli by codon optimization so 
far (Narum, et al., 2001; Zhou, Schnake, Xiao, & Lal, 2004). However, in certain 
circumstance, some malaria proteins that have been synthesized with optimized codons 
could not be expressed in E. coli or either expressed as truncated forms or precipitated 
in IBs in bacterial cells (Aguiar, et al., 2004; Mehlin, et al., 2006).  
Direct production of plasmodial proteins in prokaryotic expression system that is 
thought to be functionally active with the correct structural conformation is the most 
ideal for this study. However, proteins obtained in this way are frequently found to be 
insoluble, forming aggregates in vivo as IBs, especially during high levels expression of 
heterologous protein.  
Despite protein expression in the form of IBs is often considered undesirable; 
their formation can be advantageous, as IBs are denser thus facilitating a 
straightforward purification of the protein of interest from the cell homogenate and 
cellular contaminants. Other advantages associated with formation of IBs include enable 
the high expression of recombinant protein, protect the expressed protein from 
proteolytic degradation, and also homogeneity of the protein of interest in IBs may 
reduce the purification steps to recover pure protein. Furthermore, formation of IBs also 
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offers the alternative to produce the protein which, when active can be toxic or lethal to 
the host cell (Clark, 1998; Singh & Panda, 2005).  
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5.3.3 Expression of recombinant PkAMA1 and PvAMA1 in E.coli 
5.3.3.1 Construction of PkAMA1 and PvAMA1 protein expression clones  
In preparation to identify the potential binding peptides for AMA1 of P. 
knowlesi and P. vivax using phage display technology, two constructs for heterologous 
expression in E. coli were developed, designated as pPAL7-PkAMA1 and pPAL7-
PvAMA1. The origin of cDNA was from clinical blood samples with confirmed malaria 
caused by P. knowlesi (strain H) and P. vivax (strain Sal-1), respectively. The strains of 
Plasmodium were determined based on the 18S ssu rRNA sequence in the first part of 
the study.  
A novel Profinity eXact
TM
 Fusion-Tag prokaryotic expression system (Bio-Rad) 
was applied in the present study in order to perform heterologous expression of 
recombinant Plasmodium AMA1 ectodomain, i.e., rPkAMA1 and rPvAMA1 in E. coli. 
The pPAL7 vector and Profinity eXact
TM
 Fusion-Tag system is still new, there is no 
publication reported thus far since it was first launched in 2008. The unique feature of 
this system allows a single step affinity purification and fusion-tag cleavage of 
recombinant protein in less than one hour if compared with other expression system, as 
example, GST-tag protein purification and Thrombin cleavage in order to remove GST-
tag from the target protein requires at least two days protocol.  
Profinity eXact fusion-tag system is an affinity tag-based protein purification 
system that utilizes a modified form of the subtilisin protease, which is immobilized 
onto a chromatographic support and used to generate pure, tag-free target protein in a 
single step. The tag in this system is the prodomain of the subtilisin protease, a 75-
amino acid sequence corresponding to ~ 8.2 kDa eXact tag domain that is fused to the 
N-terminus of a target protein of interest. Application of elution buffer triggers 
subtilisin’s processing activity, which quickly and precisely cleaves the tag from the 
fusion protein and releases the purified target protein in elution fraction. At the end of 
CHAPTER FIVE: DISCUSSION 
 
 
 
207 
the purification process, the tag remains tightly bound to the resin and eluted protein 
contains only its native amino acid sequence (Appendix 4).  
Generally, the cloning steps were followed exactly as manufacturer’s 
recommendations, except the expression host used, i.e., BL21-CodonPlus (DE3)-RIL E. 
coli cells (Strategene) was used in replacement of BL21(DE3) E. coli provided together 
with the kit. The BL21-CodonPlus (DE3)-RIL E. coli was selected in consideration to 
overcome the codon bias in plasmodial genome, which is AT richness. This E. coli host 
is co-transformed with an additional ColE1-compatible, pACYC-based plasmid 
carrying extra copies of the rare codon’s cognate tRNA, i.e., argU, ileY, and leuW tRNA 
genes, suited for heterologous expression of recombinant protein consisted of AT-rich 
genome, as well as an additional chloramphenicol resistence (Cam
r
) gene to maintain 
the selection of pACYC plasmid.  
Overall, DNA sequencing results indicated that whole ectodomain cDNA of 
PkAMA1 and PvAMA1 fragments with length of 1, 338 bp were successfully cloned in-
frame into pPAL7 expression vector. ExPASy Proteomics tools 
(http://ca.expasy.org/tools/) is an amalgamation of the most popular Web-based tools 
for in silico characterization of proteins based on their primary amino acids composition. 
The inserted cDNA was translated to protein sequence using ExPASy Translate tool 
(http;//web.expasy.org/translate/). Both of the AMA1 of P. knowlesi and P. vivax cDNA 
encoded 446 amino acid residues, with DI extends from residues 42 to 248, DII from 
249 to 385, followed by DIII from 386 to 487, and the residues are numbered from the 
first residue of the signal sequence (Figure 4.11 and Figure 4.12). BLASTP search 
indicated that rPkAMA1 was concordance with P. knowlesi H strain AMA1 protein 
(PKH_093110) (GeneBank accession no: XP_002259339; Appendix 5.3), and 
rPvAMA1 with P. vivax AMA1 strain Sal-1 (GeneBank accession no: ACY68841; 
Appendix 5.4).  
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LC-MS/MS data of rPkAMA1 hit the protein named merozoite receptor PK66 
with UniProtKB/Swiss-Prot database accession number P21303, whereas rPvAMA1 hit 
two crystal structures of AMA1 from P. vivax with NCBI accession number 62738184 
(PBD ID: 1W81_A) and 62738193 (PBD ID: 1W8K_A). The ExPASy Compute 
pI/MW tool (http://web.expasy.org/compute_pi/) predicted that the theoretical 
isoelectric point (pI) of the rPkAMA1 and rPvAMA1 were 5.85 and 6.28, respectively, 
whereas the estimated molecular weight were ~ 51 kDa as concordance to both of 
present expressed rPkAMA1 and rPvAMA1.  
 
5.3.3.2 Induction of protein expression 
Soluble protein is thought to be native in structure and function, while insoluble 
aggregated protein reflects of improper fold and lack of functionality. To date, many 
studies attempt to optimize the culture conditions that favor for soluble expression. It 
has been suggested that factors such as culture pH, temperature, and protein amino acid 
composition might affect the solubility of a recombinant protein. It is well known that a 
reduced growth rate or rather rate of expression by lowering the growth temperature to 
between 20 ºC and 30 ºC with best aeration (250 rpm) usually leading to more soluble 
expression and hence reduced the tendency to form IBs. However, the drawback is that 
the overall yield of recombinant protein is also likely to decrease at lower temperature.  
For protein that expressed under the control of an inducible promoter, the rate of 
expression can also be reduced by altering the induction conditions, such as induce for a 
shorter time, induce using a lower concentration of inducing agent (IPTG), and induce 
at lower cell densities (OD600 = 0.5). However, a previous study attempted to optimize 
the various factors that influencing the expression, revealed that initiation of expression 
at post-log growth phase (with OD600 of ~ 2.0) instead of mid-log growth phase (with 
OD600 of ~ 0.5) significantly enhance the yield of soluble protein of high quality (Flick, 
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Ahuja, Chene, Bejarano, & Chen, 2004). 
By referring to the above parameters, the present study tried to optimize the 
expression conditions performed in a small scale expression (15 ml), including the 
media used (typical 2× YT medium, MagicMedia
TM
 from Invitrogen, and Overnight 
Express
TM 
Instant LB media from Novagen) and induction conditions, such as 
temperature (16 ºC, 25 ºC, and 37 ºC) and time point of inductions (OD600 of 0.6, 1.0, 
1.5, 2.0), as well as concentrations of inducer (0.1, 0.5, 1.0 mM of IPTG). However, 
there were no difference in terms of soluble protein expression; therefore the present 
study adopted the protocol to isolate and purified the rPkAMA1 and rPvAMA1 under 
denature conditions. Furthermore, the Recombinant Protein Solubility Prediction tool 
also estimation that 71.3 % of rPkAMA1 and 72.5 % of rPvAMA1 has a high 
propensity to form insoluble aggregate during overexpression in prokaryotic expression 
system based on their amino acid compositions data. 
The eukaryotic proteins intracellularly expressed in E. coli system are frequently 
sequestered into insoluble IBs. The intramolecular associated to the hydrophobic 
domains during folding is believed to play a role in the formation of IBs. Furthermore, 
for protein with high cysteine residues like AMA1, improper formation of disulfide 
bonds in the reducing environment of E. coli cytoplasm may also contribute to incorrect 
folding and formation of IBs.  
In the present study, cultures of pPAL7-PkAMA1 and pPAL7-PvAMA1 
constructs were grown to OD600 of ~ 0.6 at 37 ºC and the protein expression was 
induced with 0.5 mM IPTG and incubated at 25 ºC with vigorous shaking at 250 rpm 
for subsequent three hours. Overall, two recombinant proteins were successfully 
expressed in E. coli in a form of insoluble IB with high yield.  
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5.3.3.3 Protein isolation and inclusion body purification 
Proteins expressed in recombinant manner may be soluble in the cytoplasm or 
insoluble as IBs, which may affect the subsequence protein extraction method to obtain 
the starting material for purification. Reducing SDS-PAGE (Figure 4.13) and Western 
blot (Figure 4.14) assays showed that both of the pPAL7-PkAMA1 and pPAL7-
PvAMA1 were deposited in insoluble fraction with molecular weight appearance of ~ 
60 kDa. This made it necessary to add an additional IB purification step after cell 
disruption prior to affinity purification. Western blot assays on both Profinity eXact 
tagged rPkAMA1 and rPvAMA1 also revealed that none of the soluble and truncated 
forms of protein were being observed.  
Inclusion bodies are dense amorphous aggregates of misfolded protein contained 
within the insoluble fraction yielded from cell lysis and this make it easy to isolate from 
other cellular components in a fairly pure state by differential centrifugation. Generally, 
IBs often contain exclusively (40 % to 90 %) the overexpressed protein and successful 
in renaturation much depends on the purity of IBs (Cabrita & Bottomley, 2004). 
To date, many protocols have been established to overcome the problems due to 
IB formation. Generally, three main steps are required to recover the functional active 
protein from IB: first step is the isolation and purification of IB from E. coli cells; 
second step is the solubilization of aggregated protein or purified IB, which causes 
denaturation; and finally the refolding of the solubilized protein. 
Major contaminants of IB material after preparation are the outer membrane 
proteins, which are co-purified mainly as non-solubilized protein with IB fraction. The 
purity of IBs can be achieved by repeating the washing and centrifugation steps using 
different buffer cocktails containing low concentrations of denaturant such as urea and 
detergents such as Triton X-100 (Clark, 1998).  
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5.3.3.4 Affinity protein purification and fusion-tag removal  
Generally, handling of soluble recombinant protein is more straightforward and 
probably referred as purification under native conditions, whereas a more sophisticated 
protocol is required when handling IB as the IB must be purified and then solubilized 
using high concentration of denaturant such as 4-8 M urea or 4-6 M guanidine 
hydrochloride prior to affinity tag purification. 
In the present study, the dissolved pPAL7-PkAMA1 and pPAL7-PvAMA1 were 
affinity purified under denatured and reduced conditions, which means all buffers used 
must keep the protein in the denatured reduced stage during the procedure. In general, 
this affinity purification and fusion-tag removal protocol utilized was modified from 
manufacturer’s protocol based only on native conditions.  
Solubilized IB proteins in general can be contaminated with varying levels of 
microbial contaminants, e.g., host proteins, nucleic acids, and cell membrane 
components, sometimes may induce aggregation during refolding. Thus the targeted 
recombinant proteins, i.e., rPkAMA1 and rPvAMA1 were isolated, purified, and in the 
meantime, fusion-tag was removed with a single affinity tag purification procedure prior 
to refolding, using 1 ml or 5 ml of Bio-Scale Mini
TM
 Profinity eXact cartridge pre-
packed with 1 or 5 column volume settled resin (Bio-Rad), respectively. 
In the present study, two tag-free recombinant proteins were successfully 
isolated from purified and solubilized IB under denatured conditions. The removal of 
Profinity eXact tag with molecular mass of ~ 8.2 kDa generated two tag-free proteins, 
i.e., rPkAMA1 and rPvAMA1 of high purity and integrity with the molecular weight of 
~ 51 kDa visualized in reduced SDS-PAGE (Figure 4.18 and Figure 4.19, respectively).  
Established purification protocol under denatured conditions enhances the 
utilities of this protein expression system that allows rapid single affinity purification 
and tag-removal. 
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5.3.3.5 Renaturation of the rPkAMA1 and rPvAMA1 
In general, extracellular domains of malaria antigens, such as AMA1 almost 
invariably contain disulfide linkages, thus production of this kind of proteins in the 
native conformation remains particularly difficult (Flick, et al., 2004). Disulfide bonds 
are derived by the coupling of two thiol groups (two cysteine residues) to form a 
covalent sulphur-sulphur (S-S) bond, which can be intra- or inter-molecular bridges. 
Native AMA1 ectodomain is high-cysteines protein, consists of 16 cycteine residues 
that are responsible for eight pairs of invariant intramolecular disulfide bonds, and this 
undoubtedly increase the difficulty in protein renaturation process. Previous work with 
Plasmodium AMA1 expression in E. coli showed that it was necessary to include an in 
vitro refolding step in the process in order to obtain correctly folded protein (Anders, et 
al., 1998; Dutta, et al., 2002; Gupta, et al., 2005; Hodder, et al., 2001; Lalitha, et al., 
2004; Mufalo, et al., 2008). The renaturation process aims to remove the denaturant and 
allow the protein to fold (Cabrita & Bottomley, 2004). Dialysis, dilution, as well as 
chromatography refolding are the three most common strategies for protein renaturation.  
Protein refolding is a common procedure to recover the target protein in a native 
condition, thus regaining full biological activity and functionality of denatured and 
unfolded proteins. The efficiency of refolding depends on the competition between 
correct folding and aggregation. The correct folding of AMA1 has been shown to be 
critical for its immunological activity, only the antibodies raise against refolded AMA1 
inhibited parasite growth in vitro. In contrast, the reduced and alkylated AMA1 failed to 
induce protective immunity. Furthermore, this irreversible reduced AMA1 was not 
recognized by antibodies raised against the native antigen, and thus suggest that an 
effective immune response is much dependant on conformational epitopes maintained 
by a set of eight intramolecular disulfide bonds dispersed within an ectodomain (Anders, 
et al., 1998; Casey et al., 2004; Coley et al., 2001; Crewther, et al., 1996; Harris, et al., 
CHAPTER FIVE: DISCUSSION 
 
 
 
213 
2005; Hodder, et al., 2001; Lalitha et al., 2004; Li, et al., 2002; Pizarro, et al., 2005).  
Actually, there is no standard protocol for protein refolding, optimization of 
refolding conditions (e.g., buffer composition, temperature, redox agent, chemical 
additives etc.) is a cumbersome task and the precise conditions that give efficient 
refolding are different for each protein. In general, a more elaborate refolding procedure 
is needed in renaturation of the proteins that have multiple disulfide bonds, and usually 
a pair of oxidizing and reducing agents in the optimal concentrations are essential for 
the formation of disulfide bonds. For instance, a combination of reduced glutathione 
(GSH) and oxidized glutathione (GSSG) with molar ratio of 4:1 is commonly used as 
redox agents. The concentration of protein is also a critical factor, as high concentration 
(> 1 mg/ml) is prone to aggregation. Most refolding is done in the range of pH 5-9, with 
optimum level at about pH 8-8.5. Furthermore, addition of additives, mainly low 
molecular weight compounds, such as arginine, acetone, DMSO, PEG, etc. during 
refolding process often help in improving the yield of bioreactive proteins from IBs. 
These additives influence both the solubility and stability of the unfold protein, folding 
intermediate (molten globule), and the fully folded protein (Burgess, 2009; Cabrita & 
Bottomley, 2004; Singh & Panda, 2005). In the present study, the addition of 0.4 M L-
arginine in dialysis buffer seems to diminish protein aggregation and thus improves the 
refolding yield of solubilized protein.  
The refolding conditions utilized in present study was modified from the 
refolding parameters established by previous expression studies on recombinant 
Plasmodium AMA1 using prokaryotic system (Anders, et al., 1998; Dutta, et al., 2002; 
Gupta, et al., 2005; Hodder, et al., 2001; Lalitha, et al., 2004; Mufalo, et al., 2008). The 
present refolding protocol was performed by dialysis method, whereby the concentrated 
denatured proteins (1 mg/ml), i.e., rPkAMA1 and rPvAMA1 in 4 M urea were dialyzed 
against two changes of refolding buffer (at two progressive lower denaturant 
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concentrations, i.e., 2 M and 1 M urea). Such that, the concentration of denaturant 
decreases with buffer exchange under step-wise manner, followed by last changing to 
sample buffer with the absence of urea which is compatible for biopanning.  
To date, there are many successful expression and refolding of Plasmodium 
AMA1 ectodomain which have been published elsewhere, of which most were recorded 
in Plasmodium chabaudi, a rodent parasite (Remarque, et al., 2008), PfAMA1 (Bai, et 
al., 2005; Dutta, et al., 2002; Feng, et al., 2005; Gupta, et al., 2005; Hodder, et al., 2001; 
Lalitha, et al., 2004; Nair, et al., 2002), and a few in PvAMA1 (Mufalo, et al., 2008; 
Pizarro, et al., 2005). The REFOLD database (http://refold.med.monash.edu.au/) is a 
good platform that summarizes all established refolding protocols, including AMA1 
protein (Appendix 7) (Buckle, et al., 2005; Chow, et al., 2006).  
In general, determination of correctly folded protein is commonly performed by 
evaluating the enzymatic activity. However, for those proteins that lack of enzymatic 
activity such as AMA1, the simple way to monitor the refolding condition is by direct 
visual inspection of the turbidity of solutions, where protein aggregation has occurred. 
The formation of insoluble aggregates is an indication of non-optimize in refolding 
protocol. The turbidity of the sample solution also can be assessed more accurately by 
measuring the optical density (OD) at 390 nm of the refolded protein solution 
(Tresaugues, et al., 2004; Vincentelli, et al., 2004). Generally, the solution is not 
absorbing the light, but rather the protein aggregates scatter light and thus decrease the 
amount of transmitted light measured. In other words, OD remains unchanged if the 
protein remains soluble, in contrast, the OD increases proportionally to the amount of 
precipitated produced.  
After refolding, there is a total replacement of IB solubilization buffer that 
contains highly concentrated denaturant to the sample buffer that is free of denaturant. 
There were no insoluble aggregates being observed in both of the rPkAMA1 and 
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rPvAMA1 protein solutions after refolding. Furthermore, the protein OD390 in the 
turbidity test was less than 0.05 in both of rPkAMA1 and rPvAMA1 protein solutions, 
thus suggesting that both of the refolded AMA1 proteins were considered to be soluble. 
The reduced and non-reduced SDS-PAGE results also supported that both of the 
rPkAMA1 and rPvAMA1 were refolded.  
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5.3.4 Phage display technology and applications in Plasmodium AMA1 
Although AMA1 is long thought to be a target of natural immune response that 
can inhibit invasion, little is known about the molecular mechanisms by which 
immunologically relevant portions of AMA1 could facilitate the invasion process, 
therefore, characterization and identification of peptide ligands as well as ligand- or 
receptor-binding sites that specifically interact with, and block the function of AMA1 is 
essentially important.  
To date, protective responses against the Plasmodium AMA1 have been 
investigated using various phage display libraries. For instance, four antibodies specific 
for Plasmodium AMA1 have been identified by mouse single chain variable fragment 
(scFv) antibodies library (derived by P. chabaudi immunized mouse) and were used for 
passive immunization against P. falciparum AMA1 (Fu, et al., 1997).  
Most likely antigenic peptides were obtained from epitope mapping, in which 
direct antibody ELISA is used to affinity select antigenic peptides from very large 
libraries of peptides displayed on filamentous phage carries. If natural peptide library is 
used in selection, antigenic peptide is called epitope, while mimotope is selected from 
the random peptide library. Epitope mapping using PfAMA1 peptide library (Coley, et 
al., 2001; Coley, et al., 2006) as well as mimotopes mapping using random peptide 
library (Casey, et al., 2004; Sabo, et al., 2007) against monoclonal anti-AMA1 
antibodies (e.g., MAb5G8, MAb4G2dc1, and MAb1F9) that blocks merozoite invasion 
by P. falciparum have facilitated greater understanding of immune responses against 
AMA1.  
In addition to polyclonal and monoclonal antibodies that bind to AMA1 and 
block parasite invasion in vitro, several peptides that specifically bind to PfAMA1 and 
showed similar functionality to native anti-AMA1 have been isolated from random 
peptides libraries (Harris, et al., 2005; Keizer, et al., 2003; Li, et al., 2002). All of these 
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binding peptides and their analogues were synthesized and further validated with 
antibody competition ELISA assay as well as growth inhibition assay and 
immunofluorescence assay based on parasite cell culture (Harris, et al., 2009; Keizer, et 
al., 2003).  
In some circumstances, peptides with high affinity to the target antigen can also 
be used in a drug-discovery process, although these peptides themselves do not 
generally make good drugs, they can provide a backbone for the peptidomimetic design 
of efficient drugs (Barbas, et al., 2001). As example, the structure of a phage displayed 
15-residue peptide, F1 against PfAMA1 (Li, et al., 2002) provided a valuable starting 
point for the development of peptidomimetic as antimalarial antagonists directed at 
AMA1 (Keizer, et al., 2003). Most recently, one of the most prominent peptide inhibitor, 
a 20-residue peptide designated as R1 appears to target a site critical for PfAMA1 
function and subsequently blocks the parasite invasion has been modified to be a potent 
leading compound for antimalarial drug development (Harris, et al., 2005; Harris, et al., 
2009).  
Nowadays, applications of both phage display technique together with the three 
dimensional structuring and/or protein docking techniques have speed up the studies on 
molecular binding interactions. For instance, the AMA1-binding molecules, i.e., 
monoclonal antibodies (both the epitopes and mimotopes) and peptides selected from 
phage display libraries, all of which block merozoite invasion of erythrocytes were 
successfully characterized and have been mapped to the location on AMA1 ectoplasmic 
region by nuclear magnetic resonance spectroscopy (Harris, et al., 2009; Keizer, et al., 
2003; Sabo, et al., 2007) and X-ray crystallographic analysis (Bai, et al., 2005; Pizarro, 
et al., 2005).  
Overall, all the studies described above focused on PfAMA1. This is the first 
study carried out on AMA1 protein of two other clinical significant Plasmodium species, 
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i.e., P. vivax and P. knowlesi. 
 
5.3.5 Identification of peptides affinity for PkAMA1 and PvAMA1 
Understanding of the parasites entry into their host cells is of great interest and 
this offers an attractive target for the development of novel therapeutics. From the 
successful and promising results obtained from the previous studies on the identification 
of binding peptides for PfAMA1 as mention above, the objective of the current study 
was to identify novel and potential binding peptides that have high binding affinity to 
PkAMA1 as well as PvAMA1. Differing from the previous studies, a ready-made 
library of random 12-residue peptides expressed as N-terminal fusion to protein III of 
filamentous phages M13 was used for identification of binding peptides for refolded 
rPkAMA1 and rPvAMA1 proteins.  
In the present study, two set of peptides variants that have binding affinity to 
refolded rPkAMA1 (four dodecapeptide) and rPvAMA1 (three dodecapeptide) were 
identified through the Ph.D.-12 random peptide library (NEB) screening in separate 
biopanning experiments.  
The biopanning process often generates peptides with conserved consensus 
sequences, which can then be chemically synthesized on the basic of consensus 
sequences and are evaluated by bioassay and structural analysis (Uchiyama, Tanaka, 
Minari, & Tokui, 2005). The selected peptides (synthetic forms) can be used to 
antagonize the interactions between two particular proteins, which may have an effect 
on the biological activities of the target protein. Alternatively, these peptides may also 
have an effect on of the activity of enzyme, either through active site inhibition or long-
range interactions (Kay, Kasanov, & Yamabhai, 2001).  
In the present study, the consensus sequences/motifs of binding peptides 
selected from biopanning against rPkAMA1 and rPvAMA1 respectively were 
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investigated using ClustalW (Thompson, Higgins, & Gibson, 1994). However, as shown 
in Figure 4.23A and Figure 5.2, there is no single consensus motif that could be seen in 
all the peptides identified from biopanning on rPkAMA1. If compared to PdK1 and 
PdK2 (positive binding sequences), only a single identical amino acid (Gly, G) was 
noticed with none of consensus motif being observed. If compared between two 
peptides, i.e., PdK2 versus PdK3 and PdK3 versus PdK4 respectively, consensus motifs 
with four and three conserved amino acids were observed. Two peptides, PdK3 and 
PdK4 selected from biopanning on rPkAMA1 showed weak binding signal with only 
2.1× of binding activity when tested individually with phage ELISA binding assay 
although they shared a consensus motif.  
When a consensus motif comparison was done on peptides identified from 
biopanning on rPvAMA1 (Figure 4.23B and Figure 5.2), there was a single amino acid, 
Asn (N) occurring among three positive binding peptides, i.e., PdV1, PdV2, and PdV3. 
Additional single amino acid, Pro (P) followed after Asn (N) amino acid was also found 
between PdV1 and PdV2. When compared between PdV2 and PdV3, there were three 
consensus amino acids, i.e., Ser (S), Asn (N), and Leu (L) noticed.  
Overall, there were a lack of consensus sequence motif found among the two set 
of binding peptides selected from biopanning against rPkAMA1 (PdK1, PdK2, PdK3, 
and PdK4) and rPvAMA1 (PdV1, PdV2, and PdV3). The present observations were 
similar to two previous done biopanning against PfAMA1 that also aimed to identify the 
binding peptides (Harris, et al., 2005; Li, et al., 2002) (Table 5.1 and Figure 5.2). A 
follow up of these studies indicated that these binding peptides were mapped to 
different domains of PfAMA1 with different binding activities using NMR spectroscopy 
(Harris, et al., 2009; Keizer, et al., 2003) and it was reasonable to explain the lack of 
consensus sequence motif in such kind of study.  
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Table 5.1: Binding peptides for rPkAMA1 and rPvAMA1 in the present study and 
rPfAMA1 in the previous studies. 
Target 
protein 
Designation Sequence of binding peptide References 
rPfAMA1 
F1 GWRLLGFGPASSFSM 
Li, et al., 2002 F2 TRLFRVPVLPSGVTS 
F3 PFARAPVEHHDVVGL 
rPfAMA1 
R1 VFAEFLPLFSKFGSRMHILK 
Harris, et al., 2005 
R3 PVLRSGRCAELIQIGFRCRA 
rPkAMA1 
PdK1 GGSIAASELEYY 
Present study 
PdK2 WHWGLLYPASAN 
PdK3 WHWSWWNPNQLT 
PdK4 HSQAMPSMLHQA 
rPvAMA1 
PdV1 DLTFTVNPLSKA  
Present study PdV2 WHWSWWNPNQLT 
PdV3 TSVSYINNRHNL 
 
  
        Li, et al., 2002 
 
 
        Harris, et al., 2005 
 
 
 
Present study 
 
 
 
* Binding peptides F1 and R1 derived from phage display against PfAMA1, which exhibited 
strong invasion-inhibition effect, were modified as leading component for antimalarial drug 
development (Session 5.3.4).  
 
Figure 5.2: Consensus motif aligned using ClustalW. 
rPfAMA1 (15-mer peptide library) 
 
F1        -GWRLLGFGPASSFSM * 
F2        TRLFRVPVLPSGVTS- 
F3        -PFARAPVEHHDVVGL 
 
 
rPfAMA1 (20-mer peptide library) 
 
R1      -VF-AEFLPLFSKFGSRMHILK * 
R3       PVLRSGRCAELIQIGFRCRA— 
 
 
rPkAMA1 (12-mer peptide library) 
 
PdK1    --GGSIAASELEYY (n=6) 
PdK2    WHWGLLYPASAN-- (n=10) 
PdK3    WHWSWWNPNQLT-- (n=1) 
PdK4    -H-SQAMPSMLHQA (n=3) 
 
rPvAMA1 (12-mer peptide library) 
 
PdV1    -DLTFTVNPLSKA  (n=8) 
PdV2    WHWSW-WNPNQLT  (n=7) 
PdV3    TSVSYINNRHNL-  (n=1) 
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The binding affinity of each phage peptide variants to the target proteins, i.e., 
rPkAMA1 and rPvAMA1 was further determined using phage ELISA as well as 
Western blot binding assays. Only two out of four peptides, i.e., PdK1 
(GGSIAASELEYY) and PdK2 (WHWGLLYPASAN) selected from biopanning 
against rPkAMA1 showed strong signal in phage ELISA peptide binding assay, with 
8.3-fold and 22.6-fold respectively and the rest of two peptides, PdK3 
(WHWSWWNPNQLT) and PdK4 (HSQAMPSMLHQA) showed 2.1-fold of binding 
signal. In the Western blot binding assay, similar results were obtained where PdK1 and 
PdK2 showed the strong binding signal to rPkAMA1, whereas no positive signal were 
being observed in PdK3 and PdK4. This might be due to weak interaction (below 
threshold of Western blot assay) between these two peptides to rPkAMA1, as reflected 
in the ELISA binding assay, which only showed 2.1× binding signal, respectively.   
Whereas three peptides, i.e., PdV1 (DLTFTVNPLSLA), PdV2 
(WHWSWWNPNQLT), and PdV3 (TSVSYINNRHNL), identified from biopanning 
against rPvAMA1 showed 12.1-fold, 3.5-fold, and 3.1-fold respectively binding signal 
in phage ELISA binding assay. Even though, the peptide PdV2 showed the highest 
binding signal among three peptides, however the background binding was also quite 
high and thus lowered the fold of binding signal. In Western blot assay, sharp and clear 
binding signal was observed in PdV1, while weak binding signal observed in peptides 
PdV2 and PdV3.  
Interestingly, a single identical peptide (WHWSWWNPNQLT) was selected 
from biopanning of rPkAMA1 as well as rPvAMA1 that performed in two separated 
experiments and time. When further tested on the binding affinity of individual peptides 
to two respective target proteins, positive binding signal only appeared toward 
rPvAMA1 in both peptide binding assays but weak binding signal and non-detectable 
toward rPkAMA1 in phage ELISA and Western blot binding assays, respectively.  
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Based on the preliminary data obtained from the present study, it was hard to 
make a complete conclusion on these individual peptides with affinity to rPkAMA1 and 
rPvAMA1. In depth investigation and characterization of the individual peptides in 
terms of molecular interactions and functionality, further antibody competitive binding 
assay and growth inhibition assay are proposed for future studies.  
 
5.3.6 Future perspectives 
Generally, the anti-AMA1 antibodies are essential material for immunological 
assays such as antibody competitive binding assay (competition ELISA), in vitro 
parasite growth inhibition assay, and immunofluorescence assay. As showed by 
previous studies on P. falciparum, antibodies raised against recombinant PfAMA1 
ectoplasmic region were strain- and/or species-specific, there is lack of cross-reactive 
antibody currently available in targeting all five human Plasmodium parasites (Igonet, et 
al., 2007). Therefore, to enable further molecular characterization of these peptides 
derived from biopanning on rPkAMA1 and rPvAMA1, future study will need to 
produce antibodies raised against PkAMA1 and PvAMA1 ectoplasmic regions by 
immunizations of mice with the present expressed refolded and recombinant PkAMA1 
and PvAMA1 proteins. Furthermore, in previous study, successful refolding of 
PfAMA1 can also be validated using anti-AMA1 antibodies, as the observation that 
monoclonal antibody raised against native PfAMA1 only reacted with the correctly 
folded recombinant PfAMA1 (Kocken, et al., 1998). Besides that, availability of anti-
AMA1 antibodies of P. knowlesi and P. vivax may also allow the present study to 
proceed to epitopes/mimotopes mapping of their desired target proteins. 
The interacting point (ligand), where the protein partners bind to rPkAMA1 and 
rPvAMA1 can be studied using combination of X-ray crystallography, NMR 
spectroscopy, and protein docking techniques. 
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Peptides with high binding affinity to rPkAMA1 and rPvAMA1 have potential 
bioactivity such as inhibiting merozoite invasion will aid in the discovery of new 
peptide-based drugs or subunit vaccines as what be done in anti-PfAMA1 (Harris, et al., 
2009; Keizer, et al., 2003). Besides that, peptides with strong binding affinity to the 
target protein may also be modified and used as a protein binder or drug delivery 
compound. In addition, peptides that specifically recognize and reactive to PkAMA1 
and PvAMA1 may also act as protein probes in the development of serodiagnostic assay 
for the detection of malaria parasites other than P. falciparum.  
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5.3.7 Conclusion 
Malaria parasites have a complex life cycle during they infect humans. Basically, 
the successful completion of the parasite life cycle requires specific molecular 
interactions between the parasite and various host and vector tissues. A good 
understanding of the structure and function of Plasmodium proteins, particular those 
involved in host-cell adhesion and invasion will greatly facilitate the strategies in 
malaria controls and eradication. Thus far, there is a lot of work on the key surface 
antigens of merozoites, mainly focused on the most deadly P. falciparum, all of which 
is justified by the need to prevent and treat this fatalistic disease, but we must also be 
aware that P. falciparum is only one of the five human malaria species and thus, the 
eradication of all five species should be a priority. Among the malaria surface antigens, 
AMA1 is long thought to be the pivotal Plasmodium antigen that is responsible for 
parasite-host cell invasions. Investigation of molecular interactions that mediate 
invasion of hepatocytes by sporozoites and erythrocytes by merozoites may allow the 
development of strategies to target these key interactions and disrupt the parasite life 
cycle, thereby reducing parasites densities and provide protection against clinical 
disease.  
Overall, the present study aimed to identify peptides that have binding affinity 
towards refolded recombinant Plasmodium AMA1 ectodomain proteins from P. 
knowlesi (rPkAMA1) and P. vivax (rPvAMA1) using a 12-mer peptide displaying phage 
library. Peptide phage display is a powerful method of mapping for protein-protein 
interactions based on a simple principle that a library of phage particles displaying 
peptides is used and the phage clones that bind to the rPkAMA1 as well as rPvAMA1 
were selected, identified, and used for further research. Phage display is relatively fast 
and simple technique in mapping of protein-protein interactions if compare with other 
sophisticated laboratory technologies such as X-ray crystallography and NMR 
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spectroscopy. With the modest amount of time (two to three weeks), material (typically 
100-500 µg), resources, and cost, peptides ligands have been isolated from a wide array 
of targets from phage display combinatorial peptide libraries.  
Currently two dodecapeptides were selected from biopanning against rPkAMA1 
and three dodecapeptides were selected from biopanning against rPvAMA1, all of 
which exhibited positive binding signal to target proteins in both direct phage assays. 
Further validations and characterizations of the individual phage peptides with antibody 
competitive binding assay and in vitro parasite growth inhibition assay can be carried 
out in future. 
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Appendix 1:  Chemical agents and materials. 
A. Chemical agents and materials used and their sources 
Materials Source 
Chemical agents: 
BSA 
Boric acid (H3BO3) 
Ethylenediamine tetraacetate (EDTA) 
85 % Phosphoric acid (14.7 M) 
Sodium chloride (NaCl) 
Sodium bicarbonate (NaHCO3) 
Tris, free base 
Tris hydrochloride (Tris-HCl) 
Tween 20 
Amresco, USA 
ABTS™ Chromophore substrate solution 
Ampicillin 
Chloramphenicol  
Oxidized glutathione (GSSG) 
Reduced glutathione (GSH) 
Glycerol 
Sodium acetate (NaOAc) 
Sodium azide (NaN3) 
Sodium iodide (NaI) 
Sodium fluoride (NaF) 
Dibasic sodium phosphate (Na2HPO4) 
Monobasic sodium phosphate (NaH2PO4) 
100× Protease inhibitor Cocktail Set 1 
Triton X-100 
Calbiochem, Merck 
Millipore, Germany 
30 % Acrylamide/bis stock solution  
Ammonium persulfate (APS) 
Bio-Safe
TM
 Coomassie G-250 stain  
Dithiothreitol (DTT) 
Glycine 
2× Laemmli sample buffer 
Sodium dodecyl sulphate (SDS) 
N,N,N′,N′-tetramethyl-ethylenediamine (TEMED) 
Bio-Rad, California 
Bromophenol blue  
β-mercaptoethanol 
Dimethyl formamide (DMF) 
Ethidium bromide (EtBr) 
Polyethylene glycol-8000 
Tetracycline 
Xylene 
Sigma-Aldrich, USA 
Absolute ethanol 
95 % Ethanol 
Giemsa stain 
Methanol 
VWR International, UK 
Agarose LE 
IPTG 
Xgal 
Promega, USA 
APPPENDICES 
 
 
245 
 
 
 
 
A. Chemical agents and materials used and their sources (continued) 
Materials Source 
Chemical agents: 
L-arginine 
Calcium chloride (CaCl2) 
Sucrose 
Urea 
Nacalai Tesque, Japan 
L-cysteine monohydrate 
B-PER bacterial protein extraction reagent (in 
phosphate buffer) 
Pierces Thermo Scientific, 
USA 
Dream Taq DNA polymerase  
Taq DNA polymerase (recombinant) 
Maxima
TM
 Hot Start Taq polymerase 
50 bp DNA ladder 
100 bp plus DNA ladder 
1 kb DNA ladder 
dNTP mix 
Spectra™ Multicolor Broad Range Protein Ladder  
Fast digest restriction enzymes: BamH1, SpeI 
Fermentas Thermo 
Scientific, USA 
Benzonase 
KOD Hot Start DNA polymerase 
Lysozyme 
Overnight Express
TM 
Instant LB media 
Novagen, Merck Millipore, 
Germany 
MagicMedia
TM
 E. coli expression medium  
RNase  
Invitrogen Life 
Technologies, USA  
LB agar 
LB broth 
2× YT medium 
SOC medium 
Top agar 
BD, US 
Other materials: 
Tips 
Centrifuge tubes 
PCR tubes 
Plastic wares 
Pasteur pipette 
Axygen Scientific, 
California 
0.22 µM syringe filter 
0.45 µM syringe filter (cellulose acetate) 
Vivaspin 20 concentrator 
Sartorius Stedim Biotech, 
US 
Syringe with needle BD, US 
Zeba Desalting Column 
Slide-A-Lyzer Dialysis Cassettes 
Pierces Thermo Scientific, 
USA 
Costar 96 well plate  
50 ml Falcon tube 
15 ml Falcon  tube 
Corning Incorporated, 
USA 
Whatman Protran nitrocellulose membrane, 0.45µm 
Blotting paper 
Whatman GE Healthcare, 
USA 
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Appendix 1:  Chemical agents and materials (continued). 
B. Commercial kits and their sources 
Name Source Application 
QIAamp DNA Mini Kit Qiagen, Germany DNA extraction 
QIAquick gel extraction kit Qiagen, Germany DNA purification  
pCR®II-Topo TA cloning kit 
Invitrogen Life 
Technologies, USA 
DNA cloning 
HiYield Plasmid Mini Kit Yestern Biotech, Taiwan Plasmid isolation 
Profinity eXact cloning and 
expression starter kit  
Profinity eXact affinity-tagged 
antibody 
Bio-Rad, California 
Protein expression 
 
BL21 (DE3)-RIL codon plus 
E. coli  
Stratagene, US 
Bradford Protein Assay  
BSA standard kit 
Bio-Rad, California 
Protein concentration 
determination 
NOVEX
®
 Reversible 
membrane protein stain  
Invitrogen Life 
Technologies, USA Western blot 
Opti-4CN
TM
 substrate kit Bio-Rad, California 
Ph.D.
TM
-12 phage display 
peptide library 
M13 DNA marker 
New England Biolabs 
(NEB), USA 
Phage display 
HRP-conjugated anti-M13 
monoclonal antibody  
GE Healthcare, USA 
 
C. Equipments used and their sources 
Name Source 
TaKaRa PCR Thermal Cycler Dice
TM
  TAKARA BIO, Japan 
Mini-PROTEAN II Electrophoresis cell 
iMark microplate reader 
Bio-Rad, California 
 
Heildolph pumpdrive 5001 Heildolph, Germany 
Gel electrophoresis system 
UV gel documentation system  
MS waver shaker 
Major Science, USA 
 
NanoPhotometer
TM
  IMPLEN, Germany 
Shaker incubator Kubota, Korea 
Magnetic stirrer Eppendorf, Germany 
TE70 ECL Semi-dry Transfer Unit Amersham Biosciences, GE Healthcare, 
USA 
ImageScanner III  GE Healthcare, USA 
CT15RE refrigerated microcentrifuge Hitachi, Japan 
Velocity 14R refrigerated centrifuge Dynamica, UK 
Universal 32R refrigerated centrifuge Hettich Zentrifugen, Germany 
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Appendix 2:   Preparation of buffers, media, and stock solutions. 
A. Common used stock solutions 
0.1 M Calcium chloride (CaCl2) 
1 M Dithiothreitol (DTT) 
Ethanol (EtOH) 
0.5 M Ethylenediamine tetraacetic acid (EDTA), pH 8 
3 M Sodium acetate (NaOAc), pH 7.2 
5 % (w/v) Sodium azide (NaN3) 
5 M Sodium chloride (NaCl) 
TE-buffer, pH 8 
10× Phosphate-buffered saline (PBS), pH 7.2 
10× Tris-buffered saline (TBS), pH 7.5 
10 % (v/v) Tween 20 
1× PBST plus or 1× TBST 
 
0.1 M Calcium chloride (CaCl2) 
CaCl2 (anhydrous)   10.6 g 
sdH2O to     1,000 ml 
Calcium chloride was dissolved in 1 L of sdH2O, autoclaved, and stored at 4 °C.  
 
1 M Dithiothreitol (DTT) 
DTT (154.25 MW)   0.1542 g 
sdH2O to     1  ml   
Dithiothreitol powder was dissolved in 1 ml of sdH2O and stored in 1 ml aliquots at -
20 °C. Solution was prepared just before use. 
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Ethanol (EtOH) 
Ethanol was used in various concentrations (v/v), i.e., 70 and 100 %. The stock of 
absolute EtOH was adjusted with sdH2O accordingly.  
 
0.5 M Ethylenediamine tetraacetic acid (EDTA), pH 8 
EDTA free acid   14.61  g 
sdH2O to      100 ml 
Ethylenediamine tetraacetic acid was dissolved in 70 ml of sdH2O and stirred 
vigorously with a magnetic stirrer. The pH was adjusted to 8.0 with 10 M NaOH (< 5 
ml) and EDTA was only dissolved at pH between 7.0 and 8.0. The solution volume was 
then adjusted to 100 ml, filtered, and stored at 4 ºC. 
 
3 M Sodium acetate, pH 7.2 
Sodium acetate (anhydrose)   24.61 g 
sdH2O to     100  ml 
Sodium acetate was fully dissolved in 80 ml of sdH2O and the pH was adjusted to 7.2 
with glacial acetic acid. The final volume of the solution was then adjusted to 100 ml 
with sdH2O, autoclaved and stored at room temperature. 
 
5 % (w/v) Sodium azide (NaN3) 
NaN3     0.5 g 
sdH2O to     10 ml 
Sodium azide was fully dissolved in 10 ml of sdH2O, filter sterilized, and stored at room 
temperature. 
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5 M Sodium chloride (NaCl) 
NaCl     14.61 g 
sdH2O to     50 ml 
Sodium chloride was fully dissolved in 50 ml of sdH2O by vigorous stirring using 
magnetic stirrer bar, autoclaved, and stored at room temperature. 
 
TE-buffer (10 mM Tris–HCl, 1 mM EDTA, pH 8) 
Tris base    0.121 g 
0.5 M EDTA    0.2 ml 
sdH2O to      100 ml 
The above components were dissolved in 80 ml of sdH2O and the pH was adjusted to 8 
with HCl. The volume of the solution was then adjusted to 100 ml, autoclaved, and 
stored at room temperature. 
 
10× Phosphate-buffered saline (PBS), pH 7.2       
NaCl     80.0 g     
KCl     2.0 g       
Na2HPO4.2H2O   14.4 g (81 mM of PO4
3-
) 
KH2PO4    2.4 g (19 mM of PO4
3-
) 
sdH2O to     1,000 ml 
The above components were dissolved in 800 ml of sdH2O. The pH was adjusted to 7.2 
using 1 N HCl and topped up to 1 L. The solution was then autoclaved and stored at 
room temperature. To prepare 1× working solution [0.9% (w/v) sodium chloride in 10 
mM phosphate buffer, pH 7.4], 100 ml of 10× stock was combined with 900 ml sdH2O. 
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10× Tris-buffered saline (TBS) (0.5 M Tris-HCl, 1.5 M NaCl, pH 7.5) 
       10× working concentration 
Tris base   60.56 g  0.5 M 
NaCl    87.66 g  1.5 M 
sdH2O to   1,000 ml 
The above components were dissolved in 800 ml of sdH2O, adjusted the pH to 7.5 and 
topped up to 1 L. The solution was then autoclaved and stored at room temperature. The 
100 ml of 10× TBS buffer was than diluted in 900 ml of sdH2O into 1× working 
concentration. 
 
10 % (v/v) Tween-20 stock solution 
Ten ml of Tween-20 was added to 90 ml of sdH2O. Filter sterilized and stored at room 
temperature. 
 
1× PBS plus Tween 20 (PBST) or 1× TBS plus Tween 20 (TBST) 
1× PBST/1× TBST       + 0.1 % Tween-20       + 0.5 % Tween-20 
10× PBST/10× TBST   100 ml    100 ml 
10 % Tween 20 (v/v)   10 ml   50 ml 
sdH2O to    1,000 ml   1,000 ml 
To prepare 1× PBS or 1× TBS with 0.1 % (v/v) or 0.5 % (v/v) Tween 20, 10 or 50 ml of 
Tween 20, respectively, was added to 100 ml of 10× TBS. Then, topped up the solution 
to 1 L. Filter sterilized and stored at room temperature. 
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B. Stock solutions and buffers used in Giemsa staining of blood films 
Giemsa stain solution (VWR International) 
Methanol (Merck) 
Giemsa phosphate buffer, pH 7.2 
 
Giemsa phosphate buffer, pH 7.2 
KH2PO4    0.7 g 
Na2HPO4     1 g 
sdH2O to     1,000 ml 
Above components were dissolved in 1 L of sdH2O. Adjusted the pH to 7.2, autoclaved 
and stored at room temperature. The buffer can last for a month. 
 
C. Stock solution used in malarial DNA extraction 
5 % (w/v) Saponin solution 
One g of saponin was dissolved in 20 ml of sdH2O. Filtered sterilization and stored at 4 
ºC (Moll, Ljungström, Perlmann, Scherf, & Wahlgren, 2008). The solution can last for 
two weeks. 
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D. Stock solutions and buffers used in agarose gel electrophoresis 
6× Bromophenol blue loading dye  
10× Tris-borate-EDTA (TBE) buffer 
Ethidium bromide (EtBr) (10 mg/ml) 
 
6× Bromophenol blue loading dye 
Bromophenol blue      0.25 g 
Xylene cyanol       0.25  g 
Glycerol     50       ml 
1 M Tris, pH 8.0                    1       ml 
Deionized H2O to   100      ml 
The 100 ml stock solution was prepared by mixing all of the above components and 
stored at room temperature or -20 ºC.  
 
10× Tris-borate-EDTA (TBE) buffer, pH 8.3  
Tris base    108 g 
Boric acid                  55  g 
0.5 M EDTA                   40  ml 
sdH2O to              1,000  ml 
The above components were dissolved and mixed well with sdH2O to a final volume of 
1 L. The solution was stored at room temperature and used as soon as possible because 
precipitation occurred on extensive storage period. The 10× TBE stock solution was 
diluted to 1× strength for routine use in agarose gel electrophoresis.  
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Ethidium bromide (EtBr) (10 mg/ml) 
EtBr              100  mg 
sdH2O to               10  ml    
The above solution was prepared and filtered through a 0.2 μm pore size cellulose 
acetate membrane filter, and stored in dark at room temperature. EtBr was used at a 
final concentration of 0.5 µg/ml, thus 0.5 µl of stock solution was added to 100 ml 
molten agarose in pre-stain protocol. 
 
E. Stock solutions and buffers used in SDS-PAGE 
The following buffers and solutions used in resolving SDS-PAGE were made as 
described in Laemmli SDS-PAGE system.  
10 % (w/v) Ammonium persulfate (APS) 
4× Tris/SDS resolving gel buffer  
4× Tris/SDS staking gel buffer  
5× Tris-glycin-SDS running buffer 
2× Laemmli sample buffer  
Other chemical necessities were purchased directly from the related company:  
30 % Acrylamide/bis stock solution (Bio-Rad) 
Bio-Safe
TM
 Coomassie G-250 stain (Bio-Rad) 
N,N,N′,N′-tetramethyl-ethylenediamine (TEMED) (Bio-Rad) 
 
10 % (w/v) Ammonium persulfate (APS) 
APS                  20 mg 
sdH2O to    200 µl 
The above solution was prepared freshly prior to use.  
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4× Tris/SDS resolving gel buffer (1.5 M Tris-HCl, 4 % SDS, pH 8.8) 
Tris base       36.3 g 
SDS          0.8 g 
sdH2O to     200 ml 
Tris base was dissolved and mixed well in 150 ml sdH2O. The pH was then adjusted to 
8.8 using 1 N HCl and sdH2O was added to a final volume of 200 ml. SDS was added 
and mixed well. The solution was filtered and stored up to 3 months at 4 ºC in the dark. 
 
4× Tris/SDS staking gel buffer (0.5 M Tris-HCl, 4 % SDS, pH 6.8) 
Tris base       3 g  
SDS        0.2  g 
sdH2O to     50 ml   
Tris base was dissolved and mixed well in 40 ml of sdH2O. The pH was then adjusted to 
6.8 using 1 N HCl and sdH2O was added to a final volume of 50 ml. SDS was added 
and mixed well. The solution was filtered and stored up to 3 months at 4 ºC in the dark. 
 
5× Tris-glycin-SDS running buffer (25 mM Tris, 192 mM Glycine, 0.1 % SDS, pH 
8.3)  
Tris base     15.1 g   
Glycine     72.0 g   
SDS         5.0 g   
sdH2O to    1,000 ml   
The above components were dissolved and mixed well with sdH2O to a final volume of 
1 L and stored at room temperature for up to 1 month. The pH was not adjusted (~ 8.3). 
To prepare a working solution, 200 ml of 5× stock solution was diluted with 800 ml of 
sdH2O. 
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2× Laemmli sample buffer (0.125 M Tris-HCl, 4 % SDS, 20 % Glycerol, 0.02 % 
Bromophenol blue, 5 % β-mercaptoethanol, pH 6.8) 
0.5 M Tris-HCl, pH 6.8    2.5  ml    
10 % (w/v) SDS     4 g   
Glycerol      2 ml   
Bromophenol blue     2 mg   
β-mercaptoethanol     0.5 ml   
sdH2O to    10 ml 
The above components were dissolved and mixed well with sdH2O to a final volume of 
10 ml. The solution was then dispensed into 1 ml aliquots, covered tightly and stored at 
-20 ºC for up to 6 months. For best result, β-mercaptoethanol was added prior to use. 
Fifty µl of β-mercaptoethanol was added to the 950 µl of sample buffer for a final 
concentration of 5 % β-mercaptoethanol. 
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F. Stock solutions, buffers, and materials used in Western blot 
Towbin transfer buffer  
1× PBST [0.1 % (v/v) Tween 20] 
3 % (w/v) Blocker (BSA) 
Antibody dilution buffer [1 % (w/v) BSA in PBST] 
 
Towbin transfer buffer (25 mM Tris, 192 mM Glycine, 20 % Methanol, 0.1 % SDS) 
Tris base    30.3  g 
Glycine    144.1 g 
SDS     10.0 g 
Methanol      2  L 
sdH2O to    10  L 
Tris, glycine, and SDS were dissolved in 8 L sdH2O and the pH was measured but was 
not adjusted (it should be ~ 8.2-8.4). Two L of methanol was added to the solution and 
brought up to a final volume of 10 L with sdH2O.  
 
3 % (w/v) Blocker 
Twenty g of BSA powder was added slowly, a little bit at a time over a period of 30-45 
minutes into 665 ml of PBST under vigorously stirring. The solution was kept on 
stirring for another 60 minutes after all powder had been added and warmed slowly to 
55 °C to fully dissolved the BSA and then stored at 4 ºC. The blocker was warmed to 
room temperature before use. 
 
Antibody dilution buffer [1 % (w/v) BSA in PBST] 
A weight of 0.75 g of BSA was dissolved in 75 ml rapidly stirring PBST. The buffer 
was used for dilution of primary and secondary antibodies. 
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G. Stock solutions and buffers used in recombinant protein extraction and 
inclusion body (IB) purification and solubilization 
8M Urea stock, pH 8  
100 mg/ml Lysozyme in B-PER reagent, -20 °C 
B-PER protein extraction reagent in phosphate buffer (Pierce Biotechnology)  
100× Calbiochem
®
 Protease Inhibitor Cocktail Set I (Novagen)  
The compositions of the reagents and buffers were prepared from stock solution as 
follows: 
Bacterial lysis and extraction reagent: 
B-PER, 0.2 mg/ml lysozyme, 1× protease inhibitor 
IB wash 1: 
B-PER, 0.2 mg/ml lysozyme, 1 % (v/v) Triton X-100, 1 M urea, 1 mM EDTA, 5 
mM DTT 
IB wash 2:  
1:10 dilution of B-PER 
IB solubilization buffer: 
0.1 M  Sodium phosphate, 4 M urea, 1 mM EDTA, 5 mM DTT, pH 8 
 
8 M Urea stock, pH 8 
Tris base     1.21 g 
Urea      240.24 g 
sdH2O to      500 ml 
Above components were dissolved in 500 ml of sdH2O and adjusted to pH 7.2 or 8.0 
with concentrated phosphoric acid. The solution was filter sterilized and stored at room 
temperature. The solution was prepared freshly to prevent cyanate formation.  
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IB solubilization buffer 
            Final concentration  
0.2 M Sodium phosphate, pH 7.2 25  ml   100 mM 
8 M Urea    25  ml   4 M 
0.5 M EDTA, pH 8*   100 µl   1  mM 
1 M DTT*    250 µl  5  mM 
Final volume    50 ml 
Twenty five ml of each 0.2 M sodium phosphate (v/v) and 8 M urea (v/v) were mixed 
well. The EDTA and DTT were then added freshly to solution prior used. 
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H. Stock solutions and buffers used in tag-free recombinant protein isolation and 
purification 
The following stock solution and buffers used in Profinity exact
TM
 purification system 
were made according to the manufacturer’s instructions.  
 0.2 M Sodium phosphate, pH 7.2 
 0.2 M Sodium fluoride, pH 7.2 
0.1 M Phosphoric acid, pH 1.8 
All the working reagents and buffers used were prepared from stock solution and the 
compositions were as follows: 
Bind/wash buffer:  
4 M Urea, 0.1 M Sodium phosphate, pH 7.2 
Stringency wash:  
0.3 M Sodium acetate, 4 M urea, 0.1 M Sodium phosphate, pH 7.2 
Elution buffer:  
0.1 M Sodium fluoride, 4 M urea, 0.1 M Sodium phosphate, pH 7.2 
Column regeneration buffer: 
 0.1 M Phosphoric acid, pH 1.8 
Column wash buffer: 
 0.1 M Sodium phosphate, pH 7.2 
Column storage buffer: 
0.1 M Sodium phosphate, 0.02 % (w/v) Sodium azide, pH 7.2 
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0.2 M Sodium phosphate, pH 7.2 
0.2 M Dibasic sodium phosphate (stock solution) 
Na2HPO4    28.4 g 
sdH2O to    1,000 ml 
 
0.2 M Monobasic sodium phosphate (stock solution) 
NaH2PO4.H20    13.8 g 
sdH2O to    500 mL 
The above sodium phosphate solutions were prepared and the pH was adjusted to 7.2 
using phosphoric acid. To prepare 1 L of 0.2 M of sodium phosphate at pH 7.2, 720 ml 
of 0.2 M dibasic sodium phosphate was mixed with 280 ml of 0.2 M monobasic sodium 
phosphate, autoclaved and stored at room temperature. 
 
0.2 M Sodium fluoride, pH 7.2 
NaF      0.84 g 
sdH2O to      100  ml 
Sodium fluoride was dissolved in 100 ml of sdH2O and the pH was adjusted to 7.2 using 
phosphoric acid, autoclaved, and stored at room temperature. 
 
0.1 M Phosphoric acid, pH 1.8 
Column regeneration buffer was prepared by diluting the 0.68 ml of 85 % (14.7 M) 
concentrated phosphoric acid into 99.32 ml of sdH2O.  
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I. Stock solutions and buffers used in protein renaturation 
1 M Sodium phosphate, pH 8  
1 M Tris phosphate, pH 8 
8 M Urea 
5× Dialysis buffer stock (250 mM Tris phosphate, 2 M L-arginine, pH 8)  
All the buffers used were prepared from stock solution and the compositions were as 
follows: 
Buffer exchange: 
50 mM Tris phosphate, 4 M urea, pH 8 
Refolding sample buffer: 
1 mg/ml recombinant protein in 50 mM Tris Phosphate, 4 M urea, 1 mM EDTA, 
1 mM reduced gluthathione (GSH), 0.25 mM oxidized glutathione (GSSG), 1× 
protease inhibitor cocktail 
Dialysis buffers: 
50 mM Tris phosphate, 0.4 M L-arginine, 1 mM EDTA, 2 M urea, pH 8 
50 mM Tris phosphate, 0.4 M L-arginine, 1 mM EDTA, 1 M urea, pH 8 
25 mM Tris phosphate, 50 mM NaCl, pH 8  
 
1 M Tris phosphate, pH 8 
Tris base     60.56 g 
sdH2O to      500 ml   
Tris base was dissolved in 500 ml of sdH2O and pH was adjusted with concentrated 
phosphoric acid, then filter sterilized and stored at room temperature. 
 
200 mM reduced glutathione (GSH) 
A total of 61.4 mg of GSH (307.33 MW) powder was dissolved in 1 ml of sdH2O. The 
solution was freshly prepared before use. 
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100 mM oxidized glutathione (GSSG) 
A total of 61.2 mg of GSSG (612.64 MW) powder was dissolved in 1 ml of sdH2O. The 
solution was freshly prepared before use. 
 
5× Dialysis buffer stock (250 mM Tris phosphate, 2 M L-arginine, pH 8)  
Tris base     15.14 g 
L-arginine     174.2 g  
sdH2O to      500  ml 
Above components were dissolved in 400 ml of sdH2O with vigorous stirring. The pH 
was adjusted to 8.0 with concentrated phosphoric acid. The solution was then topped up 
to 500 ml, autoclaved and stored at 4 °C. The 5× dialysis buffer stock solution was 
diluted to 1× strength for the first and second rounds of dialysis. 
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J. Stock solutions and buffers used in biopanning 
All the buffers used in biopanning were prepared as described (Barbas, et al., 2001). 
Immobilized buffer:  
0.1 M Sodium bicarbonate (NaHCO3), pH 8.6 
Blocking buffer:  
5 mg/ml of BSA in NaHCO3, pH 8.6 
Biopanning and washing buffer:  
TBST 
Glycine elution buffer:  
1 mg/ml BSA, 0.2 M Glycine-HCl, pH 2.2 
Neutralization Buffer:  
1 M Tris-HCl, pH 9.1 
 
0.1 M Sodium bicarbonate (NaHCO3), pH 8.6  
NaHCO3    0.84 g   
sdH2O     100 ml 
Sodium bicarbonate was dissolved in 100 ml of sdH2O. The pH was adjusted to 8.6 and 
filter sterilized and stored at room temperature. 
 
Blocking buffer 
The blocking buffer was freshly prepared by dissolving 5 mg/ml of bovine serum 
albumin (BSA) (Ameresco) in immobilized buffer and 0.02 % NaN3 was then added to 
the solution, filter sterilized and stored at 4 ºC. 
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1 mg/ml of BSA, 0.2 M Glycine-HCl, pH 2.2 
Glycine   0.75 g 
BSA    0.05 g  
sdH2O to   50 ml  
The above component was dissolved in 50 ml of sdH2O and the pH was adjusted to 2.2 
with concentrated HCl. Filter sterilized and stored at 4˚C.  
 
1 M Tris-HCl, pH 9.1 
Tris base   6.06 g 
sdH2O to   50 ml  
Tris base was dissolved in 50 ml of sdH2O and the pH was adjusted to 9.1 with 
concentrated HCl, filter sterilized and stored at room temperature.  
 
K. Stock solution used in phage precipitation 
20 % (w/v) PEG/2.5 M NaCl  
Polyethylene glycol-8000   40 g 
NaCl      29.22 g 
sdH2O to   200 ml  
The above components were dissolved in sdH2O by vigorous stirring using magnetic 
stirrer and then autoclaved. The two separated layers of solution were mixed by 
vigorous stirring while still in warm after autoclave and the mixture was stored at room 
temperature. 
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L. Buffer used in single-strand M13 phage DNA extraction 
Iodide buffer  
            Final concentration 
1 M Tris base  0.121 g   10  mM 
Sodium iodide (NaI)   59.96 g      4 M 
0.5 M EDTA   0.2 ml      1 mM 
sdH2O to   100 ml  
The above components were dissolved in 100 ml of sdH2O, filter sterilized and stored at 
room temperature in the dark. The solution was discarded if color is evident. 
 
M. Stock solutions and buffers used in phage ELISA 
All the buffers used were prepared from stock solution and the compositions were as 
follows: 
Blocking buffer:  
0.5 mg/ml BSA, 0.1 M NaHCO3, pH 8.6, 0.02 % (w/v) NaN3 
Wash buffer:  
TBST [TBS plus 0.5 % (v/v) Tween 20]  
Secondary antibody: 
1:5000 HRP-conjugated anti-M13 antibody (GE Healthcare) in blocking buffer 
HRP substrate: 
ABTS
Tm 
Chromophore substrate solution (Calbiochem) 
ABTS stop solution:  
0.5 M Sulfuric acid 
 
0.5 M Sulfuric acid  
Sulfuric acid solution was prepared by adding 2.8 ml of 96 % concentrated H2SO4 (18 
M) into 97.2 ml of sdH2O.  
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N. Media, antibiotics, and stock solutions used in bacteria cultivation and phage 
amplification 
LB broth 
LB agar 
SOC broth 
Top agar 
2× Yeast Extract Tryptone (YT) broth 
100 mg/ml Ampicilin stock 
34 mg/ml Chloramphenicol stock 
20 mg/ml Tetracycline stock 
100 mg/ml IPTG stock 
50 mg/ml Xgal stock 
 
LB broth  
Bacto-Tryptone  10 g 
Yeast extract   5 g 
NaCl    5 g 
sdH2O to   1 L 
The above components were dissolved and mixed well with sdH2O to a final volume of 
1 L, autoclaved, and stored at 4 ºC. Appropriate antibiotics were added freshly to the 
broth prior to use. 
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LB agar  
Fifteen g of Bacto agar was added to LB medium components and then dissolved in 1 L 
of sdH2O, and autoclaved. Autoclaved media was cooled to 55 ºC before antibiotic or 
enzyme was added. The solution was mixed by gentle swirling and ~ 20 ml of molten 
agar was poured into Petri dish, and allowed to solidify at room temperature. Agar 
plates can store up to a month at 4 ºC. 
 
SOC broth 
Bacto-Trypton e  2 g 
Yeast extract   0.5 g 
NaCl    0.05 g 
sdH2O to   100 ml 
The above components were dissolved in 100 ml of sdH2O, then autoclaved, and stored 
at 4 ºC. Prior to use, 0.5 ml of 2 M of MgCl2 and 2 ml of 1 M glucose (both sterilized) 
were added to the broth.  
 
Top agar 
Bacto-Trypton e  1 g 
Yeast extract   0.5 g 
NaCl    0.5 g 
Bacto agar       0.7 g 
sdH2O to   100 ml 
The above components were dissolved in 100 ml of sdH2O, autoclaved, and stored solid 
at room temperature. The solidified agar was then melted in microwave as needed.  
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2× YT broth 
Tryptone       16 g 
Yeast extract       10 g 
Sodium chloride        5 g 
sdH2O to   1000 ml 
The above components were dissolved in 1L of sdH2O, autoclaved, and stored at 4 ºC. 
Appropriate antibiotics were added freshly to broth prior use. 
 
100 mg/ml Ampicilin stock 
One g of ampicillin was dissolved with sterilized sdH2O to a final volume of 10 ml. The 
solution was filter sterilized and dispensed into 1.0 ml aliquots, and stored at -20 C. 
 
34 mg/ml Chloramphenicol stock 
Thirty four mg of chloramphenicol was dissolved in 1 ml of ethanol and stored at -20 ºC. 
 
20 mg/ml Tetracycline stock 
Twenty mg of tetracycline was dissolved in 1:1 of ethanol:water and stored at -20 ºC. 
The stock solution was mixed well by vortex before each use.  
 
100 mg/ml IPTG stock 
One g of IPTG (isopropyl-β-D-thiogalactoside) was dissolved in 10 ml of sdH2O, filter 
sterilized, and dispensed into 1 ml aliquots, before being stored at -20 ºC. 
 
40 mg/ml Xgal stock 
One g of Xgal (5-bromo-4-chloro-3-β-D-galactoside) was dissolved in 25 ml DMF 
(dimethyl formamide) and stored at -20 ºC. 
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Appendix 3:  PCR reagents and oligonucleotide primers. 
A. PCR reagents 
PCR 
reagents 
Storage buffer Supplements Applications 
Dream
TM
 
Taq
 
DNA 
polymerase 
(5 U/µl) 
20 mM Tris-HCl (pH 8), 
1 mM DTT, 0.1 mM 
EDTA, 100 mM KCl, 
stabilizing agent, 50 % 
(v/v) glycerol 
 10× Dream buffer 
(containing 15 mM 
MgCl2)  
 25 mM MgCl2 
First nested 
PCR 
DNA cloning 
Recombinant 
Taq DNA 
polymerase  
(5 U/µl) 
20 mM Tris-HCl (pH 8), 
1 mM DTT, 0.1 mM 
EDTA, 100 mM KCl, 0.5 
% (v/v) Nonidet P40, 0.5 
% (v/v) Tween 20, 50 % 
(v/v) glycerol 
 10× Taq buffer 
[100 mM Tris-HCl 
(pH 8.8), 500 mM 
KCl, 0.8 (v/v) 
Nonidet P40] 
 25 mM MgCl2 
Second nested 
PCR 
Colony PCR 
Maxima
TM
 
Hot Start 
Taq DNA 
polymerase 
(5 U/µl) 
20 mM Tris-HCl (pH 
9.0), 1 mM DTT, 0.1 mM 
EDTA, 100 mM KCl, 0.5 
% (v/v) Tween 20, 0.5 % 
(v/v) Nonidet P40, 50 % 
(v/v) glycerol 
 10× Hot Start 
buffer [200 mM 
Tris-HCl (pH 8.3), 
200 mM KCl, 50 
mM (NH4)2SO4] 
 25 mM MgCl2 
Multiplex PCR 
assay 
KOD Hot 
Start DNA 
polymerase 
(1 U/µl) 
50 mM Tris-HCl, 1 mM 
DTT, 0.1 mM EDTA, 50 
% (v/v) glycerol, 0.001 % 
(v/v) Nonidet P-40, 0.001 
% (v/v) Tween 20, pH 8 
 10× KOD PCR 
buffer 
 25 mM MgSO4 
 2 mM dNTP mix 
Recombinant 
protein 
expression 
10 mM 
dNTP mix 
- - PCR reagent 
* Proper thaw and well mixed of the 10× PCR buffer and Mg
2+
 stock solution were 
required to avoid formation of concentration gradients in master mixture preparation. 
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Appendix 3:  PCR reagents and oligonucleotide primers (continued). 
B. Primers used in nested PCR 
Primer Primer sequence (5’-   -3’) 
Size 
(bp) 
References 
rPLU1  TCAAAGATTAAGCCATGCAAGTGA 1,600-
1,700 
Snounou, et 
al., 1993; 
Singh, et 
al., 1999  
 
rPLU5 CCT GTTGTTGCCTTAAACTCC 
rFAL1 TTAAACTGGTTTGGGAAAACCAAATATATT 
 205 
rFAL2 ACACAATGAACTCAATCATGACTACCCGTC 
rVIV1 CGCTTCTAGCTTAATCCACATAACTGATAC 
117 
rVIV2 ACTTCCAAGCCGAAGCAAAGAAAGTCCTTA 
rMAL1 ATAACATAGTTGTACGTTAAGAATAACCGC 
144 
rMAL2 AAAATTCCCATGCATAAAAAATTATACAAA 
rOVA1 ATCTCT TTTGCTATTTTTTAGTATTGGAGA 
787 
Singh, et 
al., 1999 rOVA2 GGAAAAGGACACATTAATTGTATCCTAGTG 
rPO (F) CGTTAAGAATAAACGCCAAGCG 
375 
Padley, et 
al., 2003 Conserve GTATCTGATCGTCTTCACTCCC 
Pmk8 GTTAGCGAGAGCCACAAAAAAGCG 
153 
Singh, et 
al., 2004 Pmrk9 ACTCAAAGTAACAAAATCTTCC 
 
C. Primers used in colony PCR and DNA sequencing 
Primer Primer sequence (5’-   -3’) Application 
M13 (-20)-F GTAAAACGACGGCCAG     
Colony PCR and 
sequencing 
M13-R CAGGAAACAGCTATGAC 
SP6 TATTTAGGTGACACTATAG 
T7 promoter TAATACGACTCACTATAGGG     
T7 terminator GCTAGTTATTGCTCAGCGG 
pPAL7 internal GTGCTTCAAATATGTAGACGCA 
-96 gIII CCCTCATAGTTAGCGTAACG Phage sequencing 
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Appendix 4:  Overview of recombinant protein production using Profinity eXact
TM
 
System. 
(A) The pPAL7 vector with Profinity eXact tag; (B) Multiple cloning sites (MSC) and 
Profinity eXact cleavage site (FKAL); (C) Single step affinity purification and tag 
cleavage of recombinant protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Profinity eXact pPAL7 vector 
B. Cloning and expression region 
C. Single step on-column purification and tag removal 
Purified 
recombinant 
protein 
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Appendix 5.1:  BLASTN search of recombinant PkAMA1. 
Plasmodium knowlesi strain H apical merozoite antigen 1 (PKH_093110) mRNA, complete cds 
Sequence ID: ref|XM_002259303.1| 
Length: 1692 
Number of Matches: 1 
 
 
 
 
 
Query  1     GGGCCTATCATTGAGAGAAGTATACGAATGAGTAACCCATGGAAAGCCTTCATGGAAAAG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  124   GGGCCTATCATTGAGAGAAGTATACGAATGAGTAACCCATGGAAAGCCTTCATGGAAAAG  183 
 
Query  61    TATGATTTAGAGAGAGCACACAATTCCGGGATTAGAATTGATTTAGGGGAAGATGCAGAA  120 
             ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  184   TATGATTTAGAAAGAGCACACAATTCCGGGATTAGAATTGATTTAGGGGAAGATGCAGAA  243 
 
Query  121   GTGGGAAATTCCAAGTATAGAATACCAGCTGGAAAATGTCCAGTTTTTGGAAAGGGTATC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  244   GTGGGAAATTCCAAGTATAGAATACCAGCTGGAAAATGTCCAGTTTTTGGAAAGGGTATC  303 
 
Query  181   GTTATAGAAAATTCTAACGTTAGCTTCTTAACACCCGTAGCTACAGGAGCTCAAAGGTTG  240 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||| 
Sbjct  304   GTTATAGAAAATTCTAACGTTAGCTTCTTAACACCCGTAGCTACAGGAGCTCAGAGGTTG  363 
 
Query  241   AAGGAAGGAGGTTTCGCCTTCCCCAATGCAGATGACCACATTTCCCCTATAACAATAGCA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  364   AAGGAAGGAGGTTTCGCCTTCCCCAATGCAGATGACCACATTTCCCCTATAACAATAGCA  423 
 
Query  301   AACCTTAAAGAGAGGTATAAAGAAAATGCAGATTTGATGAAATTAAATGATATAGCCTTG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  424   AACCTTAAAGAGAGGTATAAAGAAAATGCAGATTTGATGAAATTAAATGATATAGCCTTG  483 
 
Query  361   TGTAAAACGCATGCAGCCAGCTTTGTCATTGCAGAGGATCAAAATACATCTTACAGACAT  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  484   TGTAAAACGCATGCAGCCAGCTTTGTCATTGCAGAGGATCAAAATACATCTTACAGACAT  543 
 
Query  421   CCAGCTGTTTATGACGAAAAGAATAAAACATGTTACATGTTGTATTTGTCAGCGCAAGAA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  544   CCAGCTGTTTATGACGAAAAGAATAAAACATGTTACATGTTGTATTTGTCAGCGCAAGAA  603 
 
Query  481   AATATGGGTCCACGATACTGTAGCCCAGATTCACAAAATAAAGACGCCATGTTTTGCTTC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  604   AATATGGGTCCACGATACTGTAGCCCAGATTCACAAAATAAAGACGCCATGTTTTGCTTC  663 
 
Query  541   AAGCCAGATAAAAATGAAAAATTTGACAACCTGGTGTATTTAAGCAAAAACGTAAGTAAT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  664   AAGCCAGATAAAAATGAAAAATTTGACAACCTGGTGTATTTAAGCAAAAACGTAAGTAAT  723 
 
Query  601   GATTGGGAAAACAAGTGCCCGCGTAAAAATTTAGGAAACGCAAAATTTGGATTATGGGTG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  724   GATTGGGAAAACAAGTGCCCGCGTAAAAATTTAGGAAACGCAAAATTTGGATTATGGGTG  783 
 
Query  661   GATGGGAACTGTGAAGAAATACCATACGTTAATGAAGTGGAGGCAAGGAGCCTACGGGAA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  784   GATGGGAACTGTGAAGAAATACCATACGTTAATGAAGTGGAGGCAAGGAGCCTACGGGAA  843 
 
Query  721   TGCAACCGAATCGTTTTCGAAGCTAGCGCTTCAGATCAACCACGTCAGTACGAAGAAGAA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  844   TGCAACCGAATCGTTTTCGAAGCTAGCGCTTCAGATCAACCACGTCAGTACGAAGAAGAA  903 
 
Query  781   CTGACAGATTATGAAAAAATACAAGAGGGATTTAGACAAAATAATCGGGACATGATTAAA  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  904   CTGACAGATTATGAAAAAATACAAGAGGGATTTAGACAAAATAATCGGGACATGATTAAA  963 
 
Query  841   AGTGCCTTTCTTCCAGTGGGTGCATTTAACTCAGACAATTTTAAGAGTAAAGGAAGAGGA  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  964   AGTGCCTTTCTTCCAGTGGGTGCATTTAACTCAGACAATTTTAAGAGTAAAGGAAGAGGA  1023 
 
Query  901   TATAACTGGGCAAATTTCGATTCTGTAAATAATAAGTGTTACATTTTTAATACCAAACCT  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1024  TATAACTGGGCAAATTTCGATTCTGTAAATAATAAGTGTTACATTTTTAATACCAAACCT  1083 
 
Query  961   ACGTGTCTCATTAATGACAAAAATTTTTTTGCAACAACAGCGTTATCTCACCCTCAAGAA  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1084  ACGTGTCTCATTAATGACAAAAATTTTTTTGCAACAACAGCGTTATCTCACCCTCAAGAA  1143 
 
Query  1021  GTAGACAATGAATTTCCATGCAGCATATACAAAGATGAAATTGAAAGAGAAATTAAGAAA  1080 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1144  GTAGACAATGAATTTCCATGCAGCATATACAAAGATGAAATTGAAAGAGAAATTAAGAAA  1203 
 
Query  1081  CAGTCGAGAAATATGAATCTGTACAGTGTTGATAAGGAACGGATTGTCTTGCCAAGGATA  1140 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1204  CAGTCGAGAAATATGAATCTGTACAGTGTTGATAAGGAACGGATTGTCTTGCCAAGGATA  1263 
 
Query  1141  TTTATCTCCACCGATAAGGAGAGTATCAAATGTCCATGTGAGCCTGAACACATTTCCAAT  1200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1264  TTTATCTCCACCGATAAGGAGAGTATCAAATGTCCATGTGAGCCTGAACACATTTCCAAT  1323 
 
Query  1201  AGTACCTGCAACTTTTACGTTTGTAACTGTGTAGAGAAGAGAGCAGAAATTAAGGAAAAT  1260 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1324  AGTACCTGCAACTTTTACGTTTGTAACTGTGTAGAGAAGAGAGCAGAAATTAAGGAAAAT  1383 
 
Query  1261  AACGAAGTTATCATAAAGGAAGAATTTAAGGAGGATTATGAAAATCCGGACGGCAAACAT  1320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1384  AACGAAGTTATCATAAAGGAAGAATTTAAGGAGGATTATGAAAATCCGGACGGCAAACAT  1443 
 
Query  1321  AAGAAGAAGATGCTACTA  1338 
             |||||||||||||||||| 
Sbjct  1444  AAGAAGAAGATGCTACTA  1461 
Score Expect Identities Gaps Strand 
2460 bits(1332) 0.0 1336/1338(99%) 0/1338(0%) Plus/Plus 
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Appendix 5.2:  BLASTN search of recombinant PvAMA1. 
Plasmodium vivax isolate CTRA26 apical membrane protein-1 (AMA-1) gene, complete cds 
Sequence ID: gb|FJ785007.1| 
Length: 1689 
Number of Matches: 1 
 
Score Expect Identities Gaps Strand 
2466 bits(1335) 0.0 1337/1338(99%) 0/1338(0%) Plus/Plus 
 
Query  1     GGGCCTACCGTTGAGAGGAGCACACGAATGAGTAACCCCTGGAAAGCGTTCATGGAAAAA  60 
             ||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  124   GGGCCTACCGTTGAGAGAAGCACACGAATGAGTAACCCCTGGAAAGCGTTCATGGAAAAA  183 
 
Query  61    TACGACATCGAAAGAACACACAGTTCTGGGGTTCGAGTGGATTTAGGGGAAGATGCAGAA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  184   TACGACATCGAAAGAACACACAGTTCTGGGGTTCGAGTGGATTTAGGGGAAGATGCAGAA  243 
 
Query  121   GTGGAAAATGCAAAGTACAGAATTCCAGCTGGAAGATGTCCTGTTTTTGGAAAGGGTATC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  244   GTGGAAAATGCAAAGTACAGAATTCCAGCTGGAAGATGTCCTGTTTTTGGAAAGGGTATC  303 
 
Query  181   GTCATAGAGAATTCCGCTGTTAGCTTCTTAAAACCTGTGGCTACAGGAGATCAGAGGCTG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  304   GTCATAGAGAATTCCGCTGTTAGCTTCTTAAAACCTGTGGCTACAGGAGATCAGAGGCTG  363 
 
Query  241   AAGGATGGAGGTTTCGCCTTCCCCAATGCGAATGACCATATCTCCCCCATGACAATAGCG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  364   AAGGATGGAGGTTTCGCCTTCCCCAATGCGAATGACCATATCTCCCCCATGACAATAGCG  423 
 
Query  301   AACCTTAAGGCAAGGTATAAAGACAATGTAGAGATGATGAAGTTAAACGATATAGCTTTG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  424   AACCTTAAGGCAAGGTATAAAGACAATGTAGAGATGATGAAGTTAAACGATATAGCTTTG  483 
 
Query  361   TGCAGAACCCACGCAGCTAGCTTTGTCATGGCAGGGGATCAAAATTCGTCCTACAGACAC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  484   TGCAGAACCCACGCAGCTAGCTTTGTCATGGCAGGGGATCAAAATTCGTCCTACAGACAC  543 
 
Query  421   CCAGCTGTATACGACGAAAAGGAAAAAACATGCCACATGTTGTATTTATCAGCGCAGGAA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  544   CCAGCTGTATACGACGAAAAGGAAAAAACATGCCACATGTTGTATTTATCAGCGCAGGAA  603 
 
Query  481   AATATGGGTCCGAGGTACTGCAGCCCAGATGCACAAAATAGAGATGCCGTGTTCTGCTTC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  604   AATATGGGTCCGAGGTACTGCAGCCCAGATGCACAAAATAGAGATGCCGTGTTCTGCTTC  663 
 
Query  541   AAGCCAGATAAAAATGAAAGCTTTGAAAACCTGGTGTATTTGAGCAAAAATGTGCGTAAT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  664   AAGCCAGATAAAAATGAAAGCTTTGAAAACCTGGTGTATTTGAGCAAAAATGTGCGTAAT  723 
 
Query  601   GATTGGGATAAAAAATGCCCCCGTAAAAATTTAGGAAACGCCAAGTTCGGATTATGGGTG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  724   GATTGGGATAAAAAATGCCCCCGTAAAAATTTAGGAAACGCCAAGTTCGGATTATGGGTG  783 
 
Query  661   GATGGGAACTGCGAAGAAATTCCATACGTTAAAGAAGTGGAGGCAAAGGATCTGCGCGAA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  784   GATGGGAACTGCGAAGAAATTCCATACGTTAAAGAAGTGGAGGCAAAGGATCTGCGCGAA  843 
 
Query  721   TGCAACCGAATCGTTTTCGAAGCGAGTGCCTCAGATCAACCAACTCAGTATGAAGAAGAA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  844   TGCAACCGAATCGTTTTCGAAGCGAGTGCCTCAGATCAACCAACTCAGTATGAAGAAGAA  903 
 
Query  781   ATGACGGATTATCAAAAAATACAACAAGGGTTTAGACAAAACAACCGAGAGATGATTAAA  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  904   ATGACGGATTATCAAAAAATACAACAAGGGTTTAGACAAAACAACCGAGAGATGATTAAA  963 
 
Query  841   AGTGCCTTTCTTCCAGTGGGTGCATTCAACTCGGATAATTTCAAAAGTAAAGGAAGAGGA  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  964   AGTGCCTTTCTTCCAGTGGGTGCATTCAACTCGGATAATTTCAAAAGTAAAGGAAGAGGA  1023 
 
Query  901   TTTAACTGGGCAAATTTCGATTCTGTAAAAAAGAAGTGTTACATCTTTAATACCAAACCG  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1024  TTTAACTGGGCAAATTTCGATTCTGTAAAAAAGAAGTGTTACATCTTTAATACCAAACCG  1083 
 
Query  961   ACTTGCCTCATTAATGACAAAAATTTTATTGCAACAACGGCGTTATCTCACCCACAAGAA  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1084  ACTTGCCTCATTAATGACAAAAATTTTATTGCAACAACGGCGTTATCTCACCCACAAGAA  1143 
 
Query  1021  GTAGACCCGGAGTTCCCCTGCAGCATATATAAAGACGAAATTGAAAGAGAAATTAAGAAA  1080 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1144  GTAGACCCGGAGTTCCCCTGCAGCATATATAAAGACGAAATTGAAAGAGAAATTAAGAAA  1203 
 
Query  1081  CAATCGAGGAACATGAATCTGTACAGTGTTGATGGGGAACGCATTGTCCTGCCGAGGATA  1140 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1204  CAATCGAGGAACATGAATCTGTACAGTGTTGATGGGGAACGCATTGTCCTGCCGAGGATA  1263 
 
Query  1141  TTTATCTCCAACGATAAGGAGAGTATCAAATGTCCCTGCGAACCTGAGCACATTTCCAAC  1200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1264  TTTATCTCCAACGATAAGGAGAGTATCAAATGTCCCTGCGAACCTGAGCACATTTCCAAC  1323 
 
Query  1201  AGTACCTGCAACTTTTACGTTTGTAACTGTGTAGAGAAAAGGGCGGAAATTAAGGAAAAT  1260 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1324  AGTACCTGCAACTTTTACGTTTGTAACTGTGTAGAGAAAAGGGCGGAAATTAAGGAAAAT  1383 
 
Query  1261  AACCAAGTTGTTATAAAGGAAGAATTTAGGGATTATTACGAAAATGGGGAGGAAAAATCG  1320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1384  AACCAAGTTGTTATAAAGGAAGAATTTAGGGATTATTACGAAAATGGGGAGGAAAAATCG  1443 
 
Query  1321  AACAAGCAGATGCTACTA  1338 
             |||||||||||||||||| 
Sbjct  1444  AACAAGCAGATGCTACTA  1461 
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Appendix 5.3:  BLASTP search of recombinant PkAMA1. 
Apical merozoite antigen 1 [Plasmodium knowlesi strain H] 
Sequence ID: ref|XP_002259339.1| 
Length: 563 
Number of Matches: 1 
 
Score Expect Method Identities Positives Gaps 
929 bits(2401) 0.0 Compositional matrix adjust. 446/446(100%) 446/446(100%) 0/446(0%) 
 
Query  1    GPIIERSIRMSNPWKAFMEKYDLERAHNSGIRIDLGEDAEVGNSKYRIPAGKCPVFGKGI  60 
            GPIIERSIRMSNPWKAFMEKYDLERAHNSGIRIDLGEDAEVGNSKYRIPAGKCPVFGKGI 
Sbjct  42   GPIIERSIRMSNPWKAFMEKYDLERAHNSGIRIDLGEDAEVGNSKYRIPAGKCPVFGKGI  101 
 
Query  61   VIENSNVSFLTPVATGAQRLKEGGFAFPNADDHISPITIANLKERYKENADLMKLNDIAL  120 
            VIENSNVSFLTPVATGAQRLKEGGFAFPNADDHISPITIANLKERYKENADLMKLNDIAL 
Sbjct  102  VIENSNVSFLTPVATGAQRLKEGGFAFPNADDHISPITIANLKERYKENADLMKLNDIAL  161 
 
Query  121  CKTHAASFVIAEDQNTSYRHPAVYDEKNKTCYMLYLSAQENMGPRYCSPDSQNKDAMFCF  180 
            CKTHAASFVIAEDQNTSYRHPAVYDEKNKTCYMLYLSAQENMGPRYCSPDSQNKDAMFCF 
Sbjct  162  CKTHAASFVIAEDQNTSYRHPAVYDEKNKTCYMLYLSAQENMGPRYCSPDSQNKDAMFCF  221 
 
Query  181  KPDKNEKFDNLVYLSKNVSNDWENKCPRKNLGNAKFGLWVDGNCEEIPYVNEVEARSLRE  240 
            KPDKNEKFDNLVYLSKNVSNDWENKCPRKNLGNAKFGLWVDGNCEEIPYVNEVEARSLRE 
Sbjct  222  KPDKNEKFDNLVYLSKNVSNDWENKCPRKNLGNAKFGLWVDGNCEEIPYVNEVEARSLRE  281 
 
Query  241  CNRIVFEASASDQPRQYEEELTDYEKIQEGFRQNNRDMIKSAFLPVGAFNSDNFKSKGRG  300 
            CNRIVFEASASDQPRQYEEELTDYEKIQEGFRQNNRDMIKSAFLPVGAFNSDNFKSKGRG 
Sbjct  282  CNRIVFEASASDQPRQYEEELTDYEKIQEGFRQNNRDMIKSAFLPVGAFNSDNFKSKGRG  341 
 
Query  301  YNWANFDSVNNKCYIFNTKPTCLINDKNFFATTALSHPQEVDNEFPCSIYKDEIEREIKK  360 
            YNWANFDSVNNKCYIFNTKPTCLINDKNFFATTALSHPQEVDNEFPCSIYKDEIEREIKK 
Sbjct  342  YNWANFDSVNNKCYIFNTKPTCLINDKNFFATTALSHPQEVDNEFPCSIYKDEIEREIKK  401 
 
Query  361  QSRNMNLYSVDKERIVLPRIFISTDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKEN  420 
            QSRNMNLYSVDKERIVLPRIFISTDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKEN 
Sbjct  402  QSRNMNLYSVDKERIVLPRIFISTDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKEN  461 
 
Query  421  NEVIIKEEFKEDYENPDGKHKKKMLL  446 
            NEVIIKEEFKEDYENPDGKHKKKMLL 
Sbjct  462  NEVIIKEEFKEDYENPDGKHKKKMLL  487 
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Appendix 5.4:  BLASTP search of recombinant PvAMA1. 
Apical membrane protein-1 [Plasmodium vivax] 
Sequence ID: gb|ACY68841.1| 
Length: 562 
Number of Matches: 1 
 
 
Query  1    GPTVERSTRMSNPWKAFMEKYDIERTHSSGVRVDLGEDAEVENAKYRIPAGRCPVFGKGI  60 
            GPTVERSTRMSNPWKAFMEKYDIERTHSSGVRVDLGEDAEVENAKYRIPAGRCPVFGKGI 
Sbjct  42   GPTVERSTRMSNPWKAFMEKYDIERTHSSGVRVDLGEDAEVENAKYRIPAGRCPVFGKGI  101 
 
Query  61   VIENSAVSFLKPVATGDQRLKDGGFAFPNANDHISPMTIANLKARYKDNVEMMKLNDIAL  120 
            VIENSAVSFLKPVATGDQRLKDGGFAFPNANDHISPMTIANLKARYKDNVEMMKLNDIAL 
Sbjct  102  VIENSAVSFLKPVATGDQRLKDGGFAFPNANDHISPMTIANLKARYKDNVEMMKLNDIAL  161 
 
Query  121  CRTHAASFVMAGDQNSSYRHPAVYDEKEKTCHMLYLSAQENMGPRYCSPDAQNRDAVFCF  180 
            CRTHAASFVMAGDQNSSYRHPAVYDEKEKTCHMLYLSAQENMGPRYCSPDAQNRDAVFCF 
Sbjct  162  CRTHAASFVMAGDQNSSYRHPAVYDEKEKTCHMLYLSAQENMGPRYCSPDAQNRDAVFCF  221 
 
Query  181  KPDKNESFENLVYLSKNVRNDWDKKCPRKNLGNAKFGLWVDGNCEEIPYVKEVEAKDLRE  240 
            KPDKNESFENLVYLSKNVRNDWDKKCPRKNLGNAKFGLWVDGNCEEIPYVKEVEAKDLRE 
Sbjct  222  KPDKNESFENLVYLSKNVRNDWDKKCPRKNLGNAKFGLWVDGNCEEIPYVKEVEAKDLRE  281 
 
Query  241  CNRIVFEASASDQPTQYEEEMTDYQKIQQGFRQNNREMIKSAFLPVGAFNSDNFKSKGRG  300 
            CNRIVFEASASDQPTQYEEEMTDYQKIQQGFRQNNREMIKSAFLPVGAFNSDNFKSKGRG 
Sbjct  282  CNRIVFEASASDQPTQYEEEMTDYQKIQQGFRQNNREMIKSAFLPVGAFNSDNFKSKGRG  341 
 
Query  301  FNWANFDSVKKKCYIFNTKPTCLINDKNFIATTALSHPQEVDPEFPCSIYKDEIEREIKK  360 
            FNWANFDSVKKKCYIFNTKPTCLINDKNFIATTALSHPQEVDPEFPCSIYKDEIEREIKK 
Sbjct  342  FNWANFDSVKKKCYIFNTKPTCLINDKNFIATTALSHPQEVDPEFPCSIYKDEIEREIKK  401 
 
Query  361  QSRNMNLYSVDGERIVLPRIFISNDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKEN  420 
            QSRNMNLYSVDGERIVLPRIFISNDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKEN 
Sbjct  402  QSRNMNLYSVDGERIVLPRIFISNDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKEN  461 
 
Query  421  NQVVIKEEFRDYYENGEEKSNKQMLL  446 
            NQVVIKEEFRDYYENGEEKSNKQMLL 
Sbjct  462  NQVVIKEEFRDYYENGEEKSNKQMLL  487 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
 
 
 
 
 
 
 
 
Score Expect Method Identities Positives Gaps 
932 bits(2410) 0.0 Compositional matrix adjust. 446/446(100%) 446/446(100%) 0/446(0%) 
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Appendix 6: LC-MS/MS results and analysis.  
Matched peptides were indicated in green for the rPkAMA1 (A) and rPvAMA1 (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) rPkAMA1 
GPIIERSIRMSNPWKAFMEKYDLERAHNSGIRIDLGEDAEVGNSKYRIPAGKCPVF
GKGIVIENSNVSFLTPVATGAQRLKEGGFAFPNADDHISPITIANLKERYKENADL
MKLNDIALCKTHAASFVIAEDQNTSYRHPAVYDEKNKTCYMLYLSAQENMGPRYCS
PDSQNKDAMFCFKPDKNEKFDNLVYLSKNVSNDWENKCPRKNLGNAKFGLWVDGNC
EEIPYVNEVEARSLRECNRIVFEASASDQPRQYEEELTDYEKIQEGFRQNNRDMIK
SAFLPVGAFNSDNFKSKGRGYNWANFDSVNNKCYIFNTKPTCLINDKNFFATTALS
HPQEVDNEFPCSIYKDEIEREIKKQSRNMNLYSVDKERIVLPRIFISTDKESIKCP
CEPEHISNSTCNFYVCNCVEKRAEIKENNEVIIKEEFKEDYENPDGKHKKKMLL 
 
(B) rPvAMA1 
GPTVERSTRMSNPWKAFMEKYDIERTHSSGVRVDLGEDAEVENAKYRIPAGRCPVF
GKGIVIENSAVSFLKPVATGDQRLKDGGFAFPNANDHISPMTIANLKARYKDNVEM
MKLNDIALCRTHAASFVMAGDQNSSYRHPAVYDEKEKTCHMLYLSAQENMGPRYCS
PDAQNRDAVFCFKPDKNESFENLVYLSKNVRNDWDKKCPRKNLGNAKFGLWVDGNC
EEIPYVKEVEAKDLRECNRIVFEASASDQPTQYEEEMTDYQKIQQGFRQNNREMIK
SAFLPVGAFNSDNFKSKGRGFNWANFDSVKKKCYIFNTKPTCLINDKNFIATTALS
HPQEVDPEFPCSIYKDEIEREIKKQSRNMNLYSVDGERIVLPRIFISNDKESIKCP
CEPEHISNSTCNFYVCNCVEKRAEIKENNQVVIKEEFRDYYENGEEKSNKQMLL 
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Appendix 7: Protein expression and refolding records for Plasmodium AMA1 
deposited in REFOLD database.  
Refolding Records (18) for Protein: Apical membrane antigen 1 (modified from 
http://refold.med.monash.edu.au/). 
Class/UniProt 
Accession No. 
Organism 
Family/ 
Domain 
Molecularity 
MW 
(Da) 
Refolding Method Redox Agent Reference 
Small 
Proteins/ 
P16445 
Plasmodium 
chabaudi 
AMA1/ 
NA 
Monomer 73876.1 
Column refolding: 
Nickel-chelating 
chromatography 
None 
Burns, et al., 
2003 
Small 
Proteins/ 
Q7KQK5 
Plasmodium 
falciparum 
AMA1/ 
NA 
Monomer 54634.3 Dilution GSH/GSSG 
Dutta, et al., 
2002 
Small 
Proteins/ 
P16445 
Plasmodium 
chabaudi 
AMA1/ 
NA 
Monomer 53371.1 Dilution GSH/GSSG 
Anders, et al., 
1998 
Small 
Proteins/ 
O00784 
Plasmodium 
falciparum 
AMA1/ 
NA 
Monomer 72622.2 Dilution GSH/GSSG 
Hodder, et al., 
2001 
Small 
Proteins/ 
P50492 
Plasmodium 
falciparum 
AMA1/ 
NA 
Unknown 51425.7 Dilution GSH/GSSG 
Dutta, et al., 
2002 
Small 
Proteins/ 
P50492 
Plasmodium 
falciparum 
AMA1/ 
NA 
Unknown 69135.1 Dilution NA 
Gupta, et al., 
2005 
Small 
Proteins/ 
A3F8A6 
Plasmodium 
falciparum 
AMA1/ 
NA 
Unknown 14471.3 Dilution GSH/GSSG 
Feng, et al., 
2005 
Small 
Proteins/ 
A3F8A6 
Plasmodium 
falciparum 
AMA1/ 
DII 
Unknown 14471.3 Dilution GSH/GSSG 
Feng, et al., 
2005 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DI 
Unknown 26972.3 Dilution GSH/GSSG 
Lalitha, et al., 
2004 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DII 
Unknown 12499.1 Dilution GSH/GSSG 
Lalitha, et al., 
2004 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DIII 
Unknown 12887.5 Dilution GSH/GSSG 
Lalitha, et al., 
2004 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DI+DII 
Unknown 41081.1 Dilution GSH/GSSG 
Lalitha, et al., 
2004. 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DII+DIII 
Unknown 26244.5 Dilution GSH/GSSG 
Lalitha, et al., 
2004 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DI+DII 
Unknown 41081.1 Dilution GSH/GSSG 
Lalitha, et al., 
2004 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DI+DII 
Unknown 41081.1 Dilution GSH/GSSG 
Lalitha, et al., 
2004 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DIII 
Unknown 12887.5 Dilution GSH/GSSG 
Lalitha, et al., 
2004 
Small 
Proteins/ 
P22621 
Plasmodium 
falciparum 
AMA1/ 
DI+DIII 
Unknown 38696.5 Dilution GSH/GSSG 
Lalitha, et al., 
2004 
Small 
Proteins/ 
Q9GVB7 
Plasmodium 
falciparum 
AMA1/ 
 
Unknown 69896.9 Dilution DTT/cystamine 
Giersing, et 
al., 2005 
NA indicates not available. DI indicates domain I, DII indicates domain II, and DIII indicates domain III. 
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Appendix 8:  Identification of binding peptides for PkAMA1. 
 
PdK1 
 
 
 
 
 
5’- TCT CAC TCT GGT GGT AGT ATT GCT GCT TCG GAG CTG GAG TAT TAT GGT GGA GGT 
N’- Ser His Ser Gly Gly Ser Ile Ala Ala Ser Glu Leu Glu Thr Thr Gly Gly Gly 
   G   G   S   I   A   A   S   E   L   E   Y   Y 
 
PdK2 
 
 
 
 
 
5’- TCT CAC TCT TGG CAT TGG GGT CTT CTG TAT CCT GCG AGT GCT AAT GGT GGA GGT 
N’- Ser His Ser Trp His Trp Gly Leu Leu Tyr Pro Ala Ser Ala Asn Gly Gly Gly 
   W   H   W   G   L   L   Y   P   A   S   A   N 
 
PdK3 
 
 
 
 
 
5’- TCT CAC TCT TGG CAT TGG TCT TGG TGG AAT CCT AAT CAG CTG ACT GGT GGA GGT 
N’- Ser His Ser Trp His Trp Ser Trp Trp Asn Pro Asn Gln Leu Thr Gly Gly Gly 
   W   H   W   S   W   W   N   P   N   Q   L   T 
 
PdK4 
 
 
 
 
 
5’- TCT CAC TCT CAT TCG CAG GCG ATG CCT TCT ATG TTG CAT CAG GCG GGT GGA GGT 
N’- Ser His Ser His Ser Gln Ala Met Pro Ser Met Leu His Gln Ala Gly Gly Gly 
   H   S   Q   A   M   P   S   M   L   H   Q   A 
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Appendix 9:  Identification of binding peptides for PvAMA1. 
 
PdV1 
 
 
 
 
 
5’- TCT CAC TCT GAT CTG ACT TTT ACG GTG AAT CCG CTG AGT AAG GCT GGT GGA GGT 
N’- Ser His Ser Asp Leu Thr Phe Thr Val Asn Pro Leu Ser Lys Ala Gly Gly Gly 
   D   L   T   F   T   V   N   P   L   S   K   A 
 
PdV2 
 
 
 
 
 
5’- TCT CAC TCT TGG CAT TGG TCT TGG TGG AAT CCT AAT CAG CTG ACT GGT GGA GGT 
N’- Ser His Ser Trp His Trp Ser Trp Trp Asn Pro Asn Gln Leu Thr Gly Gly Gly 
   W   H   W   S   W   W   N   P   N   Q   L   T 
 
PdV3 
 
 
 
 
 
5’- TCT CAC TCT ACT TCG GTG TCG TAT ATT AAT AAT AGG CAT AAT CTG GGT GGA GGT 
N’- Ser His Ser Thr Ser Val Ser Tyr Ile Asn Asn Arg His Asn Leu Gly Gly Gly 
   T   S   V   S   Y   I   N   N   R   H   N   L 
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Appendix 10:  Ethics approval letter. 
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Appendix 11:  Inform consent form. 
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RESEARCH OUTCOMES 
Patent: 
A multiplex PCR assay for human malaria parasites was patented in November 2010 
with reference number: PI 2010 003802 (Malaysia) and June 2011 with reference 
number: PCT/2011/000158 (International). 
 
Human malaria detection assay:  
This hexaplex PCR assay (PlasmoNex™) is currently commercialized under Reszon 
Diagnostics International (http://www.reszonics.com/product-Malaria.html). 
 
Publications: 
Lim, Y. A. L., Mahmud, R., Chew, C. H., Thilagannthan, T., & Chua, K. H. (2010). 
Plasmodium ovale infection in Malaysia: first imported case. Malar J, 9, 272. 
Chew, C. H., Lim, Y. A. L., Lee, P. C., Mahmud, R., & Chua, K. H. (2012). Hexaplex 
PCR detection system for identification of five human Plasmodium species with 
an internal control. J Clin Microbiol, 50(12), 4012-4019. 
Goh, X. T., Lim, Y. A. L., Vythilingam, I., Chew, C. H., Lee, P. C., Ngui, R., Tan, T. 
C., Yap, N. J., Nissapatorn, V., & Chua, K. H. (2013). Increased detection of 
Plasmodium knowlesi in Sandakan division, Sabah as revealed by PlasmoNex™. 
Malar J, 12, 264. 
 
Presentations/ Awards:  
Chew, C. H., Lim, Y. A. L., Lee, P. C., Mahmud, R., and Chua, K. H. (2009). 
Development of multiplex polymerase chain reaction (PCR) for detection of 
human Plasmodium spp infection in malaria disease. In 14th Biological Sciences 
Graduate Congress (10 - 12 December 2009), Chulalongkorn University, 
Bangkok, Thailand. p.195. 
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Presentations/ Awards (continued):  
Chua, K. H., Mahmud, R., Lim, Y. A. L., Lee, P. C., and Chew, C. H. (2010). 
PlasmoNex - One step multiplex PCR detection system for malaria parasites. In 
Bio Malaysia 2010 (1 - 3 November 2010), Kuala Lumpur Convention Centre, 
Malaysia. (BioInno Award 2010 - Gold Medal). 
Chua, K. H., Mahmud, R., Lim, Y. A. L., Lee, P. C., and Chew, C. H. (2011). 
PlasmoNex - Advanced detection system for malaria parasites. In Malaysia 
Technology Expo 2011 (17 - 19 February 2011), Kuala Lumpur Convention 
Centre, Malaysia. (Malaysian Association of Research Scientist Award - Silver 
Medal). 
Chua, K. H., Mahmud, R., Lim, Y. A. L., Lee, P. C., and Chew, C. H. (2011). 
PlasmoNex II - A PCR system for detection of general and human malaria 
parasites. In 22
nd
 International Invention, Innovation and Technology Exhibition 
(ITEX) (20 - 22 May 2011), Kuala Lumpur Convention Centre, Malaysia. (ITEX 
2011 Award - Silver Medal). 
Chua, K. H., Mahmud, R., Lim, Y. A. L., Lee, P. C., and Chew, C. H. (2011). 
PlasmoNex – A single step multiplex PCR detection system for human malaria 
parasites. In Pecipta 2011 Malaysia (13 - 15 September 2011), Kuala Lumpur 
Convention Centre, Malaysia. (PECIPTA 2011 Award - Silver Medal). 
Chua, K. H., Mahmud, R., Lim, Y. A. L., Lee, P. C., and Chew, C. H. (2011). 
PlasmoNex™ - Ultimate identification of malaria parasites. In Bio Malaysia 
2011 (21 - 23 November 2011), Kuala Lumpur Convention Centre, Malaysia. 
(BioInnovation Award 2011 - Gold Medal). 
Chua, K. H., Mahmud, R., Lim, Y. A. L., Lee, P. C., and Chew, C. H. (2012). 
PlasmoNex - A detection system for human malaria parasites. In National 
Innovation Conference and Exhibition (5 - 7 November 2012), Kuala Lumpur 
Convention Centre, Malaysia.  
Chua, K. H., Mahmud, R., Lim, Y. A. L., Lee, P. C., and Chew, C. H. (2012). 
PlasmoNex
TM – A detection kit for human malaria parasites. In Seoul 
International Invention Fair 2012 (22 November - 2
 
December 2012), Seoul, 
Korea. (SIIF 2012 - Gold Medal). 
